

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40  
minutes  
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source  
(CS) field  
NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced  
NEWS 5 AUG 24 CA/CAPLUS enhanced with legal status information for  
U.S. patents  
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in  
CAS REGISTRY  
NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM  
thesaurus  
NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and  
Taiwanese Content Expanded  
NEWS 9 OCT 21 Derwent World Patents Index enhanced with human  
translated claims for Chinese Applications and  
Utility Models  
NEWS 10 OCT 27 Free display of legal status information in CA/CAPLUS,  
USPATFULL, and USPAT2 in the month of November.

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN customer  
agreement. This agreement limits use to scientific research. Use  
for software development or design, implementation of commercial  
gateways, or use of CAS and STN data in the building of commercial  
products is prohibited and may result in loss of user privileges  
and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 06:57:23 ON 29 OCT 2009

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 06:57:51 ON 29 OCT 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 OCT 2009 HIGHEST RN 1190482-45-1  
DICTIONARY FILE UPDATES: 28 OCT 2009 HIGHEST RN 1190482-45-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.44	1.66

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 06:59:33 ON 29 OCT 2009

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ


PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'REGISTRY' AT 07:30:14 ON 29 OCT 2009  
FILE 'REGISTRY' ENTERED AT 07:30:14 ON 29 OCT 2009  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.44	1.66

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary  
files\10575122\10575122 elected specie.str



```

chain nodes :
13 14 15 16 17 18 19 20 21 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
6-7 10-13 13-14 13-15 14-16 16-17 17-18 18-19 18-20 18-21 21-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
16-17 17-18
exact bonds :
6-7 10-13 13-14 13-15 14-16 18-19 18-20 18-21 21-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> search l1 exact full

FULL SEARCH INITIATED 07:31:16 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L2 0 SEA EXA FUL L1

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

68.36

68.58

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 07:35:41 ON 29 OCT 2009

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*

SESSION RESUMED IN FILE 'REGISTRY' AT 07:43:33 ON 29 OCT 2009

FILE 'REGISTRY' ENTERED AT 07:43:33 ON 29 OCT 2009

COPYRIGHT (C) 2009 American Chemical Society (ACS)

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION



FULL ESTIMATED COST

68.36

68.58

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10575122\10575122 claim 1 generic.str



chain nodes :

7 8 9 10 11 12 13 14 15 16 23

ring nodes :

1 2 3 4 5 6

chain bonds :

6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14 14-15 15-16 15-23

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

7-8 9-10 10-11 12-13 13-14 15-16 15-23

exact bonds :

6-7 8-9 11-12 14-15

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:O,S,N

G2:O,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 23:CLASS

L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS

L3 STR



G1 O,S,N

G2 O,N

Structure attributes must be viewed using STN Express query preparation.

=> search l3 sss sam

SAMPLE SEARCH INITIATED 07:44:16 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 218218 TO ITERATE

0.9% PROCESSED 2000 ITERATIONS

21 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*

BATCH \*\*INCOMPLETE\*\*

PROJECTED ITERATIONS: 4336880 TO 4391840

PROJECTED ANSWERS: 42954 TO 48696


L4 21 SEA SSS SAM L3

=> d scan

L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN Thieno[2,3-c]pyridine-3-carboxylic acid,  
2-[[2-[[3-[[2-(benzoylamino)-3-(2-ethoxyphenyl)-1-oxo-2-propen-1-yl]amino]phenyl]thio]acetyl]amino]-4,5,6,7-tetrahydro-6-(phenylmethyl)-,  
methyl ester


MF C42 H40 N4 O6 S2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzoic acid, 5-[[2-[[4-[[2-(benzoylamino)-1-oxo-3-(2,4,5-  
trimethoxyphenyl)-2-propen-1-yl]amino]phenyl]thio]acetyl]amino]-2-hydroxy-  
MF C34 H31 N3 O9 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C35 H35 N3 O5 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C33 H30 Br N3 O5 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetamide,  $\alpha$ -[[3-[[2-(benzoylamino)-3-(4-methylphenyl)-1-oxo-2-propen-1-yl]amino]phenyl]thio]-N-(4-iodophenyl)-  
 MF C37 H30 I N3 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C35 H34 N4 O4 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C37 H30 N4 O4 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN Acetic acid, [4-[[3,3-bis(3'-amino[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI)  
 MF C35 H29 Cl N2 O3 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C45 H39 N3 O4 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN L-Phenylalanine, N-[N-[N-[N2-[3,5-bis[[N-[N-[N-(N2-benzoyl-L-arginyl)glycyl]-L-alpha-aspartyl]-L-phenylalanyl]amino]cyclohexyl]carbonyl]-L-arginyl]glycyl]-L-alpha-aspartyl]- (9CI)  
 SQL 13,9,4  
 MF C84 H109 N23 O22


\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




PAGE 2-B



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C33 H29 Cl2 N3 O5 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenepropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy)carbonyl]amino]-  
 $\alpha$ -[[[(1S,3R,4R,5R)-1,3,4-tris(acetyloxy)-5-[[3-[3,4-  
 bis(acetyloxy)phenyl]-1-oxo-2-propen-1-yl]oxy]cyclohexyl]carbonyl]oxy]-,  
 (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-  
 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-  
 tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl  
 ester, ( $\alpha$ R, $\beta$ S)-  
 MF C69 H79 N O27


Absolute stereochemistry.  
 Double bond geometry unknown.

PAGE 1-A






L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzamide, N-[2-(2,5-dimethoxyphenyl)-1-[[[3-[[2-[[4-(4-fluorophenyl)-2-thiazolyl]amino]-1-methyl-2-oxoethyl]thio]phenyl]amino]carbonyl]ethenyl]-  
 MF C36 H31 F N4 O5 S2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Glycine, N-[4-[[2-[4-(difluoromethoxy)-3-methoxyphenyl]ethyl]amino]-3-nitrobenzoyl]-  
 MF C19 H19 F2 N3 O7




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C32 H26 Cl3 N3 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Glycine, N-[4-[[2-(3-fluorophenyl)acetyl]amino]benzoyl]-  
MF C17 H15 F N2 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Butanamide, N-(3,5-dichlorophenyl)-2-[[3-[(1-oxo-3-phenyl-2-propen-1-yl)amino]phenyl]thio]-  
MF C25 H22 Cl2 N2 O2 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN 3-Thiophenecarboxylic acid, 2-[[2-[[3-[[2-(benzoylamino)-3-(2-chlorophenyl)-1-oxo-2-propen-1-yl]amino]phenyl]thio]-1-oxopropyl]amino]-4-(4-methylphenyl)-, ethyl ester  
 MF C39 H34 Cl N3 O5 S2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetamide, 4-chloro-N-[3-[[2-[(3-chloro-4-methylphenyl)amino]-1-methyl-2-oxoethyl]thio]phenyl]-  
 MF C24 H22 Cl2 N2 O2 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C37 H36 N4 O4 S2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 21 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzoic acid, 4-[[2-[[4-[[2-(benzoylamino)-3-(2,5-dimethoxyphenyl)-1-oxo-2-propen-1-yl]amino]phenyl]thio]-2-phenylacetyl]amino]-, ethyl ester  
 MF C41 H37 N3 O7 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> search l3 sss full  
 FULL SEARCH INITIATED 07:45:36 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 4372779 TO ITERATE

30.2% PROCESSED	1321092 ITERATIONS	1431 ANSWERS
43.0% PROCESSED	1879691 ITERATIONS	2025 ANSWERS
45.7% PROCESSED	2000000 ITERATIONS	2046 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)		
SEARCH TIME: 00.00.49		

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
 BATCH \*\*INCOMPLETE\*\*  
 PROJECTED ITERATIONS: 4372779 TO 4372779  
 PROJECTED ANSWERS: 4273 TO 4673

L5 2046 SEA SSS FUL L3

=> save l5 pparawcmpds/a  
 ANSWER SET L5 HAS BEEN SAVED AS 'PPARAWCMPDS/A'

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	257.12	257.34

FILE 'CAPLUS' ENTERED AT 07:47:28 ON 29 OCT 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Oct 2009 VOL 151 ISS 18  
FILE LAST UPDATED: 28 Oct 2009 (20091028/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> 15

L6 90 L5

=> ppar

14036 PPAR

1687 PPARS

L7 14244 PPAR

(PPAR OR PPARS)

=> 16 and 17

L8 7 L6 AND L7

=> d 18 1-7 ti

L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of isoindolinone derivatives as PPAR activators

L8 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of aryl compounds as ligands for peroxisome proliferator-activated receptors

L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

TI Structure-based drug design of a novel family of chalcones as PPAR  $\alpha$  agonists: virtual screening, synthesis, and biological activities in vitro

L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of 1,3-diethynylbenzene derivatives as agonists of peroxisome proliferator-activated receptors

L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

TI Novel selective PPAR. $\delta$ . agonists: Optimization of activity by modification of alkynylallylic moiety

L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of cyclic alkenyl compounds as PPAR. $\delta$ . activators for treating various disease including diabetes and obesity


L8 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of alkynyl substituted phenoxyacetic acids as PPAR  $\delta$  agonists

=> d 18 1-7 ti fbib abs

L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN  
TI Preparation of isoindolinone derivatives as PPAR activators  
AN 2009:710009 CAPLUS  
DN 151:33410  
TI Preparation of isoindolinone derivatives as PPAR activators  
IN Aotsuka, Tomoji; Kanazawa, Hashime; Kumazawa, Kentarou  
PA Aska Pharmaceutical Co., Ltd., Japan  
SO PCT Int. Appl., 377pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009072581	A1	20090611	WO 2008-JP72094	20081204
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
				JP 2007-315021	A 20071205
OS	MARPAT 151:33410				
GI					



AB The title compds., e.g. I [R1 = halo, (un)substituted alkyl, (un)substituted cycloalkyl, etc.; a represents an integer of 0 to 3; m represents an integer of 0 to 2; and n = 1 ; X1 = C, O, S, N, etc.; R2 = H, (un)substituted alkyl; R3, R4 = single bond, (un)substituted bivalent (un)saturated aliphatic hydrocarbon group; X2, X3 = single bond, O, S, etc.;



A1 = single bond, (un)substituted phenylene; Y1 = H, halo, cyano, etc.], are prepared Thus, (4-ethoxycarbonylmethoxy-2-phenyl)isoindolin-1-one was prepared in a multistep process starting from 3-acetoxy-2-methylbenzoic acid. The PPAR  $\alpha$ , PPAR  $\gamma$ , and PPAR  $\delta$  agonist activity of compds. of this invention was demonstrated. Pharmaceutical formulations are given.

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of aryl compounds as ligands for peroxisome  
 proliferator-activated receptors  
 AN 2008:674203 CAPLUS  
 DN 149:9759  
 TI Preparation of aryl compounds as ligands for peroxisome  
 proliferator-activated receptors  
 IN Kang, Heonjoong; Chin, Jungwook; Lee, Jaehwan  
 PA Seoul National University Industry Foundation, S. Korea  
 SO PCT Int. Appl., 114pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008066356	A1	20080605	WO 2007-KR6170	20071201
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2007326114	A1	20080605	KR 2006-121074	A 20061202
				AU 2007-326114	20071201
				KR 2006-121074	A 20061202
				WO 2007-KR6170	W 20071201
	CA 2669639	A1	20080605	CA 2007-2669639	20071201
				KR 2006-121074	A 20061202
				WO 2007-KR6170	W 20071201
	KR 2008050348	A	20080605	KR 2007-124052	20071201
				KR 2006-121074	A 20061202
	EP 2102155	A1	20090923	EP 2007-851173	20071201
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
				KR 2006-121074	A 20061202
				WO 2007-KR6170	W 20071201
	IN 2009MN00940	A	20090522	IN 2009-MN940	20090512
				KR 2006-121074	A 20061202
				WO 2007-KR6170	W 20071201
OS	MARPAT 149:9759				
GI					



AB The title aryl compds. I [wherein A = S or Se; R1 = aryl; R2 = H, alkyl, or (un)substituted benzyl; R3 = H, alkyl, or halo; X = H or C(R4R5)CO2R6; R4 and R5 = independently H or alkyl; R6 = H, alkyl, alkenyl, alkali metal, or alkali earth metal; m = 1-4], hydrates, solvates, stereoisomers, or pharmaceutically acceptable salts thereof were prepared as activators for peroxisome proliferator-activated receptors (PPAR). For example, II was prepared in a multi-step synthesis. II showed highly selective activity with EC50 of 2.6 nM to PPAR. $\delta$ . The compds. showed biol. activity with EC50 of 2-200 nM to PPAR. $\delta$ . The compds. can be used for treating arteriosclerosis, hyperlipidemia, diabetes, obesity, dementia, Parkinson's disease, etc. Use the compds. for functional food adjuvants, functional beverages, food additives, and animal feeds were also claimed.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN  
 TI Structure-based drug design of a novel family of chalcones as PPAR  $\alpha$  agonists: virtual screening, synthesis, and biological activities in vitro  
 AN 2007:1456378 CAPLUS  
 DN 148:158854  
 TI Structure-based drug design of a novel family of chalcones as PPAR  $\alpha$  agonists: virtual screening, synthesis, and biological activities in vitro  
 AU Li, Xiang-hua; Zou, Han-jun; Wu, An-hui; Ye, Yang-liang; Shen, Jian-hua  
 CS Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, Peop. Rep. China  
 SO Acta Pharmacologica Sinica (2007), 28(12), 2040-2052  
 CODEN: APSCG5; ISSN: 1671-4083  
 PB Blackwell Publishing Asia Pty Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 148:158854  
 AB Aim: To design and synthesize a novel class of peroxisome proliferator-activated receptors (PPAR) $\alpha$  agonists, which is obtained by the combination of the classical fibrate "head group", a linker with appropriate length and a chalcone. Methods: Thirty seven compds. were designed and identified employing the virtual screening approach. Six compds. were then selected for synthesis and bioassay according to the virtual screening results, structural similarity, and synthetic complexity. Results: Six new compds. (4b and 4d-h) were

synthesized and bioassayed. All were found to be potent PPAR  $\alpha$  agonists, compound 4 h being the most prominent with a 50% effective concentration value of 0.06  $\mu\text{mol/L}$ . Conclusion: This study provides a promising novel family of chalcones with a potential hypolipidemic effect.

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN  
 TI Preparation of 1,3-diethynylbenzene derivatives as agonists of peroxisome proliferator-activated receptors  
 AN 2007:1028544 CAPLUS  
 DN 147:365259  
 TI Preparation of 1,3-diethynylbenzene derivatives as agonists of peroxisome proliferator-activated receptors  
 IN Sauerberg, Per  
 PA Novo Nordisk A/S, Den.  
 SO PCT Int. Appl., 69pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007101864	A2	20070913	WO 2007-EP52130	20070307
	WO 2007101864	A3	20071025		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	CA 2645719	A1	20070913	EP 2006-110887	A 20060309
				CA 2007-2645719	20070307
				EP 2006-110887	A 20060309
				WO 2007-EP52130	W 20070307
	EP 1999098	A2	20081210	EP 2007-726688	20070307
	R:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
				EP 2006-110887	A 20060309
				WO 2007-EP52130	W 20070307
	JP 2009529512	T	20090820	JP 2008-557754	20070307
				EP 2006-110887	A 20060309
				WO 2007-EP52130	W 20070307
	US 20090048257	A1	20090219	US 2008-282244	20080909
				EP 2006-110887	A 20060309
				WO 2007-EP52130	W 20070307
OS	CASREACT 147:365259; MARPAT 147:365259				
GI					



AB The title compds. with general formula I [wherein X1 = (un)substituted aryl, heteroaryl, heterocycle, etc.; X2 = H, halo, (un)substituted aryl-alkynyl, heteroaryl-alkynyl, etc.; Ar = (un)substituted aryl; Y and Z = independently O or S; n = 1-3; R = H, alkyl, cycloalkyl, alkenyl, etc.] or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixture of stereoisomers, or polymorphs thereof were prepared as agonists of peroxisome proliferator-activated receptors (PPAR  $\delta$ ). For example, compound II was prepared in a multi-step synthesis. PPAR transient transactivation assay, based on transient transfection into human HEK293 cells of two plasmids encoding a chimeric test protein and a reporter protein resp., was performed to evaluate the agonistic activity of I towards PPAR. $\delta$ . Formulations containing I as active ingredient was also disclosed.

L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

TI Novel selective PPAR. $\delta$ . agonists: Optimization of activity by modification of alkynylallylic moiety

AN 2007:746419 CAPLUS

DN 147:343462

TI Novel selective PPAR. $\delta$ . agonists: Optimization of activity by modification of alkynylallylic moiety

AU Havranek, Miroslav; Sauerberg, Per; Mogensen, John P.; Kratina, Pavel; Jeppesen, Claus B.; Pettersson, Ingrid; Pihera, Pavel

CS RE&D VUFB, s.r.o., Prague, 180 66 9, Czech Rep.

SO Bioorganic & Medicinal Chemistry Letters (2007), 17(15), 4144-4149  
CODEN: BMCLE8; ISSN: 0960-894X


PB Elsevier Ltd.

DT Journal

LA English

OS CASREACT 147:343462

GI



AB Y-shaped mols. bearing alkyneallylic moieties were found to be potent and selective PPAR. $\delta$ . activators. The alkyneallylic moiety was synthesized from alkyn-1-ols by hydroalumination followed by a cross-coupling reaction. Series of active compds. were obtained by stepwise changing the structure of a known PPARpan agonist into Y-shaped compds. The most active and selective compound, I, had a PPAR  $\delta$  potency of 0.13  $\mu$ M.

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN  
 TI Preparation of cyclic alkenyl compounds as PPAR. $\delta$ .  
 activators for treating various disease including diabetes and obesity  
 AN 2007:705845 CAPLUS  
 DN 147:118032  
 TI Preparation of cyclic alkenyl compounds as PPAR. $\delta$ .  
 activators for treating various disease including diabetes and obesity  
 IN Sauerberg, Per; Pihera, Pavel; Polivka, Zdenek; Havranek, Miroslav;  
 Pettersson, Ingrid; Mogensen, John Patrick  
 PA Novo Nordisk A/S, Den.  
 SO PCT Int. Appl., 216 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007071766	A2	20070628	WO 2006-EP70096	20061221
	WO 2007071766	A3	20070913		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
				EP 2005-112758	A 20051222
				EP 2006-115631	A 20060619
	AU 2006327003	A1	20070628	AU 2006-327003	20061221

			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
CA 2631390	A1	20070628	CA 2006-2631390		20061221
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
EP 1979311	A2	20081015	EP 2006-830789		20061221
			R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR		
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
JP 2009520769	T	20090528	JP 2008-546470		20061221
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
MX 2008008098	A	20080710	MX 2008-8098		20080620
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
CN 101356155	A	20090128	CN 2006-80048573		20080620
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
IN 2008DN05418	A	20080815	IN 2008-DN5418		20080623
			EP 2005-112758	A	20051222
			WO 2006-US70096	W	20061221
KR 2008078707	A	20080827	KR 2008-716288		20080704
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
US 20090093484	A1	20090409	US 2008-97564		20081023
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
OS	CASREACT 147:118032; MARPAT 147:118032				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*



AB Novel compds. of the general formula I (wherein the "large X" is a double bond, X1 is heterocyclyl, aryl, heteroaryl, etc.; X2 is (un)substituted arylene or heteroarylene; X3 is (un)substituted aryl or heteroaryl; Ar is (un)substituted arylene; Y1 is O or S; and Y2 is O, S or CH2; and Z is -(CH2)n- wherein n = 1-3; and R1 = H, halo, etc.) the use of these compds. as pharmaceuticals, pharmaceutical compns. comprising the compds. and methods of treatment employing these compds. and compns. are claimed. The present compds. are activators of PPAR. $\delta$ . and should be useful for treating conditions mediated by the same, such as diabetes, impaired glucose tolerance, insulin resistance, cardiovascular disease, etc.; no biol. data is given in the patent. Example compound II was prepared by reacting Me (Z)-[4-[3-(4-iodophenyl)-3-(4-trifluoromethylphenyl)allyloxy]-2-methylphenoxy]acetate with 2-ethynylpyridine and converting the ester obtained to the acid.

L8 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of alkynyl substituted phenoxyacetic acids as PPAR  $\delta$  agonists

AN 2005:1193203 CAPLUS  
 DN 143:459868  
 TI Preparation of alkynyl substituted phenoxyacetic acids as PPAR  
 S agonists  
 IN Havranek, Miroslav; Sauerberg, Per; Pettersson, Ingrid  
 PA Novo Nordisk A/S, Den.  
 SO PCT Int. Appl., 83 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005105725	A1	20051110	WO 2005-EP52010	20050503
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DK 2004-716	A 20040505
EP	1745002	A1	20070124	EP 2005-747382	20050503
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
				DK 2004-716	A 20040505
				WO 2005-EP52010	W 20050503
JP	2007536340	T	20071213	JP 2007-512186	20050503
				DK 2004-716	A 20040505
				WO 2005-EP52010	W 20050503
US	20080114036	A1	20080515	US 2007-579303	20071010
				DK 2004-716	A 20040505
				WO 2005-EP52010	W 20050503
OS	CASREACT 143:459868; MARPAT 143:459868				
GI					



AB The title compds. I [X1 = aryl, heteroaryl, alkyl, etc.; X2 = aryl, heteroaryl, H, etc.; X3 = arylene, heteroarylene; Ar = arylene; Y1 = O, S; Y2 = O, S; Z = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; R1 = H, halo, alkyl, etc.; R2 = H, alkyl, cycloalkyl, etc.] which are useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPAR. $\delta$ . subtype, namely, type 1 diabetes, type 2 diabetes, dyslipidemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hypertriglyceridemia and/or obesity), cardiovascular diseases (including atherosclerosis) and hypercholesterolemia (no data), were prepared and formulated. E.g., a multi-step synthesis of II, starting from 4-bromobenzaldehyde, was given.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
29.40	286.74

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-5.74	-5.74

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 07:51:23 ON 29 OCT 2009

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40  
minutes  
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source  
(CS) field  
NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced  
NEWS 5 AUG 24 CA/CAPLUS enhanced with legal status information for  
U.S. patents  
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in  
CAS REGISTRY  
NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM  
thesaurus  
NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and  
Taiwanese Content Expanded  
NEWS 9 OCT 21 Derwent World Patents Index enhanced with human  
translated claims for Chinese Applications and  
Utility Models  
NEWS 10 NOV 23 Addition of SCAN format to selected STN databases  
NEWS 11 NOV 23 Annual Reload of IFI Databases  
NEWS 12 DEC 01 FRFULL Content and Search Enhancements  
NEWS 13 DEC 01 DGENE, USGENE, and PCTGEN: new percent identity  
feature for sorting BLAST answer sets  
NEWS 14 DEC 02 Derwent World Patent Index: Japanese FI-TERM  
thesaurus added  
NEWS 15 DEC 02 PCTGEN enhanced with patent family and legal status  
display data from INPADOCDB  
NEWS 16 DEC 02 USGENE: Enhanced coverage of bibliographic and  
sequence information  
NEWS 17 DEC 21 New Indicator Identifies Multiple Basic Patent  
Records Containing Equivalent Chemical Indexing  
in CA/CAPLUS  
NEWS 18 JAN 12 Match STN Content and Features to Your Information  
Needs, Quickly and Conveniently

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN customer  
agreement. This agreement limits use to scientific research. Use  
for software development or design, implementation of commercial  
gateways, or use of CAS and STN data in the building of commercial  
products is prohibited and may result in loss of user privileges  
and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 06:06:50 ON 19 JAN 2010

=> file reg  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.22	0.22

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 06:07:14 ON 19 JAN 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JAN 2010 HIGHEST RN 1202459-43-5  
DICTIONARY FILE UPDATES: 17 JAN 2010 HIGHEST RN 1202459-43-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary  
files\10575122\10575122 responsive elected specie.str



chain nodes :  
13 14 15 16 17 18 19 20 21 22 29  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12 23 24 25 26 27 28  
chain bonds :  
6-7 10-13 13-14 13-15 14-16 16-17 17-23 18-21 18-19 18-20 18-29 21-22  
26-29  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 23-24 23-28  
24-25 25-26 26-27 27-28  
exact/norm bonds :  
16-17 17-23 18-29 26-29

exact bonds :

6-7 10-13 13-14 13-15 14-16 18-21 18-19 18-20 21-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 23-24 23-28  
24-25 25-26 26-27 27-28

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS  
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom  
28:Atom 29:CLASS

L1 STRUCTURE UPLOADED


=> dl1

L2 72 DL1

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> search l1 sss sam

SAMPLE SEARCH INITIATED 06:08:20 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 4 TO 200

PROJECTED ANSWERS: 0 TO 0

L3 0 SEA SSS SAM L1


=> search l1 exact full  
FULL SEARCH INITIATED 06:08:37 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 42 TO ITERATE

100.0% PROCESSED 42 ITERATIONS 3 ANSWERS  
SEARCH TIME: 00.00.01

L4 3 SEA EXA FUL L1

=> d scan

L4 3 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[4-[(3-[1,1'-biphenyl]-4-yl-2-buten-1-yl)oxy]phenoxy]-2-methyl-  
MF C27 H28 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L4 3 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[4-[[ (2E)-3-[1,1'-biphenyl]-4-yl-2-buten-1-yl]oxy]phenoxy]-2-methyl-, (2S)-  
MF C27 H28 O4  
CI COM

Absolute stereochemistry. Rotation (-).  
Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 3 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[4-[[ (2E)-3-[1,1'-biphenyl]-4-yl-2-buten-1-yl]oxy]phenoxy]-2-methyl-, (2R)-  
MF C27 H28 O4

CI COM

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
71.47	71.69

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 06:09:13 ON 19 JAN 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Jan 2010 VOL 152 ISS 4  
FILE LAST UPDATED: 18 Jan 2010 (20100118/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l4

L5 1 L4

=> d l5 1 ti fbib abs it



L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists  
 and inhibitors of HMG CoA reductase  
 AN 2005:395261 CAPLUS  
 DN 142:446999  
 TI Preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists  
 and inhibitors of HMG CoA reductase  
 IN Gurram, Ranga Madhavan; Bhuniya, Debnath; Das, Saibal Kumar; Chakrabarti,  
 Ranjan; Iqbal, Javed; Sharma, Sudhir Kumar  
 PA Reddy's Laboratories Ltd., India  
 SO PCT Int. Appl., 115 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040104	A1	20050506	WO 2004-IB208	20040129
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				WO 2003-IB4741	A 20031028
IN	2002MA00792	A	20050304	IN 2002-MA792	20021028
				WO 2003-IB4741	A 20031028
AU	2004283147	A1	20050506	AU 2004-283147	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
CA	2538630	A1	20050506	CA 2004-2538630	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
EP	1678128	A1	20060712	EP 2004-706247	20040129
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
BR	2004014554	A	20061107	BR 2004-14554	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
CN	1867546	A	20061122	CN 2004-80030239	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
JP	2007509921	T	20070419	JP 2006-537450	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
MX	2006003019	A	20060623	MX 2006-3019	20060316
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
NO	2006001310	A	20060728	NO 2006-1310	20060323
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
ZA	2006002491	A	20080528	ZA 2006-2491	20060327
				WO 2003-IB4741	A 20031028
US	20070043035	A1	20070222	US 2006-575122	20060407
				WO 2003-IB4741	A 20031028

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:446999; MARPAT 142:446999

GI



AB Title compds. I [Ar = (un)substituted single or fused-aryl, -heteroaryl, -heterocycle; R1 and R2 independently = H, halo, nitro, etc.; R3 and R4 independently = H, (un)substituted-alkyl, -cycloalkyl, etc.; X = O, S, NR; R = H, (un)substituted-aryl, -alkanoyl, etc.; Z = O, S, NR; R5, R6, and R7 independently = H, OH, (un)substituted alkoxy, etc.; R5 and R6 together = 5- or 6-membered ring containing one or two hetero atoms selected from O, S, or N; Y = O, NR11; R11 = H, (un)substituted-heteroaryl, -aroyl, etc.; R7 and R11 together = 5- or 6-membered ring containing one or two hetero atoms selected from O, S, or N] and their pharmaceutically acceptable salts are prepared and disclosed as useful agonists of PPAR- $\alpha$  and PPAR- $\gamma$  and inhibitors of HMG CoA reductase. Thus, e.g., II was prepared by Wittig-Horner reaction of 4-acetyl biphenyl with tri-Et phosphonoacetate followed by reduction and Mitsunobu reaction with Et 2-(4-hydroxyphenoxy)-2-methylpropanoate. The activity of I was evaluated in vivo utilizing hypercholesterolemic rat models and it was revealed that a selected compound of the invention displayed a cholesterol lowering effect of 60%, a triglyceride lowering effect of 52%, as well as an increase in HDL of 70%. I as agonists of PPAR- $\alpha$  and PPAR- $\gamma$  should prove useful in the treatment of diseases such as diabetes and dyslipidemia. Pharmaceutical compns. comprising I are disclosed.

IT Drug delivery systems

(capsules; preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase)

IT Drug delivery systems

(powders; preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase)

IT Anticholesteremic agents

Antidiabetic agents

Crystal structure

Diabetes mellitus

Human

Molecular structure

Peroxisome proliferators

Dyslipidemia

RL: BIOL (Biological study)

(preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase)

IT Drug delivery systems

(solns.; preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase)

IT Drug delivery systems

(suspensions; preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase)

IT Drug delivery systems

(syrups; preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase)

IT Drug delivery systems

(tablets; preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase)

IT Peroxisome proliferator-activated receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

( $\alpha$ ; preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase)

IT Peroxisome proliferator-activated receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

( $\gamma$ ; preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase)

IT 851297-00-2P

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(crystal structure; preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase)

IT 9028-35-7, HMG CoA reductase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase)

IT 851296-37-2P 851296-38-3P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase)

IT 851295-83-5P 851295-84-6P 851295-85-7P 851295-86-8P 851295-87-9P

851295-88-0P 851295-89-1P 851295-90-4P 851295-91-5P 851295-92-6P

851295-93-7P 851295-94-8P 851295-96-0P 851295-98-2P 851296-00-9P

851296-02-1P 851296-04-3P 851296-05-4P 851296-07-6P 851296-09-8P

851296-10-1P 851296-11-2P 851296-12-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase)

IT 851296-13-4P 851296-14-5P 851296-15-6P 851296-16-7P 851296-17-8P

851296-18-9P 851296-19-0P 851296-20-3P 851296-21-4P 851296-22-5P

851296-23-6P 851296-24-7P 851296-25-8P 851296-26-9P

851296-27-0P 851296-28-1P 851296-29-2P 851296-30-5P 851296-31-6P

851296-32-7P 851296-33-8P 851296-34-9P 851296-35-0P 851296-36-1P

851296-39-4P 851296-40-7P 851296-41-8P 851296-42-9P 851296-43-0P

851296-44-1P 851296-45-2P 851296-46-3P 851296-47-4P 851296-48-5P

851296-49-6P 851296-50-9P 851296-51-0P 851296-52-1P 851296-53-2P

851296-54-3P 851296-55-4P 851296-56-5P 851296-57-6P 851296-58-7P

851296-59-8P 851296-60-1P 851296-61-2P 851296-62-3P 851296-63-4P  
 851296-64-5P 851296-65-6P 851296-66-7P 851296-67-8P 851296-68-9P  
 851296-69-0P 851296-70-3P 851296-71-4P 851296-72-5P 851296-73-6P  
 851296-74-7P 851296-75-8P 851296-76-9P 851296-77-0P 851296-78-1P  
 851296-79-2P 851296-80-5P 851296-81-6P 851296-82-7P 851296-83-8P  
 851296-84-9P 851296-85-0P 851296-86-1P 851296-87-2P 851296-88-3P  
 851296-89-4P 851296-90-7P 851296-91-8P 851296-92-9P 851296-94-1P  
 851296-95-2P 851296-96-3P 851296-97-4P 851296-98-5P 851297-44-4P  
 851297-46-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists  
 and inhibitors of HMG CoA reductase)

IT 92-91-1, 4-Acetyl biphenyl 402-43-7 460-00-4, 1-Bromo-4-fluorobenzene  
 867-13-0, Triethyl phosphonoacetate 19752-55-7 20989-17-7 42806-90-6  
 56613-80-0 87199-17-5 149104-90-5, 4-Acetylphenylboronic acid  
 471907-19-4 672931-60-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists  
 and inhibitors of HMG CoA reductase)

IT 720-74-1P 52506-53-3P 58038-55-4P 610781-46-9P 851296-99-6P  
 851297-01-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists  
 and inhibitors of HMG CoA reductase)

IT 9004-10-8, Insulin, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (resistance; preparation of phenoxyalkanoates as PPAR- $\alpha$  and  
 PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase)

IT 50-99-7, D-Glucose, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (tolerance impaired; preparation of phenoxyalkanoates as PPAR- $\alpha$  and  
 PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase)

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	6.49	78.18
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.85	-0.85

FILE 'REGISTRY' ENTERED AT 06:12:51 ON 19 JAN 2010  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JAN 2010 HIGHEST RN 1202459-43-5  
 DICTIONARY FILE UPDATES: 17 JAN 2010 HIGHEST RN 1202459-43-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10575122\10575122 1st stab.str



chain nodes :  
13 14 15 16 17 18 19 26  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12 20 21 22 23 24 25  
chain bonds :  
6-7 10-13 13-14 13-15 14-16 16-17 17-20 18-26 18-19 23-26  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 20-21 20-25  
21-22 22-23 23-24 24-25  
exact/norm bonds :  
16-17 17-20 18-26 23-26  
exact bonds :  
6-7 10-13 13-14 13-15 14-16 18-19  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 20-21 20-25  
21-22 22-23 23-24 24-25

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS  
19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS

L6 STRUCTURE UPLOADED

=> d 16

L6 HAS NO ANSWERS

L6 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> search 16 sss sam
SAMPLE SEARCH INITIATED 06:13:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -          37 TO ITERATE


100.0% PROCESSED          37 ITERATIONS          1 ANSWERS
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   376 TO    1104
PROJECTED ANSWERS:      1 TO      80
```

```
L7          1 SEA SSS SAM L6
```

```
=> d scan
```

```
L7  1 ANSWERS  REGISTRY  COPYRIGHT 2010 ACS on STN
IN  Propanoic acid, 2-methyl-2-[4-[[3-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-buten-1-yl]oxy]phenoxy]-
MF  C27 H25 F3 O4
```



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.98	79.16
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.85

FILE 'CAPLUS' ENTERED AT 06:14:08 ON 19 JAN 2010  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Jan 2010 VOL 152 ISS 4  
 FILE LAST UPDATED: 18 Jan 2010 (20100118/ED)  
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009  
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> 17

L8 1 L7

=> d 18

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN  
 AN 2005:395261 CAPLUS  
 DN 142:446999  
 TI Preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase  
 IN Gurram, Ranga Madhavan; Bhuniya, Debnath; Das, Saibal Kumar; Chakrabarti, Ranjan; Iqbal, Javed; Sharma, Sudhir Kumar  
 PA Reddy's Laboratories Ltd., India  
 SO PCT Int. Appl., 115 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI WO 2005040104 A1 20050506 WO 2004-IB208 20040129  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 IN 2002MA00792 A 20050304 IN 2002-MA792 20021028  
 AU 2004283147 A1 20050506 AU 2004-283147 20040129  
 CA 2538630 A1 20050506 CA 2004-2538630 20040129  
 EP 1678128 A1 20060712 EP 2004-706247 20040129  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR 2004014554 A 20061107 BR 2004-14554 20040129  
 CN 1867546 A 20061122 CN 2004-80030239 20040129  
 JP 2007509921 T 20070419 JP 2006-537450 20040129  
 MX 2006003019 A 20060623 MX 2006-3019 20060316  
 NO 2006001310 A 20060728 NO 2006-1310 20060323  
 ZA 2006002491 A 20080528 ZA 2006-2491 20060327  
 US 20070043035 A1 20070222 US 2006-575122 20060407  
 PRAI WO 2003-IB4741 A 20031028  
 WO 2004-IB208 W 20040129

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:446999; MARPAT 142:446999

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.80	80.96
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.85

FILE 'REGISTRY' ENTERED AT 06:14:38 ON 19 JAN 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JAN 2010 HIGHEST RN 1202459-43-5

DICTIONARY FILE UPDATES: 17 JAN 2010 HIGHEST RN 1202459-43-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of

experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>


=> search 16 sss full  
FULL SEARCH INITIATED 06:15:03 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 739 TO ITERATE

100.0% PROCESSED 739 ITERATIONS 18 ANSWERS  
SEARCH TIME: 00.00.01

L9 18 SEA SSS FUL L6

=> d scan


L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Propanoic acid, 2-[4-[[3-(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
MF C26 H24 Cl2 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20


L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Propanoic acid, 2-methyl-2-[4-[[3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-buten-1-yl]oxy]phenoxy]-  
MF C27 H25 F3 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[4-[(3-[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenoxy]-3-methyl-  
MF C27 H26 O4


MF C27 H28 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[4-[[2-methyl-3-phenyl-2-propenyl]oxy]phenoxy]-2-methyl-, (2S)-  
MF C27 H28 O4  
CI COM


Absolute stereochemistry. Rotation (-).  
Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[4-[[2-methyl-3-phenyl-2-propenyl]oxy]phenoxy]-2-methyl-, (2R)-  
MF C27 H28 O4  
CI COM


Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN

IN Butanoic acid, 2-[4-[[3-(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
MF C27 H26 Cl2 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-methyl-2-[4-[[3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-buten-1-yl]oxy]phenoxy]-  
MF C28 H27 F3 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[4-[[3-(4'-fluoro[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-, (2S)-  
MF C27 H27 F O4


Absolute stereochemistry.  
Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-methyl-2-[4-[[3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-buten-1-yl]oxy]phenoxy]-, (2S)-  
MF C28 H27 F3 O4


Absolute stereochemistry.  
Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[4-[[3-(4'-fluoro[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-, (2R)-  
MF C27 H27 F O4


Absolute stereochemistry.  
Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-methyl-2-[4-[[3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-buten-1-yl]oxy]phenoxy]-, (2R)-  
MF C28 H27 F3 O4


Absolute stereochemistry.  
Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[4-[[2-methyl-2-[(4-(trifluoromethyl)phenyl)phenyl]but-2-en-1-yl]oxy]phenoxy]-2-methyl-, (2R)-, compd. with (βR)-β-aminobenzeneethanol (1:1) (9CI)  
MF C27 H28 O4 . C8 H11 N O  
CM 1

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.




CM 2

Absolute stereochemistry. Rotation (-).




L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[4-[[2-methyl-2-[(4-phenylphenyl)phenyl]but-2-en-1-yl]oxy]phenoxy]-2-methyl-, (2S)-, compd. with (βS)-β-aminobenzeneethanol (1:1) (9CI)  
MF C27 H28 O4 . C8 H11 N O  
CM 1

Absolute stereochemistry. Rotation (-).  
Double bond geometry as shown.




CM 2

Absolute stereochemistry. Rotation (+).




L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Propanoic acid, 2-[4-[(2Z)-3-[1,1'-biphenyl]-4-yl-4-methyl-2-penten-1-yl]oxy]phenoxy]-2-methyl-  
MF C28 H30 O4

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Propanoic acid, 2-[4-[(3-[1,1'-biphenyl]-4-yl-2-buten-1-yl)oxy]phenoxy]-2-methyl-  
MF C26 H26 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-[4-[[3-(4'-fluoro[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
 MF C26 H25 F O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-[4-[[3-(4'-fluoro[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
 MF C27 H27 F O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L9 18 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-[4-[(3-[1,1'-biphenyl]-4-yl-2-buten-1-yl)oxy]phenoxy]-2-methyl-  
 MF C27 H28 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	192.03	272.99
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.85

FILE 'CAPLUS' ENTERED AT 06:15:43 ON 19 JAN 2010  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Jan 2010 VOL 152 ISS 4  
 FILE LAST UPDATED: 18 Jan 2010 (20100118/ED)  
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009  
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> 19  
 L10 1 L9

=> d 110

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN  
 AN 2005:395261 CAPLUS  
 DN 142:446999  
 TI Preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase  
 IN Gurram, Ranga Madhavan; Bhuniya, Debnath; Das, Saibal Kumar; Chakrabarti, Ranjan; Iqbal, Javed; Sharma, Sudhir Kumar  
 PA Reddy's Laboratories Ltd., India  
 SO PCT Int. Appl., 115 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040104	A1	20050506	WO 2004-IB208	20040129
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 IN 2002MA00792 A 20050304 IN 2002-MA792 20021028  
 AU 2004283147 A1 20050506 AU 2004-283147 20040129  
 CA 2538630 A1 20050506 CA 2004-2538630 20040129  
 EP 1678128 A1 20060712 EP 2004-706247 20040129  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR 2004014554 A 20061107 BR 2004-14554 20040129  
 CN 1867546 A 20061122 CN 2004-80030239 20040129  
 JP 2007509921 T 20070419 JP 2006-537450 20040129  
 MX 2006003019 A 20060623 MX 2006-3019 20060316  
 NO 2006001310 A 20060728 NO 2006-1310 20060323  
 ZA 2006002491 A 20080528 ZA 2006-2491 20060327  
 US 20070043035 A1 20070222 US 2006-575122 20060407  
 PRAI WO 2003-IB4741 A 20031028  
 WO 2004-IB208 W 20040129

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:446999; MARPAT 142:446999

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
2.30	275.29

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-0.85

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 06:16:58 ON 19 JAN 2010

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
 SESSION RESUMED IN FILE 'CAPLUS' AT 06:46:12 ON 19 JAN 2010  
 FILE 'CAPLUS' ENTERED AT 06:46:12 ON 19 JAN 2010  
 COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
2.30	275.29

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.85

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.30	275.29

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.85

FILE 'REGISTRY' ENTERED AT 06:46:25 ON 19 JAN 2010  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JAN 2010 HIGHEST RN 1202459-43-5  
 DICTIONARY FILE UPDATES: 17 JAN 2010 HIGHEST RN 1202459-43-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.



Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary  
 files\10575122\10575122 broader claim 1 generic.str



```

chain nodes :
7 8 9 10 11 12 13 14 15 16 23
ring nodes :
1 2 3 4 5 6
chain bonds :
6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14 14-15 15-16 15-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-8 9-10 10-11 11-12 12-13 13-14 15-16 15-23
exact bonds :
6-7 8-9 14-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

G1:O,S,N

G2:O,N

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 23:CLASS


```

L11 STRUCTURE UPLOADED

=> d l11

L11 HAS NO ANSWERS

L11 STR



G1 O,S,N

G2 O,N

Structure attributes must be viewed using STN Express query preparation.

=> search l11 sss sam

SAMPLE SEARCH INITIATED 06:47:11 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 223089 TO ITERATE

0.9% PROCESSED 2000 ITERATIONS

16 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*

BATCH \*\*INCOMPLETE\*\*

PROJECTED ITERATIONS: 4434001 TO 4489559

PROJECTED ANSWERS: 33160 TO 38228

L12 16 SEA SSS SAM L11

=> d scan

L12 16 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN

IN L-Phenylalanine, N-[N-[N-[N2-[3,5-bis[ [N-[N-[N-(N2-benzoyl-L-arginyl)glycyl]-L- $\alpha$ -aspartyl]-L-phenylalanyl]amino]cyclohexyl]carbonyl]-L-arginyl]glycyl]-L- $\alpha$ -aspartyl]- (9CI)


SQL 13,9,4

MF C84 H109 N23 O22


\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):26


L12 16 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN

IN Benzenepropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy)carbonyl]amino]-  
 $\alpha$ -[[[(1S,3R,4R,5R)-1,3,4-tris(acetyloxy)-5-[[3-[3,4-  
bis(acetyloxy)phenyl]-1-oxo-2-propen-1-yl]oxy]cyclohexyl]carbonyl]oxy]-,  
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-  
2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-  
tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl  
ester, ( $\alpha$ R, $\beta$ S)-


MF C69 H79 N O27

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A




PAGE 1-B



L12 16 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN


IN Benzamide, N-[2-(3-bromophenyl)-1-[[[3-[[2-(1H-indol-6-ylamino)-2-  
oxoethyl]thio]phenyl]amino]carbonyl]ethenyl]-

MF C32 H25 Br N4 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 16 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C29 H25 Br N4 O3 S2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 16 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C38 H38 N4 O7 S2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 16 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Benzeneacetamide,  $\alpha$ -[[3-[[2-(benzoylamino)-3-[4-(dimethylamino)phenyl]-1-oxo-2-propen-1-yl]amino]phenyl]thio]-N-4-pyridinyl-  
 MF C37 H33 N5 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 16 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Benzamide, N-[2-(2,6-dichlorophenyl)-1-[[[3-[[2-[[4-(4-methoxyphenyl)-2-thiazolyl]amino]-2-oxoethyl]thio]phenyl]amino]carbonyl]ethenyl]-  
 MF C34 H26 Cl2 N4 O4 S2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 16 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C33 H31 N3 O4 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 16 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Benzeneacetamide, 4-chloro-N-[3-[[1-[[[3-cyano-4-(4-methylphenyl)-2-thienyl]amino]carbonyl]propyl]thio]phenyl]-  
 MF C30 H26 Cl N3 O2 S2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 16 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Benzeneacetamide, N-[3-[[1-[[4-(aminosulfonyl)phenyl]amino]carbonyl]propyl]thio]phenyl]-4-chloro-  
 MF C24 H24 Cl N3 O4 S2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 16 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C37 H36 N4 O7 S2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 16 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C32 H26 Cl3 N3 O4 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L12 16 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Benzoic acid, 4-[[2-[[4-[[2-(4-chlorophenyl)acetyl]amino]phenyl]thio]-2-phenylacetyl]amino]-, butyl ester  
 MF C33 H31 Cl N2 O4 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L12 16 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN L-Glutamic acid, N-[3-[4-(methoxycarbonyl)-4-[(1-oxo-3-phenylpropyl)amino]-1-piperidinyl]-1-oxo-2-phenylpropyl]-, 1-(phenylmethyl) ester  
 MF C37 H43 N3 O8  
 CI COM

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 16 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Benzeneacetamide, N-[5-[[2-[[2-chloro-5-(trifluoromethyl)phenyl]amino]-2-oxoethyl]thio]-1,3,4-thiadiazol-2-yl]-4-methoxy-  
 MF C20 H16 Cl F3 N4 O3 S2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 16 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN 2-Propenamide, N-[4-[(2-amino-2-oxoethyl)amino]-1-[2-(2-fluorophenyl)ethyl]-1,2,3,4-tetrahydro-3-methoxy-2-oxo-6-quinolinyll]-2-methyl-3-phenyl-  
 MF C30 H31 F N4 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> search l11 sss full

FULL SEARCH INITIATED 06:49:25 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4468242 TO ITERATE

29.4% PROCESSED	1315888 ITERATIONS	2754 ANSWERS
-----------------	--------------------	--------------

41.8% PROCESSED	1868154 ITERATIONS	3336 ANSWERS
-----------------	--------------------	--------------

44.4% PROCESSED	1984597 ITERATIONS	3363 ANSWERS
-----------------	--------------------	--------------

44.8% PROCESSED	2000000 ITERATIONS	3366 ANSWERS
-----------------	--------------------	--------------

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.53

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*

BATCH \*\*INCOMPLETE\*\*

PROJECTED ITERATIONS: 4468242 TO 4468242

PROJECTED ANSWERS: 7260 TO 7780

L13 3366 SEA SSS FUL L11

=> save temp l13 masterset/a

ANSWER SET L13 HAS BEEN SAVED AS 'MASTERSET/A'

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	194.97	470.26
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.85

FILE 'CAPLUS' ENTERED AT 06:51:09 ON 19 JAN 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Jan 2010 VOL 152 ISS 4

FILE LAST UPDATED: 18 Jan 2010 (20100118/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

Caplus now includes complete International Patent Classification (IPC)

reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> diabetes

L14 171385 DIABETES

=> l13

L15 247 L13

=> l14 and l15

L16 28 L14 AND L15

=> d l16 18-28 ti

L16 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of aryl compounds as ligands for peroxisome proliferator-activated receptors

L16 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

TI Design and Synthesis of Conformationally Constrained Glucagon-Like Peptide-1 Derivatives with Increased Plasma Stability and Prolonged in Vivo Activity

L16 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of substituted aniline derivatives as antifungal agents

L16 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of amino(aroyl or heteroaroyl)pyridinones, particularly amino acid derivatives of pyridin-2-ones, as inhibitors of p38 MAP kinase useful for treating inflammatory and autoimmune diseases

L16 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

TI GLP-1 analogs metabolic disorders and increasing for treating metabolic disorders and increasing insulin secretion

L16 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

TI Synthesis of phenyloxy isobutyric acid derivatives and their antidiabetic activity in vitro

L16 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of cyclic alkenyl compounds as PPAR $\delta$  activators for treating various disease including diabetes and obesity

L16 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

TI MAO-B inhibitors useful for treating obesity

L16 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of amino acid aryl or heteroaryl derivatives as glycogen phosphorylase inhibitors

L16 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of alkynyl substituted phenoxyacetic acids as PPAR $\delta$  agonists

L16 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of N-bicycyl-3-[[ (hetero)arylsulfonyl]amino]-3-

(hetero)arylpropionamides as bradykinin receptor modulators for treatment of pain, inflammation, and other conditions

=> d 116 23 , 24 ti fbib abs

L16 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Synthesis of phenyloxy isobutyric acid derivatives and their antidiabetic activity in vitro  
AN 2007:723007 CAPLUS  
DN 148:205299  
TI Synthesis of phenyloxy isobutyric acid derivatives and their antidiabetic activity in vitro  
AU Zeng, Qingle; Wang, Heqing; Luo, Huan; Gao, Xiaoping; Liu, Zhongrong; Li, Bogang; Wang, Fengpeng; Zhao, Yufen  
CS Department of Chemistry, Xiamen University, Xiamen, 361005, Peop. Rep. China  
SO Yaoxue Xuebao (2006), 41(2), 108-114  
CODEN: YHHPAL; ISSN: 0513-4870  
PB Yaoxue Xuebao Bianjibu  
DT Journal  
LA English  
OS CASREACT 148:205299  
AB The objective was to design and synthesize new phenyloxy isobutyric acid analogs as antidiabetic compds. Eight new target compds. were synthesized by combination of lipophilic moieties and acidic moiety with nucleophilic replacement or Mitsunobu condensation. The eight compds. were confirmed by <sup>1</sup>H NMR, <sup>13</sup>C NMR, IR and MS. In vitro insulin-sensitizing activity (3T3-L1 adipocyte) demonstrated, that the cultured glucose concentration of up-clear solution detected with GOD-POD assay were 5.942, 6.339, 6.226 and 6.512 mmol·L<sup>-1</sup>, resp., when rosiglitazone, pioglitazone, compds. A and B were added to the insulin-resistant system. In vitro insulin-sensitizing activity of target compound A is in between that of rosiglitazone and pioglitazone, and activity of target compound B is slightly less than that of pioglitazone.  
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Preparation of cyclic alkenyl compounds as PPAR $\delta$  activators for treating various disease including diabetes and obesity  
AN 2007:705845 CAPLUS  
DN 147:118032  
TI Preparation of cyclic alkenyl compounds as PPAR $\delta$  activators for treating various disease including diabetes and obesity  
IN Sauerberg, Per; Pihera, Pavel; Polivka, Zdenek; Havranek, Miroslav; Pettersson, Ingrid; Mogensen, John Patrick  
PA Novo Nordisk A/S, Den.  
SO PCT Int. Appl., 216 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2007071766	A2	20070628	WO 2006-EP70096	20061221
	WO 2007071766	A3	20070913		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,				

MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,  
 RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,  
 TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
AU 2006327003	A1	20070628	AU 2006-327003		20061221
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
CA 2631390	A1	20070628	CA 2006-2631390		20061221
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
EP 1979311	A2	20081015	EP 2006-830789		20061221
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
	IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
JP 2009520769	T	20090528	JP 2008-546470		20061221
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
MX 2008008098	A	20080710	MX 2008-8098		20080620
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
CN 101356155	A	20090128	CN 2006-80048573		20080620
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
IN 2008DN05418	A	20080815	IN 2008-DN5418		20080623
			EP 2005-112758	A	20051222
			WO 2006-US70096	W	20061221
KR 2008078707	A	20080827	KR 2008-716288		20080704
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
US 20090093484	A1	20090409	US 2008-97564		20081023
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 147:118032; MARPAT 147:118032

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Novel compds. of the general formula I (wherein the "large X" is a double bond, X1 is heterocyclyl, aryl, heteroaryl, etc.; X2 is (un)substituted arylene or heteroarylene; X3 is (un)substituted aryl or heteroaryl; Ar is (un)substituted arylene; Y1 is O or S; and Y2 is O, S or CH2; and Z is -(CH2)n- wherein n = 1-3; and R1 = H, halo, etc.) the use of these compds. as pharmaceuticals, pharmaceutical compns. comprising the compds. and

methods of treatment employing these compds. and compns. are claimed. The present compds. are activators of PPAR $\delta$  and should be useful for treating conditions mediated by the same, such as diabetes, impaired glucose tolerance, insulin resistance, cardiovascular disease, etc.; no biol. data is given in the patent. Example compound II was prepared by reacting Me (Z)-[4-[3-(4-iodophenyl)-3-(4-trifluoromethylphenyl)allyloxy]-2-methylphenoxy]acetate with 2-ethynylpyridine and converting the ester obtained to the acid.

=> d 116 24-28 ti fbib abs

L16 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of cyclic alkenyl compounds as PPAR $\delta$  activators for treating various disease including diabetes and obesity  
 AN 2007:705845 CAPLUS  
 DN 147:118032  
 TI Preparation of cyclic alkenyl compounds as PPAR $\delta$  activators for treating various disease including diabetes and obesity  
 IN Sauerberg, Per; Pihera, Pavel; Polivka, Zdenek; Havranek, Miroslav; Pettersson, Ingrid; Mogensen, John Patrick  
 PA Novo Nordisk A/S, Den.  
 SO PCT Int. Appl., 216 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007071766	A2	20070628	WO 2006-EP70096	20061221
	WO 2007071766	A3	20070913		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
				EP 2005-112758	A 20051222
				EP 2006-115631	A 20060619
AU	2006327003	A1	20070628	AU 2006-327003	20061221
				EP 2005-112758	A 20051222
				EP 2006-115631	A 20060619
				WO 2006-EP70096	W 20061221
CA	2631390	A1	20070628	CA 2006-2631390	20061221
				EP 2005-112758	A 20051222
				EP 2006-115631	A 20060619
				WO 2006-EP70096	W 20061221
EP	1979311	A2	20081015	EP 2006-830789	20061221
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
				EP 2005-112758	A 20051222
				EP 2006-115631	A 20060619
				WO 2006-EP70096	W 20061221
JP	2009520769	T	20090528	JP 2008-546470	20061221
				EP 2005-112758	A 20051222
				EP 2006-115631	A 20060619

MX 2008008098	A	20080710	WO 2006-EP70096	W	20061221
			MX 2008-8098		20080620
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
CN 101356155	A	20090128	WO 2006-EP70096	W	20061221
			CN 2006-80048573		20080620
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
IN 2008DN05418	A	20080815	WO 2006-EP70096	W	20061221
			IN 2008-DN5418		20080623
			EP 2005-112758	A	20051222
KR 2008078707	A	20080827	WO 2006-US70096	W	20061221
			KR 2008-716288		20080704
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
US 20090093484	A1	20090409	WO 2006-EP70096	W	20061221
			US 2008-97564		20081023
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 147:118032; MARPAT 147:118032

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Novel compds. of the general formula I (wherein the "large X" is a double bond, X1 is heterocyclyl, aryl, heteroaryl, etc.; X2 is (un)substituted arylene or heteroarylene; X3 is (un)substituted aryl or heteroaryl; Ar is (un)substituted arylene; Y1 is O or S; and Y2 is O, S or CH<sub>2</sub>; and Z is -(CH<sub>2</sub>)<sub>n</sub>- wherein n = 1-3; and R1 = H, halo, etc.) the use of these compds. as pharmaceuticals, pharmaceutical compns. comprising the compds. and methods of treatment employing these compds. and compns. are claimed. The present compds. are activators of PPAR $\delta$  and should be useful for treating conditions mediated by the same, such as diabetes, impaired glucose tolerance, insulin resistance, cardiovascular disease, etc.; no biol. data is given in the patent. Example compound II was prepared by reacting Me (Z)-[4-[3-(4-iodophenyl)-3-(4-trifluoromethylphenyl)allyloxy]-2-methylphenoxy]acetate with 2-ethynylpyridine and converting the ester obtained to the acid.

L16 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

TI MAO-B inhibitors useful for treating obesity

AN 2006:1285878 CAPLUS

DN 146:39059

TI MAO-B inhibitors useful for treating obesity

IN McElroy, John F.; Chorvat, Robert J.

PA Rajagopalan, Parthasarathi, India

SO PCT Int. Appl., 138 pp.

CODEN: PIXXD2

DT Patent

LA English



FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2006130707	A2	20061207	WO 2006-US21142	20060601
	WO 2006130707	A3	20070118		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,			

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,  
 KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,  
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,  
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
 VN, YU, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM

AU 2006252540	A1	20061207	US 2005-686585P	P	20050602
			AU 2006-252540		20060601
			US 2005-686585P	P	20050602
			WO 2006-US21142	W	20060601
CA 2620476	A1	20061207	CA 2006-2620476		20060601
			US 2005-686585P	P	20050602
			WO 2006-US21142	W	20060601
US 20070088004	A1	20070419	US 2006-445044		20060601
			US 2005-686585P	P	20050602
EP 1890690	A2	20080227	EP 2006-771748		20060601
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
	IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
			US 2005-686585P	P	20050602
			WO 2006-US21142	W	20060601
JP 2008542386	T	20081127	JP 2008-514814		20060601
			US 2005-686585P	P	20050602
			WO 2006-US21142	W	20060601
NZ 564130	A	20091224	NZ 2006-564130		20060601
			US 2005-686585P	P	20050602
			WO 2006-US21142	W	20060601
IN 2007DN09905	A	20080125	IN 2007-DN9905		20071220
			US 2005-686585P	P	20050602
			WO 2006-US21142	W	20060601
ZA 2008000036	A	20081231	ZA 2008-36		20080102
			US 2005-686585P	P	20050602
CN 101300006	A	20081105	CN 2006-80027303		20080125
			US 2005-686585P	P	20050602
			WO 2006-US21142	W	20060601

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OS MARPAT 146:39059  
 GI



AB The invention provides novel compds. of formulas I and II, both of which are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance).

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of amino acid aryl or heteroaryl derivatives as glycogen  
 phosphorylase inhibitors  
 AN 2006:469629 CAPLUS  
 DN 144:488936  
 TI Preparation of amino acid aryl or heteroaryl derivatives as glycogen  
 phosphorylase inhibitors  
 IN Evans, Karen; Cichy-Knight, Maria; Coppo, Frank Teen; Dwornik, Kate Ann;  
 Gale, Jennifer Paul; Garrido, Dulce Maria; Li, Yue Hu; Patel, Mehul P.;  
 Tavares, Francis X.; Thomson, Stephen Andrew; Dickerson, Scott Howard;  
 Peat, Andrew James; Sparks, Steven Meagher; Banker, Pierette; Cooper, Joel  
 P.  
 PA Smithkline Beecham Corporation, USA  
 SO PCT Int. Appl., 681 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006052722	A1	20060518	WO 2005-US39956	20051104
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005304962	A1	20060518	US 2004-626389P	P 20041109
	AU 2005304962	B2	20091119	AU 2005-304962	20051104
				US 2004-626389P	P 20041109
				WO 2005-US39956	W 20051104
CA	2586446	A1	20060518	CA 2005-2586446	20051104
				US 2004-626389P	P 20041109
				WO 2005-US39956	W 20051104
EP	1812383	A1	20070801	EP 2005-839433	20051104
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
				US 2004-626389P	P 20041109
				WO 2005-US39956	W 20051104
CN	101098852	A	20080102	CN 2005-80046266	20051104
				US 2004-626389P	P 20041109
				WO 2005-US39956	W 20051104
JP	2008519761	T	20080612	JP 2007-540066	20051104
				US 2004-626389P	P 20041109
				WO 2005-US39956	W 20051104
BR	2005017567	A	20080617	BR 2005-17567	20051104
				US 2004-626389P	P 20041109
				WO 2005-US39956	W 20051104
SG	155229	A1	20090930	SG 2009-5516	20051104
				US 2004-626389P	P 20041109
NO	2007002223	A	20070625	NO 2007-2223	20070430
				US 2004-60389P	P 20041109
				WO 2005-US39956	W 20051104
US	20070249670	A1	20071025	US 2007-718804	20070508
				US 2004-626389P	P 20041109

ZA 2007003713	A	20081029	WO 2005-US39956	W	20051104
			ZA 2007-3713		20070508
			US 2004-626389P	P	20041109
MX 2007005590	A	20070524	MX 2007-5590		20070509
			US 2004-626389P	P	20041109
			WO 2005-US39956	W	20051104
IN 2007KN02029	A	20070810	IN 2007-KN2029		20070605
			US 2004-626389P	P	20041109
			WO 2005-US39956	W	20051104
KR 2007086044	A	20070827	KR 2007-713158		20070611
			US 2004-626389P	P	20041109
			WO 2005-US39956	W	20051104

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 144:488936; MARPAT 144:488936

AB The invention relates to compds. R-Ar-NR1CO-X-Ar' [R is CO2H or carbamoyl which may be substituted by alkyl, aryl, carboxyalkyl, etc.; Ar is an aromatic, heteroarom., cycloaliph. or heterocyclic ring which may fused to an aromatic or heteroarom. ring; X is carbon, nitrogen, oxygen or sulfur; Ar' is an aromatic or heteroarom. ring; R1 is H or alkyl] or their pharmaceutically-acceptables salts, which are inhibitors of glycogen phosphorylase and can be used to treat diabetes, conditions associated with diabetes, or tissue ischemia, including myocardial ischemia. Thus, N-[3-[[[(2,6-dimethylphenyl)amino]carbonyl]amino]-2-naphthoyl]-L-aspartic acid was prepared by treating L-Asp(tBu)-Wang Resin with 3-amino-2-naphthalenecarboxylic acid and then 2,6-dimethylphenyl isocyanate. The product showed IC50 = 0.46  $\mu$ M for inhibition of glycogen phosphorylase.

OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of alkynyl substituted phenoxyacetic acids as PPAR $\delta$  agonists

AN 2005:1193203 CAPLUS

DN 143:459868

TI Preparation of alkynyl substituted phenoxyacetic acids as PPAR $\delta$  agonists

IN Havranek, Miroslav; Sauerberg, Per; Pettersson, Ingrid

PA Novo Nordisk A/S, Den.

SO PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2005105725	A1	20051110	WO 2005-EP52010	20050503
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DK 2004-716	A 20040505
	EP 1745002	A1	20070124	EP 2005-747382	20050503



R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

			DK 2004-716	A	20040505
			WO 2005-EP52010	W	20050503
JP 2007536340	T	20071213	JP 2007-512186		20050503
			DK 2004-716	A	20040505
			WO 2005-EP52010	W	20050503
US 20080114036	A1	20080515	US 2007-579303		20071010
			DK 2004-716	A	20040505
			WO 2005-EP52010	W	20050503

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 143:459868; MARPAT 143:459868

GI



AB The title compds. I [X1 = aryl, heteroaryl, alkyl, etc.; X2 = aryl, heteroaryl, H, etc.; X3 = arylene, heteroarylene; Ar = arylene; Y1 = O, S; Y2 = O, S; Z = (CH2)<sub>n</sub>; n = 1-3; R1 = H, halo, alkyl, etc.; R2 = H, alkyl, cycloalkyl, etc.] which are useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPAR $\delta$  subtype, namely, type 1 diabetes, type 2 diabetes, dyslipidemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hypertriglyceridemia and/or obesity), cardiovascular diseases (including atherosclerosis) and hypercholesterolemia (no data), were prepared and formulated. E.g., a multi-step synthesis of II, starting from 4-bromobenzaldehyde, was given.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of N-bicycyl-3-[[ (hetero)arylsulfonyl]amino]-3-  
(hetero)arylpropionamides as bradykinin receptor modulators for treatment



of pain, inflammation, and other conditions  
AN 2004:902334 CAPLUS  
DN 141:395300  
TI Preparation of N-bicyclyl-3-[[ (hetero)arylsulfonyl]amino]-3-(hetero)arylpropionamides as bradykinin receptor modulators for treatment of pain, inflammation, and other conditions  
IN Groneberg, Robert D.; Askew, Ben; D'Amico, Derin; Zhan, James; Toro, Andras; Suzuki, Hideo; Mareska, David A.; Han, Nianh; Fotsch, Christopher H.; Liu, Qinglan; Riahi, Babak; Yang, Kevin; Li, Aiwan; Yuan, Chester; Biswas, Kaustav; Harried, Scott; Nguyen, Tom; Qian, Wenyuan; Chen, Jian J.; Nomak, Rana  
PA Amgen, Inc., USA; Array Biopharma, Inc.  
SO PCT Int. Appl., 375 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004092116	A1	20041028	WO 2004-US11105	20040412
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004231070	A1	20041028	US 2003-461888P	P 20030410
	AU 2004231070	B2	20080214	AU 2004-231070	20040412
				US 2003-461888P	P 20030410
				WO 2004-US11105	W 20040412
	CA 2521937	A1	20041028	CA 2004-2521937	20040412
				US 2003-461888P	P 20030410
				WO 2004-US11105	W 20040412
	US 20050124654	A1	20050609	US 2004-823377	20040412
	US 7425631	B2	20080916		
				US 2003-461888P	P 20030410
	EP 1631542	A1	20060308	EP 2004-759403	20040412
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
				US 2003-461888P	P 20030410
				WO 2004-US11105	W 20040412
	JP 2006522825	T	20061005	JP 2006-509895	20040412
				US 2003-461888P	P 20030410
				WO 2004-US11105	W 20040412
	MX 2005010884	A	20070115	MX 2005-10884	20051010
				US 2003-461888P	P 20030410
				WO 2004-US11105	W 20040412
	US 20090048224	A1	20090219	US 2008-205616	20080905
				US 2003-461888P	P 20030410
				US 2004-823377	A3 20040412

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 141:395300

GI



AB Title compds. I [wherein R = (un)substituted bicyclic carbocyclic or heterocyclic ring; R1 = (un)substituted cycloalkyl, aryl(alkyl), heteroaryl, heterocyclyl; R2 = (un)substituted aryl(alkenyl), heterocyclyl, heteroaryl; Ra = independently H, NH2COCH2, alkyl, (un)substituted aryl; and pharmaceutically acceptable derivs. thereof] were prepared as bradykinin receptor ligands. For example, N-(7-formylchroman-4-yl)-3-(naphth-2-ylsulfonylamino)-3-phenylpropionamide (7-step preparation given) was condensed with piperidine in the presence of NaBH(OAc)3 in N,N-dimethylacetamide and precipitated to give II•HCl. In a radioligand binding assay, the latter showed affinity for the human B1 and human B2 bradykinin receptors with Ki values of <100 nM and >1 μM, resp. Selected compds. of the invention are effective for treatment of pain and diseases, such as inflammation mediated diseases (no data).

OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
40.80	511.06

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-5.95	-6.80

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 07:06:23 ON 19 JAN 2010

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
 NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40 minutes  
 NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source (CS) field  
 NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced  
 NEWS 5 AUG 24 CA/CAPLUS enhanced with legal status information for U.S. patents  
 NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY  
 NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus  
 NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded  
 NEWS 9 OCT 21 Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models  
 NEWS 10 NOV 23 Addition of SCAN format to selected STN databases  
 NEWS 11 NOV 23 Annual Reload of IFI Databases  
 NEWS 12 DEC 01 FRFULL Content and Search Enhancements  
 NEWS 13 DEC 01 DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets  
 NEWS 14 DEC 02 Derwent World Patent Index: Japanese FI-TERM thesaurus added  
 NEWS 15 DEC 02 PCTGEN enhanced with patent family and legal status display data from INPADOCDB  
 NEWS 16 DEC 02 USGENE: Enhanced coverage of bibliographic and sequence information  
 NEWS 17 DEC 21 New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAPLUS  
 NEWS 18 JAN 12 Match STN Content and Features to Your Information Needs, Quickly and Conveniently

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,  
 AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
 NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

\*CSCORP - ChemSources - USA and International (Company Directory)  
 \*GEOREF - Geological Reference File 1785-present

\* The files listed above are temporarily unavailable.

FILE 'HOME' ENTERED AT 05:59:46 ON 25 JAN 2010

=> file reg  
 COST IN U.S. DOLLARS                      SINCE FILE              TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 06:00:06 ON 25 JAN 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 JAN 2010 HIGHEST RN 1202965-77-2  
DICTIONARY FILE UPDATES: 22 JAN 2010 HIGHEST RN 1202965-77-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary  
files\10575122\10575122 Oxy-limited generic.str



chain nodes :

7 8 9 10 11 12 13 14 15 16 23

ring nodes :

1 2 3 4 5 6

chain bonds :

6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14 14-15 15-16 15-23

```

ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
7-8  9-10  10-11  11-12  12-13  13-14  15-16  15-23
exact bonds :
6-7  8-9  14-15
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6

```

G1:O,S,N

G2:O,N

Match level :

```

1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 23:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S,N

G2 O,N

Structure attributes must be viewed using STN Express query preparation.

=> search l1 sss sam

SAMPLE SEARCH INITIATED 06:00:40 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 45838 TO ITERATE

4.4% PROCESSED 2000 ITERATIONS

1 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 903966 TO 929554

PROJECTED ANSWERS: 171 TO 745


L2 1 SEA SSS SAM L1

=> dscan

L3 0 DSCAN

=> d scan 12

L2 1 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Acetic acid, [4-[[3,3-bis(4'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-  
2-chlorophenoxy]- (9CI)  
MF C47 H35 Cl O6



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
6.97	7.19

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 06:01:42 ON 25 JAN 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jan 2010 VOL 152 ISS 5  
FILE LAST UPDATED: 24 Jan 2010 (20100124/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

Caplus now includes complete International Patent Classification (IPC)

reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> 12

L4 1 L2

=> d 14

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2004:220310 CAPLUS

DN 140:270625

TI Preparation of [[[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR $\delta$  agonists for treatment of diabetes and related conditions

IN Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per  
PA Novo Nordisk A/s, Den.

SO PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2004022533	A1	20040318	WO 2003-DK578	20030904
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2499380	A1	20040318	CA 2003-2499380	20030904
	AU 2003260282	A1	20040329	AU 2003-260282	20030904
	US 20040143006	A1	20040722	US 2003-654699	20030904
	US 7091245	B2	20060815		
	EP 1537076	A1	20050608	EP 2003-793608	20030904
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003014335	A	20050726	BR 2003-14335	20030904
	CN 1688540	A	20051026	CN 2003-824179	20030904
	JP 2005538153	T	20051215	JP 2004-533217	20030904
	MX 2005002411	A	20050527	MX 2005-2411	20050302
	IN 2005DN00976	A	20091030	IN 2005-DN976	20050314
PRAI	DK 2002-1301	A	20020905		
	DK 2003-784	A	20030523		
	US 2002-409814P	P	20020911		
	WO 2003-DK578	W	20030904		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 140:270625

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 05:59:46 ON 25 JAN 2010)

FILE 'REGISTRY' ENTERED AT 06:00:06 ON 25 JAN 2010

L1 STRUCTURE UPLOADED  
L2 1 SEARCH L1 SSS SAM  
L3 0 DSCAN

FILE 'CAPLUS' ENTERED AT 06:01:42 ON 25 JAN 2010

L4 1 L2

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.30	10.49

FILE 'REGISTRY' ENTERED AT 06:04:03 ON 25 JAN 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 JAN 2010 HIGHEST RN 1202965-77-2

DICTIONARY FILE UPDATES: 22 JAN 2010 HIGHEST RN 1202965-77-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> search l1 sss full

FULL SEARCH INITIATED 06:04:20 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 918967 TO ITERATE

100.0% PROCESSED 918967 ITERATIONS

873 ANSWERS

SEARCH TIME: 00.00.17

L5 873 SEA SSS FUL L1

=> save temp l5 oxylddraw/a


ANSWER SET L5 HAS BEEN SAVED AS 'OXYLTDRAW/A'

=> d scan l5

L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN

IN Hexanoic acid, 2-[[3-(4-phenylbutoxy)-4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]oxy]-


MF C29 H31 F3 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C26 H31 N O8



L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanamide, N-(5-chloro-2-benzoxazolyl)-N-methyl-2-[4-[(1,3,3,3-tetrafluoro-2-phenyl-1-propen-1-yl)oxy]phenoxy]-, (2R)-  
 MF C26 H19 Cl F4 N2 O4


Absolute stereochemistry.  
 Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanamide, 2-[4-[[2-(4-chlorophenyl)-1-fluoroethenyl]oxy]phenoxy]-N-(2-fluorophenyl)-N-methyl-, (2R)-  
 MF C24 H20 Cl F2 N O3


Absolute stereochemistry.  
Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Ethanedioic acid, 1-[(1R,2R,3R,5S)-5-carboxy-2,3,5-tris[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propen-1-yl]oxy]cyclohexyl] 2-methyl ester  
MF C37 H32 O18


Absolute stereochemistry.  
Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C23 H25 N O4


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C25 H31 N2 O6 P

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-methyl-2-[4-[2-[4'-[(methylsulfonyl)oxy][1,1'-biphenyl]-4-yl]ethoxy]phenoxy]-  
 MF C25 H26 O7 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-methyl-2-[4-[2-[4'-[(methylsulfonyl)oxy][1,1'-biphenyl]-4-yl]ethoxy]phenoxy]-, ethyl ester  
 MF C28 H32 O7 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Acetic acid, 2-[4-[[ (2Z)-3-(4-fluorophenyl)-3-[4-(5-methyl-2-thienyl)phenyl]-2-propen-1-yl]oxy]-2-methylphenoxy]-, methyl ester  
MF C30 H27 F O4 S

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Acetic acid, 2-[4-[[3-[3,5-bis(2-phenylethynyl)phenyl]-2-propyn-1-yl]oxy]phenoxy]-, methyl ester  
MF C34 H24 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Acetic acid, 2-[4-[[3-[3,5-bis(2-phenylethynyl)phenyl]-2-propyn-1-yl]oxy]phenoxy]-


O=C(O)COc1ccc(OCC#Cc2cc(C#Cc3ccccc3)cc(C#Cc4ccccc4)c2)cc1

L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Acetic acid, 2-[4-[[ (2Z)-3-(4-bromophenyl)-5-(4-chlorophenyl)-2-penten-4-  
yn-1-yl]oxy]-2-methylphenoxy]-, methyl ester  
MF C27 H22 Br Cl O4

COC(=O)COc1cc(OC)ccc1OCC=C(C#Cc2ccc(Cl)cc2)c3ccc(Br)cc3

L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Acetic acid, 2-[4-[[ (2Z)-3-(4-bromophenyl)-5-[4-(trifluoromethyl)phenyl]-2-  
MF penten-4-yn-1-yl]oxy]-2-methylphenoxy]-  
C27 H20 Br F3 O4


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2-[4-[[2E)-3-(4-bromophenyl)-3-(4-methylphenyl)-2-propen-1-yl]oxy]-2-methylphenoxy]-, methyl ester  
 MF C26 H25 Br O4


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2-[2-methyl-4-[[2E)-3-phenyl-3-[4-[2-(2-pyridinyl)ethynyl]phenyl]-2-propen-1-yl]oxy]phenoxy]-, methyl ester  
 MF C31 H25 N O4


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Acetic acid, 2-[4-[[ (2E)-3-(4-bromophenyl)-3-[4-[3-(4-morpholinyl)-1-  
propyn-1-yl]phenyl]-2-propen-1-yl]oxy]-2-methylphenoxy]-  
MF C31 H30 Br N O5


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Acetic acid, 2-[4-[[[(2E)-3-[4-(cyclopropylthio)phenyl]-3-[4-[3-(  
(dimethylamino)-1-propyn-1-yl]phenyl]-2-propen-1-yl]oxy]-2-methylphenoxy]-  
MF C32 H33 N O4 S


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2-[2-methyl-4-[[ (2E)-3-[4-(methylthio)phenyl]-3-[4-[3-(1H-pyrazol-1-yl)-1-propyn-1-yl]phenyl]-2-propen-1-yl]oxy]phenoxy]-  
 MF C31 H28 N2 O4 S


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2-[2-methyl-4-[[ (2E)-3-[4-(methylsulfinyl)phenyl]-3-[4-[3-(4-morpholinyl)-1-propyn-1-yl]phenyl]-2-propen-1-yl]oxy]phenoxy]-  
 MF C32 H33 N O6 S


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 873 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2-[2-methyl-4-[[ (2E)-3-[4-[3-(4-morpholinyl)-1-propyn-1-yl]phenyl]-3-[3-(trifluoromethyl)phenyl]-2-propen-1-yl]oxy]phenoxy]-, methyl ester  
 MF C33 H32 F3 N O5

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY  
193.50

TOTAL  
SESSION  
203.99

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 06:06:52 ON 25 JAN 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jan 2010 VOL 152 ISS 5  
FILE LAST UPDATED: 24 Jan 2010 (20100124/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l5

L6 128 L5

=> save temp l6 oxyltdrefs/a

ANSWER SET L6 HAS BEEN SAVED AS 'OXYLTDREFS/A'

=> ?lipid?

L7 555427 ?LIPID?

=> diab?

L8 207636 DIAB?

=> l7 or l8

L9 733476 L7 OR L8

=> l6 and l9

L10 29 L6 AND L9

=> d l10 19-29 ti

L10 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of [[[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR $\delta$  agonists for treatment of diabetes and related conditions

L10 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of imidazole and benzimidazole derivatives that inhibit the interaction of ligands with RAGE

L10 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of 5-amino-4-phenyl-1H-imidazoles as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)

L10 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN

TI Long-chain, unsaturated, aromatic dicarboxylic acid derivatives, their preparation, and therapeutic use for treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR).

L10 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanolic acid derivatives as antagonists of prostaglandin E2 (PEG2) receptors

L10 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of thiazole and oxazole derivatives for treating human PPAR related disorders

L10 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of biaryloxa(thia)zole derivatives as PPAR modulators

L10 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Inhibition of cerebral ischemia by salvianolic acids

L10 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of tricyclic compounds as prostaglandin I2 receptor agonists

L10 ANSWER 28 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Trisubstituted benzene leukotriene B4 receptor antagonists: synthesis and structure-activity relationships

L10 ANSWER 29 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Benzofuran and benzothiophene derivatives and their pharmaceutical use

=> d l10 19,22,23,26,27-29 ti fbib abs

L10 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of [[[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR $\delta$  agonists for treatment of diabetes and related conditions

AN 2004:220310 CAPLUS  
 DN 140:270625  
 TI Preparation of [[[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR $\delta$  agonists for treatment of diabetes and related conditions

IN Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per  
 PA Novo Nordisk A/s, Den.  
 SO PCT Int. Appl., 78 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2004022533	A1	20040318	WO 2003-DK578	20030904
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DK 2002-1301	A 20020905
				DK 2003-784	A 20030523
	CA 2499380	A1	20040318	CA 2003-2499380	20030904
				DK 2002-1301	A 20020905
				DK 2003-784	A 20030523

AU 2003260282	A1	20040329	WO 2003-DK578	W	20030904
			AU 2003-260282		20030904
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
			WO 2003-DK578	W	20030904
US 20040143006	A1	20040722	US 2003-654699		20030904
US 7091245	B2	20060815			
			DK 2002-1301	A	20020905
			US 2002-409814P	P	20020911
			DK 2003-784	A	20030523
EP 1537076	A1	20050608	EP 2003-793608		20030904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
			WO 2003-DK578	W	20030904
BR 2003014335	A	20050726	BR 2003-14335		20030904
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
			WO 2003-DK578	W	20030904
CN 1688540	A	20051026	CN 2003-824179		20030904
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
JP 2005538153	T	20051215	JP 2004-533217		20030904
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
			WO 2003-DK578	W	20030904
MX 2005002411	A	20050527	MX 2005-2411		20050302
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
			WO 2003-DK578	W	20030904
IN 2005DN00976	A	20091030	IN 2005-DN976		20050314
			DK 2002-1301	A	20020905
			WO 2003-DK578	W	20030904

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 140:270625

GI



AB Title vinyl carboxylic acid derivs. I [wherein X1 and X3 = independently (un)substituted (hetero)aryl; X2 and X4 = independently (un)substituted (hetero)arylene; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; R1 = H, halo, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator-activated receptor  $\delta$  (PPAR $\delta$ ) agonists (no data). For example, 4,4'-dibromobenzophenone was coupled with tri-Et phosphonoacetate in the presence of NaH in toluene to give Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction using DIBAL-H in THF (76%), followed by ADDP-catalyzed condensation with (4-mercapto-2-methylphenoxy)acetic acid Me ester in THF (88%) afforded [4-[3,3-bis(4-bromophenyl)allylsulfanyl]-2-methylphenoxy]acetic acid Me ester. Saponification (93%) and substitution with phenylboronic acid using KF, Pd<sub>2</sub>(dba)<sub>3</sub>, and Pd[P(t-Bu)<sub>3</sub>]<sub>2</sub> in THF (53%) provided II. Also disclosed is the use of I and their pharmaceutical compns. for the treatment of PPAR $\delta$ -mediated conditions, such as diabetes, impaired glucose tolerance, insulin resistance, or obesity (no data).

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN

TI Long-chain, unsaturated, aromatic dicarboxylic acid derivatives, their preparation, and therapeutic use for treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR).

AN 2003:319859 CAPLUS

DN 138:337836

TI Long-chain, unsaturated, aromatic dicarboxylic acid derivatives, their preparation, and therapeutic use for treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR).



IN Sauerberg, Per; Bury, Paul Stanley; Jeppesen, Lone; Mogensen, John Patrick

PA Novo Nordisk A/S, Den.  
 SO PCT Int. Appl., 104 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003033453	A1	20030424	WO 2002-DK692	20021015
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DK 2001-1524	A 20011017
	CA 2462514	A1	20030424	CA 2002-2462514	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	AU 2002336916	A1	20030428	AU 2002-336916	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	EP 1438283	A1	20040721	EP 2002-772084	20021015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	BR 2002013253	A	20041026	BR 2002-13253	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	HU 2004001837	A2	20041228	HU 2004-1837	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	A 20021015
	CN 1571766	A	20050126	CN 2002-820547	20021015
				DK 2001-1524	A 20011017
	JP 2005505616	T	20050224	JP 2003-536195	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	US 20030109579	A1	20030612	US 2002-272613	20021016
	US 7220877	B2	20070522		
				DK 2001-1524	A 20011017
				US 2001-330346P	P 20011018
	IN 2004CN00771	A	20060113	IN 2004-CN771	20040415
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 138:337836  
 GI



AB A novel class of dicarboxylic acid derivs., I, is disclosed [wherein: A = (un)substituted C1-3 alkylene, or A'O or A'S where A' is (un)substituted C1-3 alkylene; B = (un)substituted C1-3 alkylene, or OB' or SB' where B' is (un)substituted C1-3 alkylene; D, E = H, C1-6 alkyl, C3-6 cycloalkyl; L, M = O or S; T, U = C3-9 divalent, (un)substituted, unsatd. carbon chain; X, Y = (un)substituted arylene or heteroarylene; Z = (un)substituted arylene, heteroarylene, or divalent polycyclic ring system]. Also disclosed is the use of I in pharmaceutical compns., pharmaceutical compns. comprising I, and methods of treatment employing I and the compns. The present compns. may be useful (no data) in the treatment and/or prevention of conditions mediated by peroxisome proliferator-activated receptors (PPAR). For example, 1,4-diiodobenzene was coupled with excess 2-penten-4-yn-1-ol in (iso-Pr)<sub>2</sub>NH in the presence of CuI and Pd(PPh<sub>3</sub>)<sub>4</sub> at 60°, to give 55% (E,E)-5-[4-(5-hydroxypent-3-en-1-ynyl)phenyl]pent-2-en-4-yn-1-ol. Mitsunobu reaction of this diol with (S)-2-ethoxy-3-(4-hydroxyphenyl)propionic acid Et ester using azodicarboxylic acid dipiperidide and PBu<sub>3</sub> in THF gave 27% invention compound II. A total of 29 synthetic examples illustrate a variety of I, mostly sym. diacids and diesters, and mostly stereoisomeric, with all stereoisomers having (E) and (S) stereochem. at double bonds and chiral centers. Claims list a wide variety of sym. and asym. I, all named without stereochem. Claimed applications include treatment of type I and II diabetes, dyslipidemia, syndrome X and its conditions, cardiovascular diseases including atherosclerosis, and hypercholesterolemia.

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)  
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanolic acid derivatives as antagonists of prostaglandin E<sub>2</sub> (PEG<sub>2</sub>) receptors


AN 2003:154382 CAPLUS

DN 138:187795  
 TI Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanolic acid derivatives as antagonists of prostaglandin E2 (PEG2) receptors  
 IN Tani, Kousuke; Asada, Masaki; Kobayashi, Kaoru; Narita, Masami; Ogawa, Mikio  
 PA Ono Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 1009 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003016254	A1	20030227	WO 2002-JP8120	20020808
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2457468	A1	20030227	JP 2001-241867 CA 2002-2457468 JP 2001-241867 WO 2002-JP8120	A 20010809 20020808 A 20010809 W 20020808
	AU 2002323916	A1	20030303	AU 2002-323916 JP 2001-241867 WO 2002-JP8120	20020808 A 20010809 W 20020808
	EP 1431267	A1	20040623	EP 2002-755874 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK	20020808 20010809 W 20020808 A 20010809 W 20020808
	BR 2002011810	A	20040824	BR 2002-11810 JP 2001-241867 WO 2002-JP8120	20020808 A 20010809 W 20020808
	CN 1551866	A	20041201	CN 2002-817376 JP 2001-241867	20020808 A 20010809
	HU 2004001963	A2	20050128	HU 2004-1963	20020808
	HU 2004001963	A3	20060130	JP 2001-241867 WO 2002-JP8120	A 20010809 W 20020808
	NZ 531153	A	20051028	NZ 2002-531153 JP 2001-241867 WO 2002-JP8120	20020808 A 20010809 W 20020808
	NZ 541950	A	20070223	NZ 2002-541950 JP 2001-241867	20020808 A 20010809
	RU 2315746	C2	20080127	RU 2004-106623 JP 2001-241867 WO 2002-JP8120	20020808 A 20010809 W 20020808
	CN 101284773	A	20081015	CN 2008-10002260 JP 2001-241867 CN 2002-817376	20020808 A 20010809 A3 20020808
	ZA 2004000973	A	20050104	ZA 2004-973 JP 2001-241867	20040205 A 20010809
	NO 2004000564	A	20040510	NO 2004-564 JP 2001-241867 WO 2002-JP8120	20040206 A 20010809 W 20020808
	MX 2004001253	A	20040603	MX 2004-1253	20040209

			JP 2001-241867	A	20010809
			WO 2002-JP8120	W	20020808
US 20060258728	A1	20061116	US 2004-486220		20040909
US 7491748	B2	20090217			
			JP 2001-241867	A	20010809
			WO 2002-JP8120	W	20020808
US 20090318703	A1	20091224	US 2008-259012		20081027
			JP 2001-241867	A	20010809
			WO 2002-JP8120	W	20020808
			US 2004-486220	A3	20040909

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OS MARPAT 138:187795  
 GI



AB Carboxylic acid derivs. (I) and nontoxic salts thereof [wherein R1 = CO2H, CO2R4, CH2OH, COR5SO2R6, CONH2, CH2NR5SO2R6, CH2NR9COR10, CH2NR9CONR5SO2R6, CH2SO2NR9COR10, CH2O2CNR5SO2R6, tetrazole, 1,2,4-oxadiazol-5-one, 1,2,4-oxadiazol-5-thione, 1,2,4-thiadiazol-5-one, etc. (wherein R4 = C1-6 alkyl, hydroxy-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, carboxy-C1-4 alkyl, etc.; R5, R9 = H, C1-6 alkyl; R6 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic carbocyclic, 3- to 13-membered mono-, di-, or tricyclic heterocyclyl, etc.; R10 = H, R6); A = a single bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc.; the ring B = C3-12 mono- or dicyclic carbocyclic ring, 3- to 12-membered mono- or dicyclic heterocyclic ring; R2 = C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6 alkynyl, halo, CHF2, CF3, NO2, cyano, Ph, oxo; m, n = 0,1,2; Q = (C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene)-Cyc2, -C1-4 alkylene-Z-Cyc3, amino-C1-4 alkyl, cyano-C1-4 alkyl, acylamino-C1-4 alkyl, 3- to 7-membered monocyclic carbocyclyl, 3- to 6-membered monocyclic heterocyclyl, etc. (wherein Cyc2, Cyc3 = C3-15 mono-, di-, or tricyclic carbocyclyl or heterocyclyl, etc.; Z = O, S, SO, SO2, NH, NHC, etc.); D = an linking chain consisting of 1-2 or 3-6 of atoms selected from C, N, O, or S, etc.; R3 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic carbocyclyl, 3- to 15-membered mono-, di-, or tricyclic heterocyclyl, etc.] are prepared These carboxylic acid derivs. include phenylpropanoic acid, phenylpropenoic acid, phenylpropanamide, phenylpropenamide, 3-oxoisindolin-1-ylacetic acid, benzylbenzoic acid, benzylaminoacetic acid, pyrazolylmethylbenzoic acid, benzoylaminoacetic acid, (pyrazolylmethylphenyl)propenoic acid, pyrazolylmethylpropanoic acid, (pyridinyloxyphenyl)propanoic acid, phenoxyacetic acid, phenylbutanoic acid, (pyrazolylmethyl)propanamide, (piperazinylmethylphenyl)propanamide, (morpholinylmethylphenyl)propanamide, (pyridinyloxyphenyl)propanamide, (pyrazolylmethyl)propenamide (oxoimidazolidinylmethylphenyl)propanamide, (oxopyrrolidinylmethylphenyl)propenamide, (thiophenylmethylphenyl)propenamide, (pyrazolylmethylphenylamino)acetamide, (thiazolylaminomethylphenyl)propanamide, thiophenylpropenamide, (pyrazolylmethylphenoxy)acetamide, (phenoxyethyl)benzamide, (pyrazolylmethylphenylethyl)-1,2,4-oxadiazol-5-one, and (pyrazolylmethylphenylindolyl)acetic acid. Because of binding to PEG2 receptors, in particular, subtype EP3 and/or subtype EP4 and having antagonism, the compds. I are useful in preventing and/or treating diseases such as pain, allodynia, hyperalgesia, pruritus (itching),

urticaria, atopic dermatitis, contact dermatitis, Urushi (Japanese lacquer tree) dermatitis, allergic conjunctivitis, symptoms during dialysis, asthma, rhinitis, allergic rhinitis, nasal congestion, sneeze, psoriasis, pollakiuria (increased urinary frequency), urination disorder, ejaculation (semination) disorder, fever (pyrexia), systemic inflammation reaction, learning disorder, Alzheimer's disease, neovascularization, cancer formation, cancer proliferation, cancer metastasis to organs, cancer metastasis to bone, hypercalcemia accompanied by cancer metastasis to bone, retinopathy, rubrum, erythema (rash), leucoma, skin moth-patch, heat burn, burn, steroid burn, kidney failure, nephropathy, acute or chronic nephritis, blood electrolyte disorder, imminent abortion, threatened abortion, excessive menstruation, dysmenorrhea, endometriosis, premenstrual syndrome, uterine gland myopathy, reproduction disorder, and stress. They are also useful in preventing and/or treating anxiety, depression, psychophysiol. disorder, mental retardation, thrombus, embolism, transient ischemic attack, cerebral infarction, atheroma, organ transplant, heart failure, hypertension, myocardial infarction, arteriosclerosis, circulation disorders or ulcers associated therewith, nerve disorders, vascular dementia, edema, diarrhea, constipation, biliary excretion disorder, ulcerative colitis, Crohn's disease, irritable bowel syndrome, reduction of rebound after using steroid drugs, aids for decreasing or removing steroid drugs, bone diseases, systemic granuloma, immune diseases, pyorrhea alveolaris, gingivitis, periodontal disease, nerve cell death, lung disorder, liver disorder, acute hepatitis, myocardial ischemia, Kawasaki disease, multiple organ failure, chronic headache, angiitis, venous failure, varicose vein (varicosis), anal fistula, diabetes insipidus, neonatal patent ductus arteriosus, and cholelithiasis. Thus, 4-hydroxymethyl-2-[2-(naphthalen-2-yl)ethoxy]cinnamic acid Et ester was mesylated by methanesulfonyl chloride in the presence of Et<sub>3</sub>N in THF at 0° for 15 min and condensed with pyrazole in the presence of NaH in DMF at 0° to give 2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid Et ester. 4-[2-[[2-(Naphthalen-1-yl)propanoyl]amino]-4-methylthiomethylphenyl]butanoic acid inhibited the binding of [3H]PGE<sub>2</sub> to prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) receptor subtype EP<sub>1</sub>, EP<sub>2</sub>, EP<sub>3</sub>, and EP<sub>4</sub> expressed in CHO cells with K<sub>i</sub> of >10, >10, 0.27, and 0.038 μM, resp. A tablet formulation containing (2E)-2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid was described.

OSC.G 21 THERE ARE 21 CAPLUS RECORDS THAT CITE THIS RECORD (40 CITINGS)  
 RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Inhibition of cerebral ischemia by salvianolic acids  
 AN 1999:449451 CAPLUS  
 DN 132:73397  
 TI Inhibition of cerebral ischemia by salvianolic acids  
 AU Wang, Jie; Wu, Junfang; Zhang, Juntian  
 CS Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, Peop. Rep. China  
 SO Zhongguo Yaolixue Tongbao (1999), 15(2), 164-166  
 CODEN: ZYTOE8; ISSN: 1001-1978  
 PB Anhui Yike Daxue Linchuan Yaoli Yanjiuso  
 DT Journal  
 LA Chinese  
 AB The anti-cerebral-ischemia effect of a mixture of salvianolic acids was studied. Middle cerebral artery occlusion of rats was used as the animal model; lipid peroxidn. by liver microsomes and the production of superoxide anion and free OH radicals in chemical systems were measured in vitro. At 12.5-25 mg/kg, the acids inhibited cerebral ischemia, decreasing the infarction area and cerebral edema. In vitro, the total acids at 5-50 mg/L inhibited lipid peroxidn. induced by the

Fe2+-cysteine system in liver microsomes and scavenged the superoxide anion produced by the xanthine-xanthine oxidase system and the free OH radicals produced by the Fe2+-H2O2 system. Antioxidative activity is suggested as being one of the mechanisms of salvianolic acids in inhibiting cerebral ischemia.

OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L10 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of tricyclic compounds as prostaglandin I2 receptor agonists

AN 1998:208535 CAPLUS

DN 128:257432

OREF 128:50963a,50966a

TI Preparation of tricyclic compounds as prostaglandin I2 receptor agonists

IN Ohkawa, Shigenori; Setoh, Masaki; Terashita, Zen-ichi

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 151 pp.

CODEN: PIXXD2

DT Patent

LA English



FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9813356	A1	19980402	WO 1997-JP3384	19970924
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				JP 1996-252912	A 19960925
	TW 416953	B	20010101	TW 1997-86113705	19970920
				JP 1996-252912	A 19960925
	CA 2264641	A1	19980402	CA 1997-2264641	19970924
				JP 1996-252912	A 19960925
				WO 1997-JP3384	W 19970924
	AU 9743973	A	19980417	AU 1997-43973	19970924
				JP 1996-252912	A 19960925
				WO 1997-JP3384	W 19970924
	JP 10152480	A	19980609	JP 1997-257408	19970924
				JP 1996-252912	A 19960925
	EP 929534	A1	19990721	EP 1997-942196	19970924
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				JP 1996-252912	A 19960925
				WO 1997-JP3384	W 19970924
	US 6248766	B1	20010619	US 1999-254446	19990309
				JP 1996-252912	A 19960925
				WO 1997-JP3384	W 19970924
	US 20020006944	A1	20020117	US 2001-800988	20010307
	US 6417213	B2	20020709		
				JP 1996-252912	A 19960925
				WO 1997-JP3384	W 19970924
				US 1999-254446	A3 19990309

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 128:257432

GI




AB The title compds. [I; R1 = H, a substituent; m = 1-3; Ar = (un)substituted aromatic group; X = a bond, (un)substituted divalent straight-chain group having 1-6 atoms; Y = S, O, N(R2) (R2 = H, a substituent); Z = N, C(R3) (R3 = H, a hydrocarbon); ring A = a benzene ring; ring B = (un)substituted 5-7 membered ring], useful for eliciting a prostaglandin I2 receptor agonistic effect, inhibiting a platelet aggregation, and for the prophylaxis or treatment of transient ischemic attack, diabetic neuropathy, peripheral vascular diseases or ulcer, were prepared and formulated. Thus, reaction of Et [(2-mercapto-4,5-dihydronaphtho[1,2-d]thiazol-6-yl)oxy]acetate with 2,2-diphenylethyl methanesulfonate in the presence of K2CO3 in DMF followed by hydrolysis the resulting Et {[2-(2,2-diphenylethyl)thio-4,5-dihydronaphtho[1,2-d]thiazol-6-yl]oxy}acetate with 1N NaOH afforded 61% II which showed IC50 of 0.024  $\mu$ M against PGI2 receptor binding, and IC50 of 0.54  $\mu$ M against platelet aggregation.

OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)  
 RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 28 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Trisubstituted benzene leukotriene B4 receptor antagonists: synthesis and structure-activity relationships  
 AN 1997:645809 CAPLUS  
 DN 127:318788  
 OREF 127:62477a,62480a  
 TI Trisubstituted benzene leukotriene B4 receptor antagonists: synthesis and structure-activity relationships  
 AU Konno, Mitoshi; Nakae, Takahiko; Sakuyama, Shigeru; Odagaki, Yoshihiko; Nakai, Hisao; Hamanaka, Nobuyuki  
 CS Department of Medicinal Chemistry, Minase Research Institute, Ono Pharmaceutical Co., Ltd, Mishima, 618, Japan  
 SO Bioorganic & Medicinal Chemistry (1997), 5(8), 1649-1674  
 CODEN: BMECEP; ISSN: 0968-0896  
 PB Elsevier  
 DT Journal  
 LA English

GI



AB A series of trisubstituted benzenes which demonstrate leukotriene B4 (LTB4, 1) receptor affinity was prepared. Previous trisubstituted benzenes from our laboratory showed high affinity to the LTB4 receptor but demonstrated agonist activity in functional assays. (I) (R1 = H, R2 = 4-MeOC6H4) (II), the initial lead compound of this new series, showed only modest affinity (IC50 = 0.20  $\mu$ M). However, II was a receptor antagonist with no demonstrable agonist activity up to 30  $\mu$ M. Further modification of the lipid tail and aryl head groups region led to the discovery of I [R1 = O(CH2)4CO2H, R2 = 4-MeOC6H4] (III) (ONO-4057). III, free of agonist activity, possesses high affinity to the LTB4 receptor (Ki = 3.7 $\pm$ 0.9 nM).

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 29 OF 29 CAPLUS COPYRIGHT 2010 ACS on STN

TI Benzofuran and benzothiophene derivatives and their pharmaceutical use

AN 1981:83926 CAPLUS

DN 94:83926

OREF 94:13685a,13688a

TI Benzofuran and benzothiophene derivatives and their pharmaceutical use

IN Grell, Wolfgang; Sauter, Robert; Griss, Gerhart; Hurnaus, Rudolf; Eisele, Bernhard; Kaubisch, Nikolaus; Rupprecht, Eckhard; Kaehling, Joachim

PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.

SO Ger. Offen., 92 pp.

CODEN: GWXXBX

DT Patent




LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 2909754	A1	19800918	DE 1979-2909754	19790313
				DE 1979-2909754	19790313

OS MARPAT 94:83926

GI



AB The title derivs. I [R1 = C1-7 alkyl, C7-9 aralkyl, pyridyl, thienyl, PhC6H4, Ph optionally substituted with 1 or 2 halo, Me, OH, C1-3 alkoxy or arylamino, PhCH2O, NH2, NO2, CO2H, C2-4 alkoxy carbonyl; R2 = C1-14 alkyl, halo(un)substituted Ph, C7-9 aralkyl, pyridyl; R3 = H, C1-8 alkyl; R4, R5 = H, C1-3 alkyl; R6 = H, halo, X = O, S; n = 0-2] and their physiol. tolerable salts with bases when R3 = H and with acids when R1 and(or) R2 = pyridyl, useful as anticholesteremics, hypolipemics, and antiarteriosclerotics (extensive data tabulated for 7 compds)., were prepared by several methods. Thus, cyclizing 2-(4-methoxyphenoxy)-1-(2-pyridyl)-1-propanone in polyphosphoric acid in 30 min at 60° gave 91% methoxybenzofuran II (R7 = Me). This was demethylated in refluxing HBr to give 64.2% benzofuranol II.HBr (R7 = H), which was alkylated with Me2CBrCO2Et to 28.5% II.HCl (R7 = EtO2CCMe2).HCl via the free base. Saponifying II.HCl (R7 = EtO2CCMe2) with aqueous alc. NaOH gave 64.7% II.HCl (R6 = HO2CCMe2). Benzofuran III, at 20 mg/kg orally in rats, lowered serum cholesterol 70.5%, serum triglycerides 39.7%, and serum  $\beta$ -lipoproteins 87.0% vs. a control.

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 05:59:46 ON 25 JAN 2010)

FILE 'REGISTRY' ENTERED AT 06:00:06 ON 25 JAN 2010

L1 STRUCTURE UPLOADED  
L2 1 SEARCH L1 SSS SAM  
L3 0 DSCAN

FILE 'CAPLUS' ENTERED AT 06:01:42 ON 25 JAN 2010

L4 1 L2

FILE 'REGISTRY' ENTERED AT 06:04:03 ON 25 JAN 2010

L5 873 SEARCH L1 SSS FULL  
SAVE TEMP L5 OXYLTDRAW/A

FILE 'CAPLUS' ENTERED AT 06:06:52 ON 25 JAN 2010

L6 128 L5

SAVE TEMP L6 OXYLTDFEFS/A  
L7 555427 ?LIPID?  
L8 207636 DIAB?  
L9 733476 L7 OR L8  
L10 29 L6 AND L9

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	40.61	244.60
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.95	-5.95

FILE 'REGISTRY' ENTERED AT 06:18:48 ON 25 JAN 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 JAN 2010 HIGHEST RN 1202965-77-2  
DICTIONARY FILE UPDATES: 22 JAN 2010 HIGHEST RN 1202965-77-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary  
files\10575122\10575122 H-Fixed Oxy-limited generic.str



```

chain nodes :
7  8  9 10 11 12 13 14 15 16 23
ring nodes :
1  2  3  4  5  6
chain bonds :
6-7  7-8  8-9  9-10 10-11 11-12 12-13 13-14 14-15 15-16 15-23
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
7-8  9-10 10-11 11-12 12-13 13-14 15-16 15-23
exact bonds :
6-7  8-9 14-15
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6

```

G1:O,S,N

G2:O,N

Hydrogen count :

9:>= minimum 2 12:>= minimum 2

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 23:CLASS

L11 STRUCTURE UPLOADED

=> d l11

L11 HAS NO ANSWERS

L11 STR



G1 O,S,N

G2 O,N

Structure attributes must be viewed using STN Express query preparation.

```
=> search l11 subset =L5 sss sam
SAMPLE SUBSET SEARCH INITIATED 06:19:45 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -      48 TO ITERATE
```

```
100.0% PROCESSED      48 ITERATIONS      43 ANSWERS
SEARCH TIME: 00.00.01
```


```
PROJECTIONS (WITHIN SPECIFIED SUBSET):      ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):      545 TO      1375
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):      467 TO      1253
```

```
L12      43 SEA SUB=L5 SSS SAM L11
```

```
=> d scan
```

```
L12  43 ANSWERS  REGISTRY  COPYRIGHT 2010 ACS on STN
IN   Acetic acid, 2-[[7-[[[(2E)-3-[4-[3-(4-morpholinyl)-1-propyn-1-yl]phenyl]-3-
MF   [4-(trifluoromethyl)phenyl]-2-propen-1-yl]oxy]-4-benzofuranyl]oxy]-
```

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10


L12 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2-[4-[[[(2Z)-3-(4-bromophenyl)-5-phenyl-2-penten-4-yn-1-yl]oxy]-2-methylphenoxy]-  
 MF C26 H21 Br O4

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L12 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, [4-[[[2-ethoxy-3,3-bis[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI)  
 MF C40 H32 F6 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN  $\beta$ -Muramic acid, N-acetyl-1-O-[2-(1-naphthalenyl)ethyl]-4,6-O-(phenylmethylene)- (9CI)  
 MF C30 H33 N O8


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L12 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2-[4-[[ (2Z)-3-[4-(cyclopropylthio)phenyl]-3-(4-iodophenyl)-2-propen-1-yl]oxy]-2-methylphenoxy]-, methyl ester  
 MF C28 H27 I O4 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2-[4-[[3,3-bis[4-[3-(1-pyrrolidinyl)-1-propyn-1-yl]phenyl]-2-propen-1-yl]oxy]-2-methylphenoxy]-, methyl ester  
 MF C39 H42 N2 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L12 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2-[4-[[3,3-bis(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propen-1-yl]oxy]-2-methylphenoxy]-  
 MF C38 H30 Cl4 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

```
L12 43 ANSWERS   REGISTRY   COPYRIGHT 2010 ACS on STN
IN   Benzoic acid, 3-[3-(2-ethoxy-2-oxoethoxy)-4-[[6-(4-methoxyphenyl)-5-
MF   hexenyl]oxy]benzoyl]-, methyl ester, (E)- (9CI)
      C32 H34 O8
```


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


```
L12 43 ANSWERS   REGISTRY  COPYRIGHT 2010 ACS on STN
IN   Acetic acid, 2-[4-[[ (2Z)-3-[4-(1,1-dimethylethyl)phenyl]-3-[4-[3-(1H-
      pyrazol-1-yl)-1-propyn-1-yl]phenyl]-2-propen-1-yl]oxy]-2-methylphenoxy]-,
MF   methyl ester
      C35 H36 N2 O4
```

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2-[4-[[3,3-bis[4-[3-(1-pyrrolidiny)]-1-propyn-1-yl]phenyl]-2-propen-1-yl]oxy]-2-methylphenoxy]-  
 MF C38 H40 N2 O4  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L12 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, [4-[[2-ethoxy-3,3-bis[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI)  
 MF C40 H38 O9 S2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L12 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-[4-(3-phenylpropoxy)phenoxy]-  
 MF C18 H20 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2-[2-methyl-4-[[[(2E)-3-[4-(5-methyl-2-thienyl)phenyl]-3-[4-[3-(4-morpholinyl)-1-propyn-1-yl]phenyl]-2-propen-1-yl]oxy]phenoxy]-  
 MF C36 H35 N O5 S


Double bond geometry as shown.

L12 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Acetic acid, 2-[4-[2-[bis(3',4'-difluoro[1,1'-biphenyl]-4-  
yl)methylene]butoxy]-2-methylphenoxy]-  
MF C38 H30 F4 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L12 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-methyl-2-[[4-(4-phenylbutoxy)-4'-(trifluoromethoxy)[1,1'-  
 biphenyl]-3-yl]oxy]-, ethyl ester  
 MF C29 H31 F3 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L12 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2-[4-[[2E)-3-(4-chlorophenyl)-3-[4-[3-(1H-pyrazol-1-yl)-1-  
 propyn-1-yl]phenyl]-2-propen-1-yl]oxy]-2-methylphenoxy]-  
 MF C30 H25 Cl N2 O4

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-methyl-2-[4-[3-[4-  
 [(methylsulfonyl)oxy]phenyl]propoxy]phenoxy]-, ethyl ester  
 MF C23 H30 O7 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L12 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, [4-[2-[bis[4'-(trifluoromethyl)[1,1'-biphenyl]-4-  
 yl]methylene]butoxy]-2-methylphenoxy]- (9CI)  
 MF C40 H32 F6 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanamide, N-(5-chloro-2-benzoxazolyl)-2-[4-[[2-(4-chlorophenyl)-1,3,3,3-tetrafluoro-1-propen-1-yl]oxy]phenoxy]-, (2R)-  
 MF C25 H16 Cl2 F4 N2 O4


Absolute stereochemistry.  
 Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2-[2-methyl-4-[[2-(2-pyridinyl)ethynyl]phenyl]-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]oxy]phenoxy]-  
 MF C32 H24 F3 N O4

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> search l11 subset =L5 sss full  
 FULL SUBSET SEARCH INITIATED 06:20:48 FILE 'REGISTRY'  
 FULL SUBSET SCREEN SEARCH COMPLETED - 873 TO ITERATE

100.0% PROCESSED 873 ITERATIONS 766 ANSWERS  
 SEARCH TIME: 00.00.01

L13 766 SEA SUB=L5 SSS FUL L11

=> file caplus  
 COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	47.46	292.06

	SINCE FILE ENTRY	TOTAL SESSION
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
CA SUBSCRIBER PRICE	0.00	-5.95

FILE 'CAPLUS' ENTERED AT 06:21:09 ON 25 JAN 2010  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jan 2010 VOL 152 ISS 5  
FILE LAST UPDATED: 24 Jan 2010 (20100124/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

CAPLUS now includes complete International Patent Classification (IPC)  
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> l13

L14 68 L13

=> d l14 58-68 ti

L14 ANSWER 58 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Preparation of 2'-(6-phenyl-5-hexenyloxy)phenylpropionates and analogs as  
leukotriene B4 inhibitors

L14 ANSWER 59 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Stereochemistry of the macrolactins

L14 ANSWER 60 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Silver halide photographic material containing improved  
development-inhibitor-releasing coupler for good image sharpness

L14 ANSWER 61 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Preparation of benzamide phenylenealkyl ether derivatives as  
leukotriene-like drugs

L14 ANSWER 62 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN  
TI High-speed silver halide photographic material containing a useful  
group-releasing coupler

L14 ANSWER 63 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Anti SRS-A carboxylic acid derivatives and pharmaceutical formulations  
containing them

L14 ANSWER 64 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Benzofuran and benzothiophene derivatives and their pharmaceutical use

L14 ANSWER 65 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Phenoxypropionic acid derivatives

L14 ANSWER 66 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Phenoxyalkanoic acids

L14 ANSWER 67 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Neuromuscular blocking properties of a series of bisquaternary tropines



L14 ANSWER 68 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Urinary excretion of a ninhydrin-positive compound, probably a peptide,  
after administration of  $\beta$ -aminoisobutyric acid to the mouse

=> d l14 65-66 ti fbib abs

L14 ANSWER 65 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Phenoxypropionic acid derivatives  
 AN 1978:50520 CAPLUS  
 DN 88:50520  
 OREF 88:7961a,7964a  
 TI Phenoxypropionic acid derivatives  
 IN Majoie, Bernard  
 PA Societe de Recherches Industrielles (SORI) S. A., Fr.  
 SO Ger. Offen., 35 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 2716189	A1	19771027	DE 1977-2716189	19770412
				GB 1976-15777	A 19760415
	GB 1565972	A	19800423	GB 1976-15777	19760415
	FR 2348182	A1	19771110	FR 1977-10456	19770406
				GB 1976-15777	A 19760415
	AU 7724216	A	19781019	AU 1977-24216	19770413
				GB 1976-15777	A 19760415
	BE 853574	A1	19771014	BE 1977-55831	19770414
				GB 1976-15777	A 19760415
	SE 7704303	A	19771016	SE 1977-4303	19770414
				GB 1976-15777	A 19760415
	DD 129777	A5	19780208	DD 1977-198400	19770414
				GB 1976-15777	A 19760415
	NL 7704174	A	19771018	NL 1977-4174	19770415
				GB 1976-15777	A 19760415
	JP 52136138	A	19771114	JP 1977-44020	19770415
				GB 1976-15777	A 19760415
	ZA 7702310	A	19780329	ZA 1977-2310	19770415
				GB 1976-15777	A 19760415

GI



AB A series of 3-ArZC6H4OCRMeCO2R1 (Ar = aryl; Z = e.g., O, S, OCH2, CH2O, CH:CH; R = H, (usually) Me; R1 = H, lower alkyl) (e.g., I, II) were prepared. Thus, 4-ClC6H4CH2OC6H4OH-3 condensed with Me2CO and CHCl3 in the presence of NaOH to give I. The compds. were active as anticholesteremics and hypolipemics.

L14 ANSWER 66 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Phenoxyalkanoic acids  
 AN 1976:164480 CAPLUS

DN 84:164480  
 OREF 84:26691a,26694a  
 TI Phenoxyalkanoic acids  
 IN Kawamatsu, Yutaka; Asakawa, Hiroyuki; Saraie, Takahiro; Imamiya, Eiko;  
 Matano, Mitsuo; Hamuro, Yukihiro  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 9 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 51008228	A	19760123	JP 1974-79612	19740710
				JP 1974-79612	A 19740710
AB	Phenoxyalkanoic acids or esters RC6H4ZC6H4OCHR1CO2R2 [I; R = alkyl, alkoxy, haloalkyl, halo; Z = Z1Z2 or Z2Z1 (Z1 = O, S, CO; Z2 = alkylene, alkenylene, alkyleneoxy, direct bond), but not Z = O; R1 and R2 = H, alkyl] were prepared by treating phenols RC6H4ZC6H4OH (II) with XCHR1CO2R2 (X = halo). I are hypolipemic agents (no data). Thus, 11 g II (R = 3-CF3, Z = CH2O, 4-substituted), prepared from 17 g 3-CF3C6H4CH2Br and 15.6 g hydroquinone, was refluxed with 7.9 g 28% NaOMe and 5 g ClCHMeCO2Me in EtOH for 2.5 hr and hydrolyzed with aqueous NaOH to give 6 g I (R = 3-CF3, Z = CH2O, R1 = Me, R2 = H, 4-substituted). Among 14 addnl. I prepared were (R, Z, R1, R2, and substitution position given): H, (CH2)3O, Me, H, 4; 3-Cl, CH2O, Me, Me, 4; 4-Cl, CH2O, H, Me, 4; H, CH2O, Me, H, 3.				

=> d his

(FILE 'HOME' ENTERED AT 05:59:46 ON 25 JAN 2010)

FILE 'REGISTRY' ENTERED AT 06:00:06 ON 25 JAN 2010

L1 STRUCTURE UPLOADED  
 L2 1 SEARCH L1 SSS SAM  
 L3 0 DSCAN

FILE 'CAPLUS' ENTERED AT 06:01:42 ON 25 JAN 2010

L4 1 L2

FILE 'REGISTRY' ENTERED AT 06:04:03 ON 25 JAN 2010

L5 873 SEARCH L1 SSS FULL  
 SAVE TEMP L5 OXYLTDRAW/A

FILE 'CAPLUS' ENTERED AT 06:06:52 ON 25 JAN 2010

L6 128 L5  
 SAVE TEMP L6 OXYLTDFEFS/A  
 L7 555427 ?LIPID?  
 L8 207636 DIAB?  
 L9 733476 L7 OR L8  
 L10 29 L6 AND L9

FILE 'REGISTRY' ENTERED AT 06:18:48 ON 25 JAN 2010

L11 STRUCTURE UPLOADED  
 L12 43 SEARCH L11 SSS SAM SUB=L5  
 L13 766 SEARCH L11 SSS FULL SUB=L5

FILE 'CAPLUS' ENTERED AT 06:21:09 ON 25 JAN 2010

L14 68 L13

=> 19 and 114

L15 22 L9 AND L14

=> d 115 1-22 ti fbib abs

L15 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Structure-based drug design of a novel family of chalcones as PPAR $\alpha$   
agonists: virtual screening, synthesis, and biological activities in vitro  
AN 2007:1456378 CAPLUS  
DN 148:158854  
TI Structure-based drug design of a novel family of chalcones as PPAR $\alpha$   
agonists: virtual screening, synthesis, and biological activities in vitro  
AU Li, Xiang-hua; Zou, Han-jun; Wu, An-hui; Ye, Yang-liang; Shen, Jian-hua  
CS Drug Discovery and Design Center, State Key Laboratory of Drug Research,  
Shanghai Institute of Materia Medica, Chinese Academy of Sciences,  
Shanghai, 201203, Peop. Rep. China  
SO Acta Pharmacologica Sinica (2007), 28(12), 2040-2052  
CODEN: APSCG5; ISSN: 1671-4083  
PB Blackwell Publishing Asia Pty Ltd.  
DT Journal  
LA English  
OS CASREACT 148:158854  
AB Aim: To design and synthesize a novel class of peroxisome  
proliferator-activated receptors (PPAR) $\alpha$  agonists, which is obtained  
by the combination of the classical fibrate "head group", a linker with  
appropriate length and a chalcone. Methods: Thirty seven compds. were  
designed and identified employing the virtual screening approach. Six  
compds. were then selected for synthesis and bioassay according to the  
virtual screening results, structural similarity, and synthetic  
complexity. Results: Six new compds. (4b and 4d-h) were synthesized and  
bioassayed. All were found to be potent PPAR $\alpha$  agonists, compound 4 h  
being the most prominent with a 50% effective concentration value of 0.06  
 $\mu$ mol/L. Conclusion: This study provides a promising novel family of  
chalcones with a potential hypolipidemic effect.  
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Preparation of 1,3-diethynylbenzene derivatives as agonists of peroxisome  
proliferator-activated receptors  
AN 2007:1028544 CAPLUS  
DN 147:365259  
TI Preparation of 1,3-diethynylbenzene derivatives as agonists of peroxisome  
proliferator-activated receptors  
IN Sauerberg, Per  
PA Novo Nordisk A/S, Den.  
SO PCT Int. Appl., 69pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2007101864	A2	20070913	WO 2007-EP52130	20070307
	WO 2007101864	A3	20071025		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				



IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,  
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

CA 2645719	A1	20070913	EP 2006-110887	A	20060309
			CA 2007-2645719		20070307
			EP 2006-110887	A	20060309
EP 1999098	A2	20081210	WO 2007-EP52130	W	20070307
			EP 2007-726688		20070307
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,					
IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR			EP 2006-110887	A	20060309
			WO 2007-EP52130	W	20070307
JP 2009529512	T	20090820	JP 2008-557754		20070307
			EP 2006-110887	A	20060309
			WO 2007-EP52130	W	20070307
US 20090048257	A1	20090219	US 2008-282244		20080909
			EP 2006-110887	A	20060309
			WO 2007-EP52130	W	20070307

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 147:365259; MARPAT 147:365259

GI



AB The title compds. with general formula I [wherein X1 = (un)substituted aryl, heteroaryl, heterocycle, etc.; X2 = H, halo, (un)substituted aryl-alkynyl, heteroaryl-alkynyl, etc.; Ar = (un)substituted aryl; Y and Z = independently O or S; n = 1-3; R = H, alkyl, cycloalkyl, alkenyl, etc.] or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixture of stereoisomers, or polymorphs thereof were prepared as agonists of peroxisome proliferator-activated receptors (PPAR $\delta$ ). For example, compound II was prepared in a multi-step synthesis. PPAR transient transactivation assay, based on transient transfection into human HEK293 cells of two plasmids encoding a chimeric test protein and a reporter protein resp., was performed to evaluate the agonistic activity

of I towards PPAR $\delta$ . Formulations containing I as active ingredient was also disclosed.

L15 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Synthesis of phenyloxy isobutyric acid derivatives and their antidiabetic activity in vitro  
AN 2007:723007 CAPLUS  
DN 148:205299  
TI Synthesis of phenyloxy isobutyric acid derivatives and their antidiabetic activity in vitro  
AU Zeng, Qingle; Wang, Heqing; Luo, Huan; Gao, Xiaoping; Liu, Zhongrong; Li, Bogang; Wang, Fengpeng; Zhao, Yufen  
CS Department of Chemistry, Xiamen University, Xiamen, 361005, Peop. Rep. China  
SO Yaoxue Xuebao (2006), 41(2), 108-114  
CODEN: YHHPAL; ISSN: 0513-4870  
PB Yaoxue Xuebao Bianjibu  
DT Journal  
LA English  
OS CASREACT 148:205299  
AB The objective was to design and synthesize new phenyloxy isobutyric acid analogs as antidiabetic compds. Eight new target compds. were synthesized by combination of lipophilic moieties and acidic moiety with nucleophilic replacement or Mitsunobu condensation. The eight compds. were confirmed by <sup>1</sup>H NMR, <sup>13</sup>CN MR, IR and MS. In vitro insulin-sensitizing activity (3T3-L1 adipocyte) demonstrated, that the cultured glucose concentration of up-clear solution detected with GOD-POD assay were 5.942, 6.339, 6.226 and 6.512 mmol·L<sup>-1</sup>, resp., when rosiglitazone, pioglitazone, compds. A and B were added to the insulin-resistant system. In vitro insulin-sensitizing activity of target compound A is in between that of rosiglitazone and pioglitazone, and activity of target compound B is slightly less than that of pioglitazone.  
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Preparation of cyclic alkenyl compounds as PPAR $\delta$  activators for treating various disease including diabetes and obesity  
AN 2007:705845 CAPLUS  
DN 147:118032  
TI Preparation of cyclic alkenyl compounds as PPAR $\delta$  activators for treating various disease including diabetes and obesity  
IN Sauerberg, Per; Pihera, Pavel; Polivka, Zdenek; Havranek, Miroslav; Pettersson, Ingrid; Mogensen, John Patrick  
PA Novo Nordisk A/S, Den.  
SO PCT Int. Appl., 216 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1  
PATENT NO. KIND DATE APPLICATION NO. DATE  
-----  
PI WO 2007071766 A2 20070628 WO 2006-EP70096 20061221  
WO 2007071766 A3 20070913  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
AU 2006327003	A1	20070628	AU 2006-327003		20061221
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
CA 2631390	A1	20070628	CA 2006-2631390		20061221
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
EP 1979311	A2	20081015	EP 2006-830789		20061221
R:			AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR		
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
JP 2009520769	T	20090528	JP 2008-546470		20061221
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
MX 2008008098	A	20080710	MX 2008-8098		20080620
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
CN 101356155	A	20090128	CN 2006-80048573		20080620
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
IN 2008DN05418	A	20080815	IN 2008-DN5418		20080623
			EP 2005-112758	A	20051222
			WO 2006-US70096	W	20061221
KR 2008078707	A	20080827	KR 2008-716288		20080704
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
US 20090093484	A1	20090409	US 2008-97564		20081023
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 147:118032; MARPAT 147:118032

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Novel compds. of the general formula I (wherein the "large X" is a double bond, X1 is heterocyclyl, aryl, heteroaryl, etc.; X2 is (un)substituted arylene or heteroarylene; X3 is (un)substituted aryl or heteroaryl; Ar is (un)substituted arylene; Y1 is O or S; and Y2 is O, S or CH2; and Z is -(CH2)n- wherein n = 1-3; and R1 = H, halo, etc.) the use of these compds. as pharmaceuticals, pharmaceutical compns. comprising the compds. and methods of treatment employing these compds. and compns. are claimed. The present compds. are activators of PPAR $\delta$  and should be useful for treating conditions mediated by the same, such as diabetes,

impaired glucose tolerance, insulin resistance, cardiovascular disease, etc.; no biol. data is given in the patent. Example compound II was prepared by reacting Me (Z)-[4-[3-(4-iodophenyl)-3-(4-trifluoromethylphenyl)allyloxy]-2-methylphenoxy]acetate with 2-ethynylpyridine and converting the ester obtained to the acid.

L15 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

TI MAO-B inhibitors useful for treating obesity

AN 2006:1285878 CAPLUS

DN 146:39059

TI MAO-B inhibitors useful for treating obesity

IN McElroy, John F.; Chorvat, Robert J.

PA Rajagopalan, Parthasarathi, India

SO PCT Int. Appl., 138 pp.

CODEN: PIXXD2

DT Patent

LA English



FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2006130707	A2	20061207	WO 2006-US21142	20060601
	WO 2006130707	A3	20070118		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
				US 2005-686585P	P 20050602
AU	2006252540	A1	20061207	AU 2006-252540	20060601
				US 2005-686585P	P 20050602
				WO 2006-US21142	W 20060601
CA	2620476	A1	20061207	CA 2006-2620476	20060601
				US 2005-686585P	P 20050602
				WO 2006-US21142	W 20060601
US	20070088004	A1	20070419	US 2006-445044	20060601
US	7649115	B2	20100119		
				US 2005-686585P	P 20050602
EP	1890690	A2	20080227	EP 2006-771748	20060601
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
				US 2005-686585P	P 20050602
				WO 2006-US21142	W 20060601
JP	2008542386	T	20081127	JP 2008-514814	20060601
				US 2005-686585P	P 20050602
				WO 2006-US21142	W 20060601
NZ	564130	A	20091224	NZ 2006-564130	20060601
				US 2005-686585P	P 20050602
				WO 2006-US21142	W 20060601
IN	2007DN09905	A	20080125	IN 2007-DN9905	20071220
				US 2005-686585P	P 20050602
				WO 2006-US21142	W 20060601
ZA	2008000036	A	20081231	ZA 2008-36	20080102
				US 2005-686585P	P 20050602
CN	101300006	A	20081105	CN 2006-80027303	20080125
				US 2005-686585P	P 20050602

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 146:39059

GI



AB The invention provides novel compds. of formulas I and II, both of which are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance).

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of hydroxyphenol derivatives as agonists of PPAR $\gamma$  for the treatment of dyslipidemia, atherosclerosis and diabetes

AN 2006:700040 CAPLUS

DN 145:145425

TI Preparation of hydroxyphenol derivatives as agonists of PPAR $\gamma$  for the treatment of dyslipidemia, atherosclerosis and diabetes

IN Adje, Nathalie; Vidal, Catherine; Zeiller, Jean-Jacques; Yvon, Stephane

PA Merck Patent GmbH, Germany

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006074798	A1	20060720	WO 2005-EP13858	20051222
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	FR 2880887	A1	20060721	FR 2005-420	A 20050114
	FR 2880887	B1	20090130	FR 2005-420	20050114

AU 2005324904	A1	20060720	AU 2005-324904	20051222
			FR 2005-420	A 20050114
			WO 2005-EP13858	W 20051222
CA 2594707	A1	20060720	CA 2005-2594707	20051222
			FR 2005-420	A 20050114
			WO 2005-EP13858	W 20051222
EP 1836150	A1	20070926	EP 2005-823908	20051222
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
			FR 2005-420	A 20050114
			WO 2005-EP13858	W 20051222
CN 101098846	A	20080102	CN 2005-80046545	20051222
			FR 2005-420	A 20050114
			WO 2005-EP13858	W 20051222
JP 2008526904	T	20080724	JP 2007-550706	20051222
			FR 2005-420	A 20050114
			WO 2005-EP13858	W 20051222
BR 2005019855	A2	20090324	BR 2005-19855	20051222
			FR 2005-420	A 20050114
			WO 2005-EP13858	W 20051222
MX 2007008351	A	20070725	MX 2007-8351	20070709
			FR 2005-420	A 20050114
			WO 2005-EP13858	W 20051222
KR 2007092278	A	20070912	KR 2007-716038	20070713
			FR 2005-420	A 20050114
			WO 2005-EP13858	W 20051222
US 20080161308	A1	20080703	US 2007-813933	20070713
			FR 2005-420	A 20050114
			WO 2005-EP13858	W 20051222
IN 2007KN02862	A	20070907	IN 2007-KN2862	20070806
			FR 2005-420	A 20050114
			WO 2005-EP13858	W 20051222
ZA 2007006706	A	20080925	ZA 2007-6706	20070813
			FR 2005-420	A 20050114


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 145:145425; MARPAT 145:145425

GI



I



II

AB Title compds. I [wherein R<sub>1</sub> = OH, (un)substituted alkoxy, amine, etc.; A = divalent hydrocarbonyl; R<sub>2</sub> = alkyl, (un)substituted cycloalkylalkyl, arylalkyl, etc.; X = O or S; Y, Z = H, halo, alkyl, etc.; Y and Z may link together to form a oxo-containing 5-membered ring] and optical isomers, oxide forms, solvates, and pharmaceutically acceptable addition salts thereof were prepared as partial or full agonists of peroxisome proliferator-activated receptor PPAR $\gamma$ , with differing degrees of PPAR $\alpha$  and/or PPAR $\delta$  activity. For instance, double etherification of 5,6-dihydroxyindan-1-one with 1-iodopentane (48% yield) followed by Me 3-bromomethylbenzoate (71% yield) gave II. Basic hydrolysis of this Me ester led to the corresponding benzoic acid in 68% yield. One analog of

the acid was tested and found to have activation factor of the chimeric protein PPAR $\gamma$ -Gal4 of 9.10 at a concentration of 10  $\mu$ M. Therefore, I and their pharmaceutical compns. are useful in the treatment of dyslipidemia, atherosclerosis and diabetes.

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Preparation of bis-phenylethynyl-phenyl-allylsulfanyl-phenoxy acetic acids as agonists of PPAR  
AN 2005:1193221 CAPLUS  
DN 143:459867  
TI Preparation of bis-phenylethynyl-phenyl-allylsulfanyl-phenoxy acetic acids as agonists of PPAR  
IN Polivka, Zdenek; Sindelar, Karel; Sauerberg, Per; Pettersson, Ingrid  
PA Novo Nordisk A/S, Den.  
SO PCT Int. Appl., 103 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005105735	A1	20051110	WO 2005-EP52012	20050503
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DK 2004-717	A 20040505
EP	1763511	A1	20070321	EP 2005-742988	20050503
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR DK 2004-717 A 20040505 WO 2005-EP52012 W 20050503				
JP	2007536341	T	20071213	JP 2007-512187	20050503
	DK 2004-717 A 20040505 WO 2005-EP52012 W 20050503				
OS	CASREACT 143:459867; MARPAT 143:459867				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [X1 = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; X2 and X4 independently = (un)substituted arylene or heteroarylene; X3 = (un)substituted aryl, heteroaryl, alkyl, etc.; Ar = (un)substituted arylene; Y1 and Y2 independently = O or S; Z = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; R1 = H, halo, (un)substituted alkyl, etc.; R2 = H, alkenyl, alkynyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as agonists of PPAR. Thus, e.g., II was prepared by coupling of 4,4'-(phenyl-ethynyl)benzophenone with tri-Et phosphonoacetate followed by reduction/bromination sequence to give 3,3-bis[4-(phenylethynyl)phenyl]allyl



bromide (III). Then, III underwent coupling with Et (4-mercapto-2-methylphenoxy)acetate and subsequent hydrolysis yielded acid II. The activity of I was evaluated using in vitro transactivation assay using human HEK293 cells (no data). I as agonist of PPAR should prove useful in the treatment of diabetes type I, diabetes type II and metabolic syndrome X. Pharmaceutical compns. comprising I are disclosed.

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of alkynyl substituted phenoxyacetic acids as PPARS  
 agonists  
 AN 2005:1193203 CAPLUS  
 DN 143:459868  
 TI Preparation of alkynyl substituted phenoxyacetic acids as PPARS  
 agonists  
 IN Havranek, Miroslav; Sauerberg, Per; Pettersson, Ingrid  
 PA Novo Nordisk A/S, Den.  
 SO PCT Int. Appl., 83 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005105725	A1	20051110	WO 2005-EP52010	20050503
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DK 2004-716	A 20040505
EP	1745002	A1	20070124	EP 2005-747382	20050503
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
				DK 2004-716	A 20040505
				WO 2005-EP52010	W 20050503
JP	2007536340	T	20071213	JP 2007-512186	20050503
				DK 2004-716	A 20040505
				WO 2005-EP52010	W 20050503
US	20080114036	A1	20080515	US 2007-579303	20071010
				DK 2004-716	A 20040505
				WO 2005-EP52010	W 20050503

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OS CASREACT 143:459868; MARPAT 143:459868  
 GI



AB The title compds. I [X1 = aryl, heteroaryl, alkyl, etc.; X2 = aryl, heteroaryl, H, etc.; X3 = arylene, heteroarylene; Ar = arylene; Y1 = O, S; Y2 = O, S; Z = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; R1 = H, halo, alkyl, etc.; R2 = H, alkyl, cycloalkyl, etc.] which are useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPAR $\delta$  subtype, namely, type 1 diabetes, type 2 diabetes, dyslipidemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hypertriglyceridemia and/or obesity), cardiovascular diseases (including atherosclerosis) and hypercholesterolemia (no data), were prepared and formulated. E.g., a multi-step synthesis of II, starting from 4-bromobenzaldehyde, was given.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase  
AN 2005:395261 CAPLUS  
DN 142:446999  
TI Preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase  
IN Gurram, Ranga Madhavan; Bhuniya, Debnath; Das, Saibal Kumar; Chakrabarti, Ranjan; Iqbal, Javed; Sharma, Sudhir Kumar  
PA Reddy's Laboratories Ltd., India  
SO PCT Int. Appl., 115 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040104	A1	20050506	WO 2004-IB208	20040129
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

				CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
	RW:			BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
IN	2002MA00792	A	20050304	WO 2003-IB4741	A 20031028
				IN 2002-MA792	20021028
AU	2004283147	A1	20050506	WO 2003-IB4741	A 20031028
				AU 2004-283147	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
CA	2538630	A1	20050506	CA 2004-2538630	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
EP	1678128	A1	20060712	EP 2004-706247	20040129
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
BR	2004014554	A	20061107	BR 2004-14554	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
CN	1867546	A	20061122	CN 2004-80030239	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
JP	2007509921	T	20070419	JP 2006-537450	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
MX	2006003019	A	20060623	MX 2006-3019	20060316
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
NO	2006001310	A	20060728	NO 2006-1310	20060323
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
ZA	2006002491	A	20080528	ZA 2006-2491	20060327
				WO 2003-IB4741	A 20031028
US	20070043035	A1	20070222	US 2006-575122	20060407
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:446999; MARPAT 142:446999

GI



AB Title compds. I [Ar = (un)substituted single or fused-aryl, -heteroaryl, -heterocycle; R1 and R2 independently = H, halo, nitro, etc.; R3 and R4 independently = H, (un)substituted-alkyl, -cycloalkyl, etc.; X = O, S, NR; R = H, (un)substituted-aryl, -alkanoyl, etc.; Z = O, S, NR; R5, R6, and R7 independently = H, OH, (un)substituted alkoxy, etc.; R5 and R6 together = 5- or 6-membered ring containing one or two hetero atoms selected from O, S, or N; Y = O, NR11; R11 = H, (un)substituted-heteroaryl, -aroyl, etc.; R7 and R11 together = 5- or 6-membered ring containing one or two hetero atoms selected from O, S, or N] and their pharmaceutically acceptable salts are prepared and disclosed as useful agonists of PPAR- $\alpha$  and PPAR- $\gamma$  and inhibitors or HMG CoA reductase. Thus, e.g., II was prepared by Wittig-Horner reaction of 4-acetyl biphenyl with tri-Et phosphonoacetate followed by reduction and Mitsunobu reaction with Et 2-(4-hydroxyphenoxy)-2-methylpropanoate. The activity of I was evaluated in vivo utilizing hypercholesterolemic rat models and it was revealed that a selected compound of the invention displayed a cholesterol lowering effect of 60%, a triglyceride lowering effect of 52%, as well as an increase in HDL of 70%. I as agonists of PPAR- $\alpha$  and PPAR- $\gamma$  should prove useful in the treatment of diseases such as diabetes and dyslipidemia. Pharmaceutical compns. comprising I are disclosed.

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L15 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of dimeric dicarboxylic acid derivatives as PPAR agonists  
 AN 2004:546467 CAPLUS  
 DN 141:106263  
 TI Preparation of dimeric dicarboxylic acid derivatives as PPAR agonists  
 IN Sauerberg, Per; Jeppesen, Lone; Polivka, Zdenek; Sindelar, Karel  
 PA Novo Nordisk A/S, Den.  
 SO PCT Int. Appl., 114 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056740	A1	20040708	WO 2003-DK895	20031218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20040259950	A1	20041223	DK 2002-1966	A 20021220
				US 2003-734368	20031212
				DK 2002-1966	A 20021220
				US 2003-439410P	P 20030110
	AU 2003287912	A1	20040714	AU 2003-287912	20031218
				DK 2002-1966	A 20021220
				WO 2003-DK895	W 20031218
	EP 1578716	A1	20050928	EP 2003-779752	20031218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK DK 2002-1966 A 20021220 WO 2003-DK895 W 20031218				
	JP 2006510687	T	20060330	JP 2004-561080	20031218
				DK 2002-1966	A 20021220
				WO 2003-DK895	W 20031218

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 141:106263

GI



AB The title compds. DOC(O)AXLTZUMYBC(O)OE [I; A, B = (un)substituted alkylene, O(alkylene), S(alkylene); D, E = H, alkyl, cycloalkyl; L, M = O, S; T, U = (un)substituted divalent saturated carbon chain, NR1(alkylene) (wherein R1 = H, alkyl); X, Y = (un)substituted arylene, heteroarylene; Z = (un)substituted arylene, heteroarylene, divalent polycyclic ring system] which may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR) (no specific biol. data given), were prepared and formulated. E.g., a multi-step synthesis of II, is given. The compds. I are claimed as selective PPAR $\delta$  agonists useful in treating diabetes, syndrome X, cardiovascular diseases, dyslipidemia, and hypercholesterolemia.

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Receptor function controlling agent  
 AN 2004:412803 CAPLUS  
 DN 141:1264  
 TI Receptor function controlling agent  
 IN Fukatsu, Kohji; Sasaki, Shinobu; Hinuma, Shuji; Ito, Yasuaki; Suzuki,  
 Nobuhiro; Harada, Masataka; Yasuma, Tsuneo  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 442 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041266	A1	20040521	WO 2003-JP14139	20031106
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				JP 2002-324632	A 20021108
				JP 2003-16889	A 20030127
				JP 2003-153986	A 20030530
	CA 2505322	A1	20040521	CA 2003-2505322	20031106
				JP 2002-324632	A 20021108
				JP 2003-16889	A 20030127
				JP 2003-153986	A 20030530
				WO 2003-JP14139	W 20031106
	AU 2003277576	A1	20040607	AU 2003-277576	20031106
				JP 2002-324632	A 20021108
				JP 2003-16889	A 20030127
				JP 2003-153986	A 20030530
				WO 2003-JP14139	W 20031106
	JP 2005015461	A	20050120	JP 2003-376833	20031106
				JP 2002-324632	A 20021108
				JP 2003-16889	A 20030127
				JP 2003-153986	A 20030530
	EP 1559422	A1	20050803	EP 2003-810621	20031106
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				JP 2002-324632	A 20021108
				JP 2003-16889	A 20030127
				JP 2003-153986	A 20030530
				WO 2003-JP14139	W 20031106
	CN 1735408	A	20060215	CN 2003-80108260	20031106
				JP 2002-324632	A 20021108
				JP 2003-16889	A 20030127
				JP 2003-153986	A 20030530
	US 20090012093	A1	20090108	US 2005-534081	20050613
				JP 2002-324632	A 20021108
				JP 2003-16889	A 20030127
				JP 2003-153986	A 20030530
				WO 2003-JP14139	W 20031106

PATENT FAMILY INFORMATION:

FAN 2004:1059297

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI WO 2004106276 A1 20041209 WO 2004-JP7770 20040528  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

JP 2003-153986 A 20030530

JP 2004-139144 A 20040507

CA 2527691 A1 20041209 CA 2004-2527691 20040528

JP 2003-153986 A 20030530

JP 2004-139144 A 20040507

WO 2004-JP7770 W 20040528

JP 2005343792 A 20051215 JP 2004-158907 20040528

JP 2003-153986 A 20030530

JP 2004-139144 A 20040507

EP 1630152 A1 20060301 EP 2004-745580 20040528

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

JP 2003-153986 A 20030530

JP 2004-139144 A 20040507

WO 2004-JP7770 W 20040528

US 20060258722 A1 20061116 US 2005-558846 20051130

JP 2003-153986 A 20030530

JP 2004-139144 A 20040507

WO 2004-JP7770 W 20040528

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 141:1264

AB A GPR40 receptor function controlling agent which contains a compound having  
an aromatic ring and a group capable of releasing a cation and is useful as a  
insulin secretion promoting agent or a preventive/remedy for  
diabetes, etc.

OSC.G 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (37 CITINGS)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of [[[diarylallyl)sulfanyl]phenoxy]acetic acids and esters as  
PPAR activators for treatment of diabetes and related conditions

AN 2004:370892 CAPLUS

DN 140:374984

TI Preparation of [[[diarylallyl)sulfanyl]phenoxy]acetic acids and esters as  
PPAR activators for treatment of diabetes and related conditions

IN Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg,  
Per; Pihera, Pavel; Havranek, Miroslav

PA Novo Nordisk A/S, Den.

SO PCT Int. Appl., 124 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2004037776	A2	20040506	WO 2003-DK722	20031027
	WO 2004037776	A3	20040610		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,			
		CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,			



GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,  
 OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
 TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			DK 2002-1631	A	20021028
			DK 2003-793	A	20030526
US 20050070583	A1	20050331	US 2003-693161		20031024
US 7129268	B2	20061031			
			DK 2002-1631	A	20021028
			US 2002-423467P	P	20021104
			DK 2003-793	A	20030526
CA 2503280	A1	20040506	CA 2003-2503280		20031027
			DK 2002-1631	A	20021028
			DK 2003-793	A	20030526
			WO 2003-DK722	W	20031027
AU 2003273783	A1	20040513	AU 2003-273783		20031027
			DK 2002-1631	A	20021028
			DK 2003-793	A	20030526
			WO 2003-DK722	W	20031027
EP 1558572	A2	20050803	EP 2003-757741		20031027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
			DK 2002-1631	A	20021028
			DK 2003-793	A	20030526
			WO 2003-DK722	W	20031027
BR 2003015683	A	20050830	BR 2003-15683		20031027
			DK 2002-1631	A	20021028
			DK 2003-793	A	20030526
			WO 2003-DK722	W	20031027
CN 1708468	A	20051214	CN 2003-80102228		20031027
CN 100491316	C	20090527			
			DK 2002-1631	A	20021028
			DK 2003-793	A	20030526
JP 2006503908	T	20060202	JP 2005-501509		20031027
			DK 2002-1631	A	20021028
			DK 2003-793	A	20030526
			WO 2003-DK722	W	20031027
RU 2349582	C2	20090320	RU 2005-116243		20031027
			DK 2002-1631	A	20021028
			DK 2003-793	A	20030526
			WO 2003-DK722	W	20031027
IN 2005DN01364	A	20080808	IN 2005-DN1364		20050405
			DK 2002-1631	A	20021028
			WO 2003-DK722	W	20031027
ZA 2005002814	A	20051018	ZA 2005-2814		20050407
			DK 2002-1631	A	20021028
MX 2005004402	A	20050726	MX 2005-4402		20050425
			DK 2002-1631	A	20021028
			DK 2003-793	A	20030526
			WO 2003-DK722	W	20031027
NO 2005002575	A	20050527	NO 2005-2575		20050527
			DK 2002-1631	A	20021028
			DK 2003-793	A	20030526
			WO 2003-DK722	W	20031027

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 140:374984

GI



AB Title compds. I [wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, alkenynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixts. of stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPAR $\delta$ , such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesterolemia (no data). For example, coupling of 4,4'-dibromobenzophenone with tri-Et phosphonoacetate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction of the ester to the alc. (76%) using DIBAL-H in THF and toluene, followed by reaction with (4-mercapto-2-methylphenoxy)acetic acid Me ester in the presence of ADDP and tributylphosphine in THF gave II (88%).

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of [[[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR $\delta$  agonists for treatment of diabetes and related conditions

AN 2004:220310 CAPLUS

DN 140:270625

TI Preparation of [[[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR $\delta$  agonists for treatment of diabetes and related conditions

IN Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per  
 PA Novo Nordisk A/s, Den.

SO PCT Int. Appl., 78 pp.  
 CODEN: PIXXD2

DT Patent

LA English



FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022533	A1	20040318	WO 2003-DK578	20030904
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DK 2002-1301	A 20020905
				DK 2003-784	A 20030523
	CA 2499380	A1	20040318	CA 2003-2499380	20030904
				DK 2002-1301	A 20020905
				DK 2003-784	A 20030523
				WO 2003-DK578	W 20030904
	AU 2003260282	A1	20040329	AU 2003-260282	20030904
				DK 2002-1301	A 20020905
				DK 2003-784	A 20030523
				WO 2003-DK578	W 20030904
	US 20040143006	A1	20040722	US 2003-654699	20030904
	US 7091245	B2	20060815		
				DK 2002-1301	A 20020905
				US 2002-409814P	P 20020911
				DK 2003-784	A 20030523
	EP 1537076	A1	20050608	EP 2003-793608	20030904
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				DK 2002-1301	A 20020905
				DK 2003-784	A 20030523
				WO 2003-DK578	W 20030904
	BR 2003014335	A	20050726	BR 2003-14335	20030904
				DK 2002-1301	A 20020905
				DK 2003-784	A 20030523
				WO 2003-DK578	W 20030904
	CN 1688540	A	20051026	CN 2003-824179	20030904
				DK 2002-1301	A 20020905
				DK 2003-784	A 20030523
	JP 2005538153	T	20051215	JP 2004-533217	20030904
				DK 2002-1301	A 20020905
				DK 2003-784	A 20030523
				WO 2003-DK578	W 20030904
	MX 2005002411	A	20050527	MX 2005-2411	20050302
				DK 2002-1301	A 20020905
				DK 2003-784	A 20030523
				WO 2003-DK578	W 20030904
	IN 2005DN00976	A	20091030	IN 2005-DN976	20050314
				DK 2002-1301	A 20020905
				WO 2003-DK578	W 20030904

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 140:270625

GI



AB Title vinyl carboxylic acid derivs. I [wherein X1 and X3 = independently (un)substituted (hetero)aryl; X2 and X4 = independently (un)substituted (hetero)arylene; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; R1 = H, halo, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator-activated receptor  $\delta$  (PPAR $\delta$ ) agonists (no data). For example, 4,4'-dibromobenzophenone was coupled with tri-Et phosphonoacetate in the presence of NaH in toluene to give Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction using DIBAL-H in THF (76%), followed by ADDP-catalyzed condensation with (4-mercapto-2-methylphenoxy)acetic acid Me ester in THF (88%) afforded [4-[3,3-bis(4-bromophenyl)allylsulfanyl]-2-methylphenoxy]acetic acid Me ester. Saponification (93%) and substitution with phenylboronic acid using KF, Pd<sub>2</sub>(dba)<sub>3</sub>, and Pd[P(t-Bu)<sub>3</sub>]<sub>2</sub> in THF (53%) provided II. Also disclosed is the use of I and their pharmaceutical compns. for the treatment of PPAR $\delta$ -mediated conditions, such as diabetes, impaired glucose tolerance, insulin resistance, or obesity (no data).

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of imidazole and benzimidazole derivatives that inhibit the interaction of ligands with RAGE

AN 2003:737580 CAPLUS

DN 139:261298

TI Preparation of imidazole and benzimidazole derivatives that inhibit the interaction of ligands with RAGE

IN Mjalli, Adnan M. M.; Andrews, Robert C.; Gopalaswamy, Ramesh; Hari, Anitha; Avor, Kwasi; Qabaja, Ghassan; Guo, Xiao-Chuan; Gupta, Suparna; Jones, David R.; Chen, Xin

PA Transtech Pharma, Inc., USA  
 SO PCT Int. Appl., 462 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003075921	A2	20030918	WO 2003-US6749	20030305
	WO 2003075921	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-361983P	P 20020305
CA	2476594	A1	20030918	CA 2003-2476594	20030305
				US 2002-361983P	P 20020305
				WO 2003-US6749	W 20030305
AU	2003217943	A1	20030922	AU 2003-217943	20030305
				US 2002-361983P	P 20020305
				WO 2003-US6749	W 20030305
EP	1482931	A2	20041208	EP 2003-713918	20030305
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				US 2002-361983P	P 20020305
				WO 2003-US6749	W 20030305
CN	1633290	A	20050629	CN 2003-805204	20030305
				US 2002-361983P	P 20020305
JP	2005525378	T	20050825	JP 2003-574195	20030305
				US 2002-361983P	P 20020305
				WO 2003-US6749	W 20030305
CN	101597262	A	20091209	CN 2009-10150857	20030305
				US 2002-361983P	P 20020305
				CN 2003-805204	A3 20030305
CN	101613321	A	20091230	CN 2009-10150500	20030305
				US 2002-361983P	P 20020305
				CN 2003-805204	A3 20030305
AU	2007202350	A1	20070614	AU 2007-202350	20070524
AU	2007202350	B2	20090730		
				US 2002-361983P	P 20020305
				AU 2003-217943	A3 20030305
				WO 2003-US6749	W 20030305
AU	2007203289	A1	20070802	AU 2007-203289	20070717
				AU 2002-245591	A3 20020305
JP	2009096806	A	20090507	JP 2008-271566	20081022
				US 2002-361983P	P 20020305
				JP 2003-574195	A3 20030305
AU	2009202814	A1	20090806	AU 2009-202814	20090713
				US 2002-361983P	P 20020305
				AU 2003-217943	A 20030305
				WO 2003-US6749	W 20030305
				AU 2007-202350	A3 20070524

PATENT FAMILY INFORMATION:

FAN 2001:886043

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	WO 2001092210	A1	20011206	WO 2001-US17251	20010525
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-207343P	P 20000530
				US 2001-799317	A 20010305
	US 20020006957	A1	20020117	US 2001-799317	20010305
	US 6613801	B2	20030902		
				US 2000-207343P	P 20000530
	CA 2379695	A1	20011206	CA 2001-2379695	20010525
	CA 2379695	C	20071127		
				US 2000-207343P	P 20000530
				US 2001-799317	A 20010305
				WO 2001-US17251	W 20010525
	CA 2599562	A1	20011206	CA 2001-2599562	20010525
				US 2000-207343P	P 20000530
				US 2001-799317	A 20010305
				CA 2001-2379695	A3 20010525
	AU 2001065083	A	20011211	AU 2001-65083	20010525
	AU 780368	B2	20050317		
				US 2000-207343P	P 20000530
				US 2001-799317	A 20010305
				WO 2001-US17251	W 20010525
	EP 1284959	A1	20030226	EP 2001-939581	20010525
	EP 1284959	B1	20050720		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-207343P	P 20000530
				US 2001-799317	A 20010305
				WO 2001-US17251	W 20010525
	JP 2004519416	T	20040702	JP 2002-500825	20010525
				US 2000-207343P	P 20000530
				US 2001-799317	A 20010305
				WO 2001-US17251	W 20010525
	AT 299860	T	20050815	AT 2001-939581	20010525
				US 2000-207343P	P 20000530
				US 2001-799317	A 20010305
				WO 2001-US17251	W 20010525
	ES 2243506	T3	20051201	ES 2001-939581	20010525
				US 2000-207343P	P 20000530
				US 2001-799317	A 20010305
	EP 1642888	A1	20060405	EP 2005-76535	20010525
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
				US 2000-207343P	P 20000530
				US 2001-799317	A 20010305
				EP 2001-939581	A3 20010525
	MX 2002001099	A	20040405	MX 2002-1099	20020130
				US 2000-207343P	P 20000530
				US 2001-799317	A 20010305
				WO 2001-US17251	W 20010525
	HK 1052338	A1	20060303	HK 2003-103492	20030516
				US 2000-207343P	P 20000530
				US 2001-799317	A 20010305
				WO 2001-US17251	W 20010525
	AU 2005200425	A1	20050224	AU 2005-200425	20050202

	AU 2005200425	B2	20090115	US 2000-207343P	P	20000530
				US 2001-799317	A	20010305
				AU 2001-65083	A3	20010525
				WO 2001-US17251	W	20010525
	AU 2007203289	A1	20070802	AU 2007-203289		20070717
				AU 2002-245591	A3	20020305
FAN	2002:695779					
	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2002069965	A1	20020912	WO 2002-US6706		20020305
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-273377P	P	20010305
	CA 2440037	A1	20020912	CA 2002-2440037		20020305
				US 2001-273377P	P	20010305
				WO 2002-US6706	W	20020305
	AU 2002245590	A1	20020919	AU 2002-245590		20020305
	AU 2002245590	B2	20060629			
				US 2001-273377P	P	20010305
				WO 2002-US6706	W	20020305
	EP 1387680	A1	20040211	EP 2002-713757		20020305
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
				US 2001-273377P	P	20010305
				WO 2002-US6706	W	20020305
	CN 1494423	A	20040505	CN 2002-805957		20020305
	CN 1235583	C	20060111			
				US 2001-273377P	P	20010305
	JP 2004523565	T	20040805	JP 2002-569141		20020305
				US 2001-273377P	P	20010305
				WO 2002-US6706	W	20020305
	AU 2006203512	A1	20060907	AU 2006-203512		20060815
	AU 2006203512	B2	20090709			
				US 2001-273377P	P	20010305
				AU 2002-245590	A3	20020305
				WO 2002-US6706	W	20020305
	AU 2007203289	A1	20070802	AU 2007-203289		20070717
				AU 2002-245591	A3	20020305
FAN	2002:695943					
	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2002070473	A2	20020912	WO 2002-US6707		20020305
	WO 2002070473	A3	20021227			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-273403P	P	20010305
				US 2001-273404P	P	20010305

			US 2001-273429P	P	20010305
			US 2001-273445P	P	20010305
			US 2001-273446P	P	20010305
			US 2001-273454P	P	20010305
			US 2001-273455P	P	20010305
CA 2440042	A1	20020912	CA 2002-2440042		20020305
			US 2001-273403P	P	20010305
			US 2001-273404P	P	20010305
			US 2001-273429P	P	20010305
			US 2001-273445P	P	20010305
			US 2001-273446P	P	20010305
			US 2001-273454P	P	20010305
			US 2001-273455P	P	20010305
AU 2002245591	A1	20020919	WO 2002-US6707	W	20020305
AU 2002245591	B2	20070517	AU 2002-245591		20020305
			US 2001-273403P	P	20010305
			US 2001-273404P	P	20010305
			US 2001-273429P	P	20010305
			US 2001-273445P	P	20010305
			US 2001-273446P	P	20010305
			US 2001-273454P	P	20010305
			US 2001-273455P	P	20010305
			WO 2002-US6707	W	20020305
EP 1377295	A2	20040107	EP 2002-713758		20020305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
			US 2001-273403P	P	20010305
			US 2001-273404P	P	20010305
			US 2001-273429P	P	20010305
			US 2001-273445P	P	20010305
			US 2001-273446P	P	20010305
			US 2001-273454P	P	20010305
			US 2001-273455P	P	20010305
			WO 2002-US6707	W	20020305
CN 1494425	A	20040505	CN 2002-805994		20020305
			US 2001-273403P	P	20010305
			US 2001-273404P	P	20010305
			US 2001-273429P	P	20010305
			US 2001-273445P	P	20010305
			US 2001-273446P	P	20010305
			US 2001-273454P	P	20010305
			US 2001-273455P	P	20010305
JP 2005500254	T	20050106	JP 2002-569794		20020305
			US 2001-273403P	P	20010305
			US 2001-273404P	P	20010305
			US 2001-273429P	P	20010305
			US 2001-273445P	P	20010305
			US 2001-273446P	P	20010305
			US 2001-273454P	P	20010305
			US 2001-273455P	P	20010305
			WO 2002-US6707	W	20020305
AU 2007203289	A1	20070802	AU 2007-203289		20070717
			AU 2002-245591	A3	20020305
FAN 2005:14210					
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
-----	-----	-----	-----	-----	
PI WO 2005000295	A1	20050106	WO 2004-US16104		20040520
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,					

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

AU 2004251599	A1	20050106	US 2003-471969P	P	20030520
			AU 2004-251599		20040520
			US 2003-471969P	P	20030520
CA 2522275	A1	20050106	WO 2004-US16104	W	20040520
			CA 2004-2522275		20040520
			US 2003-471969P	P	20030520
EP 1635823	A1	20060322	WO 2004-US16104	W	20040520
			EP 2004-753004		20040520
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			US 2003-471969P	P	20030520
			WO 2004-US16104	W	20040520
BR 2004010436	A	20060530	BR 2004-10436		20040520
			US 2003-471969P	P	20030520
			WO 2004-US16104	W	20040520
CN 1805743	A	20060719	CN 2004-80013791		20040520
			US 2003-471969P	P	20030520
JP 2007503469	T	20070222	JP 2006-533311		20040520
			US 2003-471969P	P	20030520
			WO 2004-US16104	W	20040520
ZA 2005008300	A	20070328	ZA 2005-8300		20040520
			US 2003-471969P	P	20030520
MX 2005012350	A	20060525	MX 2005-12350		20051116
			US 2003-471969P	P	20030520
			WO 2004-US16104	W	20040520
AU 2007203289	A1	20070802	AU 2007-203289		20070717
			AU 2002-245591	A3	20020305

FAN 2009:145901  
 PATENT NO.

KIND

DATE

APPLICATION NO.



DATE

PI	US 20090035302	A1	20090205	US 2008-238087		20080925
				US 2000-207343P	P	20000530
				US 2001-273377P	P	20010305
				US 2001-273403P	P	20010305
				US 2001-273404P	P	20010305
				US 2001-273429P	P	20010305
				US 2001-273445P	P	20010305
				US 2001-273446P	P	20010305
				US 2001-273454P	P	20010305
				US 2001-273455P	P	20010305
				US 2001-799317	A3	20010305
				US 2002-361983P	P	20020305
				US 2002-91609	A1	20020305
				US 2002-91759	A1	20020305
				US 2003-382203	A3	20030305
				US 2003-471969P	P	20030520
				US 2003-611741	A1	20030701
				US 2004-850238	B1	20040520
				US 2005-225277	A3	20050913
				US 2006-362993	A2	20060227
				US 2006-511163	A2	20060828
				US 2007-946641	A2	20071128
				US 2008-19045	A2	20080124
US 20020006957	A1	20020117	US 2001-799317			20010305
US 6613801	B2	20030902				

CA 2599562	A1	20011206	US 2000-207343P	P	20000530
			CA 2001-2599562		20010525
			US 2000-207343P	P	20000530
			US 2001-799317	A	20010305
			CA 2001-2379695	A3	20010525
EP 1642888	A1	20060405	EP 2005-76535		20010525
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR					
			US 2000-207343P	P	20000530
			US 2001-799317	A	20010305
			EP 2001-939581	A3	20010525
US 20020193432	A1	20021219	US 2002-91759		20020305
US 7423177	B2	20080909			
			US 2001-273403P	P	20010305
			US 2001-273404P	P	20010305
			US 2001-273429P	P	20010305
			US 2001-273445P	P	20010305
			US 2001-273446P	P	20010305
			US 2001-273454P	P	20010305
			US 2001-273455P	P	20010305
US 20030032663	A1	20030213	US 2002-91609		20020305
US 7087632	B2	20060808			
			US 2001-273377P	P	20010305
US 20040082542	A1	20040429	US 2003-382203		20030305
US 7361678	B2	20080422			
			US 2002-361983P	P	20020305
CN 101597262	A	20091209	CN 2009-10150857		20030305
			US 2002-361983P	P	20020305
			CN 2003-805204	A3	20030305
CN 101613321	A	20091230	CN 2009-10150500		20030305
			US 2002-361983P	P	20020305
			CN 2003-805204	A3	20030305
US 20040097407	A1	20040520	US 2003-611741		20030701
US 7067554	B2	20060627			
			US 2000-207343P	P	20000530
			US 2001-799317	A3	20010305
US 20050026811	A1	20050203	US 2004-850238		20040520
			US 2003-471969P	P	20030520
US 20060025464	A1	20060202	US 2005-225277		20050913
US 7329684	B2	20080212			
			US 2001-273377P	P	20010305
			US 2002-91609	A1	20020305
US 20060189578	A1	20060824	US 2006-331256		20060112
			US 2000-207343P	P	20000530
			US 2001-799317	A3	20010305
			US 2003-611741	A1	20030701
US 20060148760	A1	20060706	US 2006-362993		20060227
			US 2000-207343P	P	20000530
			US 2001-799317	A3	20010305
			US 2003-611741	A1	20030701
US 20070021386	A1	20070125	US 2006-511163		20060828
			US 2002-361983P	P	20020305
			US 2003-382203	A3	20030305
US 20070213347	A1	20070913	US 2007-800085		20070503
			US 2002-361983P	P	20020305
			US 2003-382203	A1	20030305
AU 2007203289	A1	20070802	AU 2007-203289		20070717
			AU 2002-245591	A3	20020305
US 20080119534	A1	20080522	US 2007-946641		20071128
			US 2001-273377P	P	20010305
			US 2002-91609	A1	20020305
			US 2005-225277	A3	20050913

US 20080119512	A1	20080522	US 2008-19045	20080124
			US 2001-273403P	P 20010305
			US 2001-273404P	P 20010305
			US 2001-273429P	P 20010305
			US 2001-273445P	P 20010305
			US 2001-273446P	P 20010305
			US 2001-273454P	P 20010305
			US 2001-273455P	P 20010305
			US 2002-91759	A1 20020305
JP 2009096806	A	20090507	JP 2008-271566	20081022
			US 2002-361983P	P 20020305
			JP 2003-574195	A3 20030305

OS MARPAT 139:261298  
GI



II


AB Title compds. and analogs I [wherein A = O, S, or NR<sub>2</sub>; R<sub>1</sub> and R<sub>2</sub> = independently H or (un)substituted (hetero)aryl, (cyclo)alkyl, heterocyclyl, alkenyl, alkynyl, alkylene(hetero)aryl, alkylene heterocyclyl, alkylene cycloalkyl, etc.; R<sub>3</sub> and R<sub>4</sub> = independently H, halo, OH, CN, CONH<sub>2</sub>, CO<sub>2</sub>H, or (un)substituted (hetero)aryl, (cyclo)alkyl, heterocyclyl, alkenyl, alkynyl, alkylene(hetero)aryl, alkylene heterocyclyl, alkylene cycloalkyl, etc.; and pharmaceutically acceptable salts thereof] were prepared as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE,  $\beta$ -amyloid, and amphoterin. For example, 1-BOC-4-[2-(4-amino-3-butylaminophenoxy)ethyl]piperazine was condensed with 3-hydroxybenzaldehyde to give the hydroxybenzimidazole. Coupling with cyclohexylmethyl bromide in the presence of NaH in THF afforded II. In binding studies employing S100b as the RAGE ligand, five hundred fifty-one invention compds. exhibited binding with IC<sub>50</sub> values of < 10  $\mu$ M. Thus, I and their pharmaceutical compns. are useful for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE, including acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis (no data).

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)  
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD

## ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of 5-amino-4-phenyl-1H-imidazoles as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)  
 AN 2003:331970 CAPLUS  
 DN 138:338171  
 TI Preparation of 5-amino-4-phenyl-1H-imidazoles as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)  
 IN Behnke, Dirk; Taube, Roswita; Cappi, Michael William  
 PA Morphochem AG, Germany  
 SO Ger. Offen., 22 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	DE 10150172	A1	20030430	DE 2001-10150172	20011011
				DE 2001-10150172	20011011
OS	MARPAT 138:338171				
GI					



AB Title compds. [I; R1-R5 = H, halo, OH, amino, NO<sub>2</sub>, thiolyl, (hetero)alkyl, (hetero)aryl, (hetero)cycloalkyl, (hetero)aralkyl; R6-R8 = H, (hetero)alkyl, (hetero)aryl, (hetero)cycloalkyl, (hetero)aralkyl; or R7R8 together with the adjoining atoms = heteroaryl, heteroalkyl, heterocycloalkyl], were prepared Several I inhibited PTP-1B with IC<sub>50</sub> = 0.18-0.83 μM. I are especially useful for the prevention and treatment of diabetes or obesity (fatty degeneration).

OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Long-chain, unsaturated, aromatic dicarboxylic acid derivatives, their preparation, and therapeutic use for treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR).  
 AN 2003:319859 CAPLUS  
 DN 138:337836  
 TI Long-chain, unsaturated, aromatic dicarboxylic acid derivatives, their preparation, and therapeutic use for treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR).  
 IN Sauerberg, Per; Bury, Paul Stanley; Jeppesen, Lone; Mogensen, John Patrick  
 PA Novo Nordisk A/S, Den.  
 SO PCT Int. Appl., 104 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English



FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003033453	A1	20030424	WO 2002-DK692	20021015
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2462514	A1	20030424	DK 2001-1524	A 20011017
				CA 2002-2462514	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	AU 2002336916	A1	20030428	AU 2002-336916	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	EP 1438283	A1	20040721	EP 2002-772084	20021015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	BR 2002013253	A	20041026	BR 2002-13253	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	HU 2004001837	A2	20041228	HU 2004-1837	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	A 20021015
	CN 1571766	A	20050126	CN 2002-820547	20021015
				DK 2001-1524	A 20011017
	JP 2005505616	T	20050224	JP 2003-536195	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	US 20030109579	A1	20030612	US 2002-272613	20021016
	US 7220877	B2	20070522		
				DK 2001-1524	A 20011017
				US 2001-330346P	P 20011018
	IN 2004CN00771	A	20060113	IN 2004-CN771	20040415
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 138:337836

GI



AB A novel class of dicarboxylic acid derivs., I, is disclosed [wherein: A = (un)substituted C1-3 alkylene, or A'O or A'S where A' is (un)substituted C1-3 alkylene; B = (un)substituted C1-3 alkylene, or OB' or SB' where B' is (un)substituted C1-3 alkylene; D, E = H, C1-6 alkyl, C3-6 cycloalkyl; L, M = O or S; T, U = C3-9 divalent, (un)substituted, unsatd. carbon chain; X, Y = (un)substituted arylene or heteroarylene; Z = (un)substituted arylene, heteroarylene, or divalent polycyclic ring system]. Also disclosed is the use of I in pharmaceutical compns., pharmaceutical compns. comprising I, and methods of treatment employing I and the compns. The present compns. may be useful (no data) in the treatment and/or prevention of conditions mediated by peroxisome proliferator-activated receptors (PPAR). For example, 1,4-diiodobenzene was coupled with excess 2-penten-4-yn-1-ol in (iso-Pr)<sub>2</sub>NH in the presence of CuI and Pd(PPh<sub>3</sub>)<sub>4</sub> at 60°, to give 55% (E,E)-5-[4-(5-hydroxypent-3-en-1-ynyl)phenyl]pent-2-en-4-yn-1-ol. Mitsunobu reaction of this diol with (S)-2-ethoxy-3-(4-hydroxyphenyl)propionic acid Et ester using azodicarboxylic acid dipiperidide and PBu<sub>3</sub> in THF gave 27% invention compound II. A total of 29 synthetic examples illustrate a variety of I, mostly sym. diacids and diesters, and mostly stereoisomeric, with all stereoisomers having (E) and (S) stereochem. at double bonds and chiral centers. Claims list a wide variety of sym. and asym. I, all named without stereochem. Claimed applications include treatment of type I and II diabetes, dyslipidemia, syndrome X and its conditions, cardiovascular diseases including atherosclerosis, and hypercholesterolemia.

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)  
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanolic acid derivatives as antagonists of prostaglandin E<sub>2</sub> (PEG<sub>2</sub>) receptors


AN 2003:154382 CAPLUS

DN 138:187795  
 TI Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanolic acid derivatives as antagonists of prostaglandin E2 (PEG2) receptors  
 IN Tani, Kousuke; Asada, Masaki; Kobayashi, Kaoru; Narita, Masami; Ogawa, Mikio  
 PA Ono Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 1009 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003016254	A1	20030227	WO 2002-JP8120	20020808
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2457468	A1	20030227	JP 2001-241867 CA 2002-2457468 JP 2001-241867 WO 2002-JP8120	A 20010809 20020808 A 20010809 W 20020808
	AU 2002323916	A1	20030303	AU 2002-323916 JP 2001-241867 WO 2002-JP8120	20020808 A 20010809 W 20020808
	EP 1431267	A1	20040623	EP 2002-755874 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK	20020808 20010809 W 20020808 A 20010809 W 20020808
	BR 2002011810	A	20040824	BR 2002-11810 JP 2001-241867 WO 2002-JP8120	20020808 A 20010809 W 20020808
	CN 1551866	A	20041201	CN 2002-817376 JP 2001-241867	20020808 A 20010809
	HU 2004001963	A2	20050128	HU 2004-1963	20020808
	HU 2004001963	A3	20060130	JP 2001-241867 WO 2002-JP8120	A 20010809 W 20020808
	NZ 531153	A	20051028	NZ 2002-531153 JP 2001-241867 WO 2002-JP8120	20020808 A 20010809 W 20020808
	NZ 541950	A	20070223	NZ 2002-541950 JP 2001-241867	20020808 A 20010809
	RU 2315746	C2	20080127	RU 2004-106623 JP 2001-241867 WO 2002-JP8120	20020808 A 20010809 W 20020808
	CN 101284773	A	20081015	CN 2008-10002260 JP 2001-241867 CN 2002-817376	20020808 A 20010809 A3 20020808
	ZA 2004000973	A	20050104	ZA 2004-973 JP 2001-241867	20040205 A 20010809
	NO 2004000564	A	20040510	NO 2004-564 JP 2001-241867 WO 2002-JP8120	20040206 A 20010809 W 20020808
	MX 2004001253	A	20040603	MX 2004-1253	20040209

			JP 2001-241867	A	20010809
			WO 2002-JP8120	W	20020808
US 20060258728	A1	20061116	US 2004-486220		20040909
US 7491748	B2	20090217			
			JP 2001-241867	A	20010809
			WO 2002-JP8120	W	20020808
US 20090318703	A1	20091224	US 2008-259012		20081027
			JP 2001-241867	A	20010809
			WO 2002-JP8120	W	20020808
			US 2004-486220	A3	20040909

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OS MARPAT 138:187795  
 GI



AB Carboxylic acid derivs. (I) and nontoxic salts thereof [wherein R1 = CO2H, CO2R4, CH2OH, COR5SO2R6, CONH2, CH2NR5SO2R6, CH2NR9COR10, CH2NR9CONR5SO2R6, CH2SO2NR9COR10, CH2O2CNR5SO2R6, tetrazole, 1,2,4-oxadiazol-5-one, 1,2,4-oxadiazol-5-thione, 1,2,4-thiadiazol-5-one, etc. (wherein R4 = C1-6 alkyl, hydroxy-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, carboxy-C1-4 alkyl, etc.; R5, R9 = H, C1-6 alkyl; R6 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic carbocyclic, 3- to 13-membered mono-, di-, or tricyclic heterocyclyl, etc.; R10 = H, R6); A = a single bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc.; the ring B = C3-12 mono- or dicyclic carbocyclic ring, 3- to 12-membered mono- or dicyclic heterocyclic ring; R2 = C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6 alkynyl, halo, CHF2, CF3, NO2, cyano, Ph, oxo; m, n = 0,1,2; Q = (C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene)-Cyc2, -C1-4 alkylene-Z-Cyc3, amino-C1-4 alkyl, cyano-C1-4 alkyl, acylamino-C1-4 alkyl, 3- to 7-membered monocyclic carbocyclyl, 3- to 6-membered monocyclic heterocyclyl, etc. (wherein Cyc2, Cyc3 = C3-15 mono-, di-, or tricyclic carbocyclyl or heterocyclyl, etc.; Z = O, S, SO, SO2, NH, NHC, etc.); D = an linking chain consisting of 1-2 or 3-6 of atoms selected from C, N, O, or S, etc.; R3 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic carbocyclyl, 3- to 15-membered mono-, di-, or tricyclic heterocyclyl, etc.] are prepared These carboxylic acid derivs. include phenylpropanoic acid, phenylpropenoic acid, phenylpropanamide, phenylpropenamide, 3-oxoisindolin-1-ylacetic acid, benzylbenzoic acid, benzylaminoacetic acid, pyrazolylmethylbenzoic acid, benzoylaminoacetic acid, (pyrazolylmethylphenyl)propenoic acid, pyrazolylmethylpropanoic acid, (pyridinyloxyphenyl)propanoic acid, phenoxyacetic acid, phenylbutanoic acid, (pyrazolylmethyl)propanamide, (piperazinylmethylphenyl)propanamide, (morpholinylmethylphenyl)propanamide, (pyridinyloxyphenyl)propanamide, (pyrazolylmethyl)propenamide (oxoimidazolidinylmethylphenyl)propanamide, (oxopyrrolidinylmethylphenyl)propenamide, (thiophenylmethylphenyl)propenamide, (pyrazolylmethylphenylamino)acetamide, (thiazolylaminomethylphenyl)propanamide, thiophenylpropenamide, (pyrazolylmethylphenoxy)acetamide, (phenoxyethyl)benzamide, (pyrazolylmethylphenylethyl)-1,2,4-oxadiazol-5-one, and (pyrazolylmethylphenylindolyl)acetic acid. Because of binding to PEG2 receptors, in particular, subtype EP3 and/or subtype EP4 and having antagonism, the compds. I are useful in preventing and/or treating diseases such as pain, allodynia, hyperalgesia, pruritus (itching),

urticaria, atopic dermatitis, contact dermatitis, Urushi (Japanese lacquer tree) dermatitis, allergic conjunctivitis, symptoms during dialysis, asthma, rhinitis, allergic rhinitis, nasal congestion, sneeze, psoriasis, pollakiuria (increased urinary frequency), urination disorder, ejaculation (semination) disorder, fever (pyrexia), systemic inflammation reaction, learning disorder, Alzheimer's disease, neovascularization, cancer formation, cancer proliferation, cancer metastasis to organs, cancer metastasis to bone, hypercalcemia accompanied by cancer metastasis to bone, retinopathy, rubrum, erythema (rash), leucoma, skin moth-patch, heat burn, burn, steroid burn, kidney failure, nephropathy, acute or chronic nephritis, blood electrolyte disorder, imminent abortion, threatened abortion, excessive menstruation, dysmenorrhea, endometriosis, premenstrual syndrome, uterine gland myopathy, reproduction disorder, and stress. They are also useful in preventing and/or treating anxiety, depression, psychophysiol. disorder, mental retardation, thrombus, embolism, transient ischemic attack, cerebral infarction, atheroma, organ transplant, heart failure, hypertension, myocardial infarction, arteriosclerosis, circulation disorders or ulcers associated therewith, nerve disorders, vascular dementia, edema, diarrhea, constipation, biliary excretion disorder, ulcerative colitis, Crohn's disease, irritable bowel syndrome, reduction of rebound after using steroid drugs, aids for decreasing or removing steroid drugs, bone diseases, systemic granuloma, immune diseases, pyorrhea alveolaris, gingivitis, periodontal disease, nerve cell death, lung disorder, liver disorder, acute hepatitis, myocardial ischemia, Kawasaki disease, multiple organ failure, chronic headache, angiitis, venous failure, varicose vein (varicosis), anal fistula, diabetes insipidus, neonatal patent ductus arteriosus, and cholelithiasis. Thus, 4-hydroxymethyl-2-[2-(naphthalen-2-yl)ethoxy]cinnamic acid Et ester was mesylated by methanesulfonyl chloride in the presence of Et3N in THF at 0° for 15 min and condensed with pyrazole in the presence of NaH in DMF at 0° to give 2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid Et ester. 4-[2-[[2-(Naphthalen-1-yl)propanoyl]amino]-4-methylthiomethylphenyl]butanoic acid inhibited the binding of [3H]PGE2 to prostaglandin E2 (PEG2) receptor subtype EP1, Ep2, EP3, and EP4 expressed in CHO cells with Ki of >10, >10, 0.27, and 0.038 μM, resp. A tablet formulation containing (2E)-2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid was described.

OSC.G 21 THERE ARE 21 CAPLUS RECORDS THAT CITE THIS RECORD (40 CITINGS)  
 RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of thiazole and oxazole derivatives for treating human PPAR related disorders  
 AN 2002:615588 CAPLUS  
 DN 137:169510  
 TI Preparation of thiazole and oxazole derivatives for treating human PPAR related disorders  
 IN Cadilla, Rodolfo; Gosmini, Romain Luc Marie; Lambert, Millard Hurst, III; Sierra, Michael Lawrence  
 PA Glaxo Group Limited, UK  
 SO PCT Int. Appl., 63 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062774	A1	20020815	WO 2001-US49230	20011219
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,	



			GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
			RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
TW	292759	B	20080121	GB 2000-31107	A	20001220
				TW 2001-90131348		20011218
CA	2432188	A1	20020815	GB 2000-31107	A	20001220
				CA 2001-2432188		20011219
				GB 2000-31107	A	20001220
AU	2002246713	A1	20020819	WO 2001-US49230	W	20011219
AU	2002246713	B2	20040909	AU 2002-246713		20011219
				GB 2000-31107	A	20001220
EP	1343773	A1	20030917	WO 2001-US49230	W	20011219
EP	1343773	B1	20061102	EP 2001-994305		20011219
			R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
				GB 2000-31107	A	20001220
BR	2001016370	A	20031209	WO 2001-US49230	W	20011219
				BR 2001-16370		20011219
				GB 2000-31107	A	20001220
JP	2004518702	T	20040624	WO 2001-US49230	W	20011219
JP	4209681	B2	20090114	JP 2002-562729		20011219
				GB 2000-31107	A	20001220
HU	2004000837	A2	20040830	WO 2001-US49230	W	20011219
HU	2004000837	A3	20071128	HU 2004-837		20011219
				GB 2000-31107	A	20001220
CN	1527822	A	20040908	WO 2001-US49230	W	20011219
CN	1252057	C	20060419	CN 2001-822309		20011219
				GB 2000-31107	A	20001220
NZ	526543	A	20041126	NZ 2001-526543		20011219
				GB 2000-31107	A	20001220
				WO 2001-US49230	W	20011219
AT	344253	T	20061115	AT 2001-994305		20011219
				GB 2000-31107	A	20001220
PT	1343773	E	20070228	PT 2001-994305		20011219
				GB 2000-31107	A	20001220
ES	2274914	T3	20070601	ES 2001-994305		20011219
				GB 2000-31107	A	20001220
IL	156436	A	20080605	IL 2001-156436		20011219
				GB 2000-31107	A	20001220
				WO 2001-US49230	W	20011219
IN	2003KN00757	A	20051007	IN 2003-KN757		20030611
				GB 2000-31107	A	20001220
				WO 2001-US49230	W	20011219
ZA	2003004679	A	20041004	ZA 2003-4679		20030617
				GB 2000-31107	A	20001220
NO	2003002801	A	20030804	NO 2003-2801		20030619
				GB 2000-31107	A	20001220
				WO 2001-US49230	W	20011219
MX	2003005699	A	20031006	MX 2003-5699		20030620
				GB 2000-31107	A	20001220
				WO 2001-US49230	W	20011219
KR	815022	B1	20080318	KR 2003-708392		20030620
				GB 2000-31107	A	20001220

US 20040063964	A1	20040401	WO 2001-US49230	W	20011219
US 7105551	B2	20060912	US 2003-451313		20031020
			GB 2000-31107	A	20001220
			WO 2001-US49230	W	20011219
HK 1059925	A1	20070615	HK 2004-101319		20040224
			GB 2000-31107	A	20001220
US 20060276519	A1	20061207	WO 2001-US49230	W	20011219
US 7439259	B2	20081021	US 2006-465135		20060817
			GB 2000-31107	A	20001220
			WO 2001-US49230	W	20011219
			US 2003-451313	A1	20031020

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 137:169510

GI



AB Title compds. I [wherein R1 and R2 = independently H, or alkyl; or CR1R2 = cycloalkyl; and at least one or R1 and R2 ≠ H; X2 = O, S, or (CR10R11)<sub>n</sub>; n = 1-2; R3-R5 = independently H, alkyl, OMe, CF<sub>3</sub>, allyl, or halo; R10 and R11 = independently H, F, or alkyl; one of Y and Z is N, and the other is S or O; R6 and R7 = independently H, Ph, PhCH<sub>2</sub>, F, OH, alkyl, or allyl; or CR6R7 = CO; R9 = H, CF<sub>3</sub>, or Me; R8 = independently CF<sub>3</sub>, alkyl, OMe, or halo; m = 0-5; or pharmaceutically acceptable salts, solvates, or hydrolyzable esters thereof] were prepared as selective human peroxisome proliferator-activated receptor (hPPAR) activators. For example, Et 2-(4-hydroxy-2-methylphenoxy)-2-methylpropanoate was condensed with (R)-α,4-dimethyl-2-(4-trifluoromethylphenyl)-5-thiazolemethanol using Mitsunobu protocol to give the Et ester of (S)-II (52.5%).

#### Saponification

afforded the acid (S)-II (52.5%), which activated hPPAR $\alpha$ , hPPAR $\delta$ , and hPPAR $\gamma$  with EC<sub>50</sub> values of 16 nM, 3 nM, and 7000 nM, resp. I are useful for the treatment hPPAR mediated diseases or conditions, such as dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia, and anorexia nervosa (no data).

OSC.G 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)



RE.CNT 2        THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of biaryloxa(thia)zole derivatives as PPAR modulators  
 AN 2001:167982 CAPLUS  
 DN 134:207811  
 TI Preparation of biaryloxa(thia)zole derivatives as PPAR modulators  
 IN Brooks, Dawn A.; Rito, Christopher J.; Shuker, Anthony J.; Dominianni,  
 Samuel J.; Warshawsky, Alan M.; Gossett, Lynn S.; Matthews, Donald P.;  
 Hay, David A.; Ardecky, Robert J.; Michellys, Pierre-Yves; Tyhonas, John  
 S.  
 PA Eli Lilly and Company, USA; Ligand Pharmaceuticals Incorporated  
 SO PCT Int. Appl., 232 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001016120	A1	20010308	WO 2000-US23358	20000823
	WO 2001016120	A9	20020711		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				US 1999-151162P	P 19990827
	CA 2382966	A1	20010308	CA 2000-2382966	20000823
				US 1999-151162P	P 19990827
				WO 2000-US23358	W 20000823
	EP 1206457	A1	20020522	EP 2000-959401	20000823
	EP 1206457	B1	20031015		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
				US 1999-151162P	P 19990827
				WO 2000-US23358	W 20000823
	US 6417212	B1	20020709	US 2000-644457	20000823
				US 1999-151162P	P 19990827
	JP 2003508389	T	20030304	JP 2001-519687	20000823
				US 1999-151162P	P 19990827
				WO 2000-US23358	W 20000823
	AT 252091	T	20031115	AT 2000-959401	20000823
				US 1999-151162P	P 19990827
				WO 2000-US23358	W 20000823
	PT 1206457	E	20040331	PT 2000-959401	20000823
				US 1999-151162P	P 19990827
	ES 2204684	T3	20040501	ES 2000-959401	20000823
				US 1999-151162P	P 19990827
	US 20030045558	A1	20030306	US 2002-121373	20020411
	US 6610696	B2	20030826		
				US 1999-151162P	P 19990827
				US 2000-644457	A3 20000823
	US 20040019090	A1	20040129	US 2003-434425	20030507
	US 6825222	B2	20041130		
				US 1999-151162P	P 19990827
				US 2000-644457	A3 20000823
				US 2002-121373	A3 20020411



AB Title compds. (I) [wherein n = 2-4; V = O or S; W = O, S, or SO<sub>2</sub>; R<sub>1</sub> = H, alkyl, Ph, or CF<sub>3</sub>; R<sub>2</sub> = independently H, (cyclo)alkyl, cycloalkylalkyl, aryl(alkyl), or together with the Ph to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R<sub>3</sub> = independently H, (cyclo)alkyl, cycloalkylalkyl, or aryl(alkyl); R<sub>4</sub> = independently H, alkyl, aryl, or benzyl; R<sub>5</sub> = independently H or (un)substituted (hetero)aryl, provided that at least one R<sub>5</sub> = (un)substituted (hetero)aryl; and R<sub>6</sub> = H or (amino)alkyl] were prepared as are modulators of peroxisome proliferator activated receptors (PPARs) and are useful in the treatment of type II diabetes and cardiovascular diseases. For example, a mixture of the toluene-4-sulfonic acid 2-(2-(biphenyl-4-yl)-5-methyloxazol-4-yl)ethyl ester and 2-(3-hydroxyphenoxy)-2-methylpropanoic acid Et ester was heated at 55°C in DMF for 18 h and the intermediate deesterified using NaOH in EtOH and THF to afford the title compound II. II bound to human PPAR $\alpha$  and PPAR $\gamma$  with IC<sub>50</sub> values of 97 nM and 532 nM, resp., and activated human PPAR $\alpha$  and PPAR $\gamma$  with efficacies of 97% and 70%, resp. In assays evaluating triglyceride and cholesterol levels in mice transgenic for human apoA1, administration of II reduced triglyceride serum levels by 60.5% and increased HDLc serum levels by 204%. Glucose normalization of 95% was attained in male diabetic (db/db) mice dosed with II.

OSC.G 32 THERE ARE 32 CAPLUS RECORDS THAT CITE THIS RECORD (36 CITINGS)  
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L15 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of tricyclic compounds as prostaglandin I<sub>2</sub> receptor agonists  
 AN 1998:208535 CAPLUS  
 DN 128:257432  
 OREF 128:50963a,50966a  
 TI Preparation of tricyclic compounds as prostaglandin I<sub>2</sub> receptor agonists  
 IN Ohkawa, Shigenori; Setoh, Masaki; Terashita, Zen-ichi

PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 151 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9813356	A1	19980402	WO 1997-JP3384	19970924
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				JP 1996-252912	A 19960925
	TW 416953	B	20010101	TW 1997-86113705	19970920
				JP 1996-252912	A 19960925
	CA 2264641	A1	19980402	CA 1997-2264641	19970924
				JP 1996-252912	A 19960925
				WO 1997-JP3384	W 19970924
	AU 9743973	A	19980417	AU 1997-43973	19970924
				JP 1996-252912	A 19960925
				WO 1997-JP3384	W 19970924
	JP 10152480	A	19980609	JP 1997-257408	19970924
				JP 1996-252912	A 19960925
	EP 929534	A1	19990721	EP 1997-942196	19970924
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				JP 1996-252912	A 19960925
				WO 1997-JP3384	W 19970924
	US 6248766	B1	20010619	US 1999-254446	19990309
				JP 1996-252912	A 19960925
				WO 1997-JP3384	W 19970924
	US 20020006944	A1	20020117	US 2001-800988	20010307
	US 6417213	B2	20020709		
				JP 1996-252912	A 19960925
				WO 1997-JP3384	W 19970924
				US 1999-254446	A3 19990309

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 128:257432  
 GI




AB The title compds. [I; R1 = H, a substituent; m = 1-3; Ar = (un)substituted aromatic group; X = a bond, (un)substituted divalent straight-chain group having 1-6 atoms; Y = S, O, N(R2) (R2 = H, a substituent); Z = N, C(R3) (R3 = H, a hydrocarbon); ring A = a benzene ring; ring B = (un)substituted 5-7 membered ring], useful for eliciting a prostaglandin I2 receptor agonistic effect, inhibiting a platelet aggregation, and for the prophylaxis or treatment of transient ischemic attack, diabetic neuropathy, peripheral vascular diseases or ulcer, were prepared and formulated. Thus, reaction of Et [(2-mercapto-4,5-dihydronaphtho[1,2-d]thiazol-6-yl)oxy]acetate with 2,2-diphenylethyl methanesulfonate in the presence of K2CO3 in DMF followed by hydrolysis the resulting Et {[2-(2,2-diphenylethyl)thio-4,5-dihydronaphtho[1,2-d]thiazol-6-yl]oxy}acetate with 1N NaOH afforded 61% II which showed IC50 of 0.024  $\mu$ M against PGI2 receptor binding, and IC50 of 0.54  $\mu$ M against platelet aggregation.

OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)  
 RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Trisubstituted benzene leukotriene B4 receptor antagonists: synthesis and structure-activity relationships  
 AN 1997:645809 CAPLUS  
 DN 127:318788  
 OREF 127:62477a,62480a  
 TI Trisubstituted benzene leukotriene B4 receptor antagonists: synthesis and structure-activity relationships  
 AU Konno, Mitoshi; Nakae, Takahiko; Sakuyama, Shigeru; Odagaki, Yoshihiko; Nakai, Hisao; Hamanaka, Nobuyuki  
 CS Department of Medicinal Chemistry, Minase Research Institute, Ono Pharmaceutical Co., Ltd, Mishima, 618, Japan  
 SO Bioorganic & Medicinal Chemistry (1997), 5(8), 1649-1674  
 CODEN: BMECEP; ISSN: 0968-0896  
 PB Elsevier  
 DT Journal  
 LA English

GI



AB A series of trisubstituted benzenes which demonstrate leukotriene B<sub>4</sub> (LTB<sub>4</sub>, 1) receptor affinity was prepared. Previous trisubstituted benzenes from our laboratory showed high affinity to the LTB<sub>4</sub> receptor but demonstrated agonist activity in functional assays. (I) (R<sub>1</sub> = H, R<sub>2</sub> = 4-MeOC<sub>6</sub>H<sub>4</sub>) (II), the initial lead compound of this new series, showed only modest affinity (IC<sub>50</sub> = 0.20 μM). However, II was a receptor antagonist with no demonstrable agonist activity up to 30 μM. Further modification of the lipid tail and aryl head groups region led to the discovery of I [R<sub>1</sub> = O(CH<sub>2</sub>)<sub>4</sub>CO<sub>2</sub>H, R<sub>2</sub> = 4-MeOC<sub>6</sub>H<sub>4</sub>] (III) (ONO-4057). III, free of agonist activity, possesses high affinity to the LTB<sub>4</sub> receptor (K<sub>i</sub> = 3.7±0.9 nM).

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

TI Benzofuran and benzothiophene derivatives and their pharmaceutical use

AN 1981:83926 CAPLUS

DN 94:83926

OREF 94:13685a,13688a

TI Benzofuran and benzothiophene derivatives and their pharmaceutical use

IN Grell, Wolfgang; Sauter, Robert; Griss, Gerhart; Hurnaus, Rudolf; Eisele, Bernhard; Kaubisch, Nikolaus; Rupprecht, Eckhard; Kaehling, Joachim

PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.

SO Ger. Offen., 92 pp.

CODEN: GWXXBX

DT Patent




LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 2909754	A1	19800918	DE 1979-2909754	19790313
				DE 1979-2909754	19790313

OS MARPAT 94:83926

GI



AB The title derivs. I [R1 = C1-7 alkyl, C7-9 aralkyl, pyridyl, thienyl, PhC6H4, Ph optionally substituted with 1 or 2 halo, Me, OH, C1-3 alkoxy or arylamino, PhCH2O, NH2, NO2, CO2H, C2-4 alkoxy carbonyl; R2 = C1-14 alkyl, halo(un)substituted Ph, C7-9 aralkyl, pyridyl; R3 = H, C1-8 alkyl; R4, R5 = H, C1-3 alkyl; R6 = H, halo, X = O, S; n = 0-2] and their physiol. tolerable salts with bases when R3 = H and with acids when R1 and(or) R2 = pyridyl, useful as anticholesteremics, hypolipemics, and antiarteriosclerotics (extensive data tabulated for 7 compds)., were prepared by several methods. Thus, cyclizing 2-(4-methoxyphenoxy)-1-(2-pyridyl)-1-propanone in polyphosphoric acid in 30 min at 60° gave 91% methoxybenzofuran II (R7 = Me). This was demethylated in refluxing HBr to give 64.2% benzofuranol II.HBr (R7 = H), which was alkylated with Me2CBrCO2Et to 28.5% II.HCl (R7 = EtO2CCMe2).HCl via the free base. Saponifying II.HCl (R7 = EtO2CCMe2) with aqueous alc. NaOH gave 64.7% II.HCl (R6 = HO2CCMe2). Benzofuran III, at 20 mg/kg orally in rats, lowered serum cholesterol 70.5%, serum triglycerides 39.7%, and serum  $\beta$ -lipoproteins 87.0% vs. a control.

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

=> d cost

COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
CONNECT CHARGES	4.73	20.24
NETWORK CHARGES	0.77	3.36
SEARCH CHARGES	0.00	246.67
DISPLAY CHARGES	93.79	121.08
	-----	-----
FULL ESTIMATED COST	99.29	391.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-20.40	-26.35

IN FILE 'CAPLUS' AT 06:27:54 ON 25 JAN 2010

=> d his

(FILE 'HOME' ENTERED AT 05:59:46 ON 25 JAN 2010)

FILE 'REGISTRY' ENTERED AT 06:00:06 ON 25 JAN 2010

L1 STRUCTURE UPLOADED  
L2 1 SEARCH L1 SSS SAM  
L3 0 DSCAN

FILE 'CAPLUS' ENTERED AT 06:01:42 ON 25 JAN 2010

L4 1 L2

FILE 'REGISTRY' ENTERED AT 06:04:03 ON 25 JAN 2010

L5 873 SEARCH L1 SSS FULL  
SAVE TEMP L5 OXYLTDRAW/A

FILE 'CAPLUS' ENTERED AT 06:06:52 ON 25 JAN 2010

L6 128 L5  
SAVE TEMP L6 OXYLTDREFS/A  
L7 555427 ?LIPID?  
L8 207636 DIAB?  
L9 733476 L7 OR L8  
L10 29 L6 AND L9

FILE 'REGISTRY' ENTERED AT 06:18:48 ON 25 JAN 2010

L11 STRUCTURE UPLOADED  
L12 43 SEARCH L11 SSS SAM SUB=L5  
L13 766 SEARCH L11 SSS FULL SUB=L5

FILE 'CAPLUS' ENTERED AT 06:21:09 ON 25 JAN 2010

L14 68 L13  
L15 22 L9 AND L14

=> save temp l14 HOxyltdrefs/a  
ANSWER SET L14 HAS BEEN SAVED AS 'HOXYLTDREFS/A'

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	100.29	392.35
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-20.40	-26.35

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 06:29:12 ON 25 JAN 2010

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 06:37:48 ON 25 JAN 2010  
FILE 'CAPLUS' ENTERED AT 06:37:48 ON 25 JAN 2010  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	100.79	392.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-20.40	-26.35

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	100.79	392.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-20.40	-26.35

FILE 'REGISTRY' ENTERED AT 06:38:02 ON 25 JAN 2010  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 22 JAN 2010 HIGHEST RN 1202965-77-2  
 DICTIONARY FILE UPDATES: 22 JAN 2010 HIGHEST RN 1202965-77-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.



Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary  
 files\10575122\10575122 ph sub oxyltd.str



```

chain nodes :
7 8 9 10 11 12 13 14 15 16 23
ring nodes :
1 2 3 4 5 6 26 27 28 29 30 31
chain bonds :
6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14 14-15 15-16 15-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 26-27 26-31 27-28 28-29 29-30 30-31
exact/norm bonds :
7-8 9-10 10-11 11-12 12-13 13-14 15-16 15-23
exact bonds :
6-7 8-9 14-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 26-27 26-31 27-28 28-29 29-30 30-31

```

G1:O,S,N

G2:O,N

Hydrogen count :

9:>= minimum 2 12:>= minimum 2

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 23:CLASS 26:Atom  
27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom

L16 STRUCTURE UPLOADED

=> d l16

L16 HAS NO ANSWERS

L16 STR



G1 O,S,N

G2 O,N

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 05:59:46 ON 25 JAN 2010)

FILE 'REGISTRY' ENTERED AT 06:00:06 ON 25 JAN 2010

L1 STRUCTURE UPLOADED

L2 1 SEARCH L1 SSS SAM

L3 0 DSCAN

FILE 'CAPLUS' ENTERED AT 06:01:42 ON 25 JAN 2010

L4 1 L2

FILE 'REGISTRY' ENTERED AT 06:04:03 ON 25 JAN 2010

L5 873 SEARCH L1 SSS FULL

SAVE TEMP L5 OXYLTDRAW/A

FILE 'CAPLUS' ENTERED AT 06:06:52 ON 25 JAN 2010

L6 128 L5  
SAVE TEMP L6 OXYLTDREFS/A  
L7 555427 ?LIPID?  
L8 207636 DIAB?  
L9 733476 L7 OR L8  
L10 29 L6 AND L9

FILE 'REGISTRY' ENTERED AT 06:18:48 ON 25 JAN 2010

L11 STRUCTURE UPLOADED  
L12 43 SEARCH L11 SSS SAM SUB=L5  
L13 766 SEARCH L11 SSS FULL SUB=L5

FILE 'CAPLUS' ENTERED AT 06:21:09 ON 25 JAN 2010

L14 68 L13  
L15 22 L9 AND L14  
SAVE TEMP L14 HOXYLTDREFS/A

FILE 'REGISTRY' ENTERED AT 06:38:02 ON 25 JAN 2010

L16 STRUCTURE UPLOADED

=> search l16 sub = 15 sss sam  
SAMPLE SUBSET SEARCH INITIATED 06:41:49 FILE 'REGISTRY'  
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 47 TO ITERATE


100.0% PROCESSED 47 ITERATIONS 15 ANSWERS  
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):	ONLINE	**COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):	529 TO	1351
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):	68 TO	532

L17 15 SEA SUB=L5 SSS SAM L16

=> d scan


L17 15 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Propanoic acid, 2-[4-(2-[1,1'-biphenyl]-4-ylethoxy)phenoxy]-2-methyl-,  
ethyl ester  
MF C26 H28 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):15

L17 15 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Acetic acid, 2-[4-[2-[bis(3',4'-difluoro[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]-  
MF C38 H30 F4 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L17 15 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-methyl-2-[4-[[3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-buten-1-yl]oxy]phenoxy]-  
 MF C27 H25 F3 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L17 15 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, [4-[[2-ethoxy-3,3-bis[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI)  
 MF C40 H38 O9 S2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L17 15 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-[4-[2-([1,1'-biphenyl]-4-ylmethylene)-3-methylbutoxy]phenoxy]-2-methyl-  
 MF C29 H32 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L17 15 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2-[4-[[3,3-bis(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propen-1-yl]oxy]-2-methylphenoxy]-  
 MF C38 H30 Cl4 O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L17 15 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN D- $\alpha$ -Glutamine, N-[N-acetyl-1-O-(2-[1,1'-biphenyl]-4-ylethyl)- $\beta$ -  
 muramoyl]-L-alanyl- (9CI)  
 MF C33 H44 N4 O11

Absolute stereochemistry. Rotation (+).

PAGE 1-A




PAGE 1-B

—Ph


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L17 15 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, [4-[[2-ethoxy-3,3-bis[3'-(trifluoromethyl)[1,1'-biphenyl]-4-  
 yl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI)  
 MF C40 H32 F6 O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L17 15 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2-[4-[[3,3-bis([1,1'-biphenyl]-4-yl)-2-propen-1-yl]oxy]-2-methylphenoxy]-  
 MF C36 H30 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L17 15 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, [4-[[3,3-bis(4'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-chlorophenoxy]- (9CI)  
 MF C47 H35 Cl O6




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L17 15 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, [4-[[3,3-bis(4'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-  
 2-methylphenoxy]-(9CI)  
 MF C48 H38 O6




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L17 15 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, [4-[[3,3-bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-  
 propenyl]oxy]-2-chlorophenoxy]-(9CI)  
 MF C35 H23 Cl3 F2 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L17 15 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, [4-[[3,3-bis(3'-chloro-4'-fluorophenyl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI)  
 MF C36 H26 Cl2 F2 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L17 15 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2,2'-[[3,3'-bis(trifluoromethyl)[1,1'-biphenyl]-4,4'-diyl]bis(3,1-propanediyoxy)-4,1-phenyleneoxy]bis- (9CI)  
 MF C36 H32 F6 O8

PAGE 1-A




PAGE 1-B



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L17 15 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Acetic acid, [4-[2-[bis[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methylene]butoxy]-2-methylphenoxy]- (9CI)  
MF C40 H32 F6 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> search l16 sub = 15 sss full  
FULL SUBSET SEARCH INITIATED 06:42:27 FILE 'REGISTRY'  
FULL SUBSET SCREEN SEARCH COMPLETED - 863 TO ITERATE

100.0% PROCESSED 863 ITERATIONS 210 ANSWERS  
SEARCH TIME: 00.00.01

L18 210 SEA SUB=L5 SSS FUL L16

=> save temp l17 biphenylsraw/a

ANSWER SET L17 HAS BEEN SAVED AS 'BIPHENYLSRAW/A'

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	49.91	442.76
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-26.35

FILE 'CAPLUS' ENTERED AT 06:43:19 ON 25 JAN 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jan 2010 VOL 152 ISS 5  
FILE LAST UPDATED: 24 Jan 2010 (20100124/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l18

L19 5 L18

=> d l19 1-5 ti fbib abs

L19 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Synthesis and Protective Activity of  $\beta$ -Glycosides of  
N-Acetylmuramyl-L-Alanyl-D-Isoglutamine with Alkyl-Alicyclic and  
Aryl-Aliphatic Aglycons  
AN 2005:1346992 CAPLUS  
DN 145:471761  
TI Synthesis and Protective Activity of  $\beta$ -Glycosides of  
N-Acetylmuramyl-L-Alanyl-D-Isoglutamine with Alkyl-Alicyclic and  
Aryl-Aliphatic Aglycons  
AU Zemlyakov, A. E.; Tsikalova, V. N.; Tsikalov, V. V.; Chirva, V. Ya.;  
Mulik, E. L.; Kalyuzhin, O. V.  
CS Vernadsky Tauric National University, Simferopol, 95007, Ukraine  
SO Russian Journal of Bioorganic Chemistry (2005), 31(6), 576-582  
CODEN: RJBCEJ; ISSN: 1068-1620  
PB Pleiades Publishing, Inc.

DT Journal  
 LA English  
 OS CASREACT 145:471761  
 AB The starting peracetylated  $\beta$ -N-acetylglucosaminides were prepared by the oxazoline method. They were converted into 4,6-O-isopropylidene-N-acetyl-D-muramic acids, which were coupled with L-Ala-D-Glu(NH<sub>2</sub>)OBn. The target glycopeptides were obtained after their deprotection. The stimulation of the anti-infection resistance of mice against Staphylococcus aureus by the MDP glycosides was studied.  
 OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)  
 RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase  
 AN 2005:395261 CAPLUS  
 DN 142:446999  
 TI Preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase  
 IN Gurram, Ranga Madhavan; Bhuniya, Debnath; Das, Saibal Kumar; Chakrabarti, Ranjan; Iqbal, Javed; Sharma, Sudhir Kumar  
 PA Reddy's Laboratories Ltd., India  
 SO PCT Int. Appl., 115 pp.  
 CODEN: PIXXD2



DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040104	A1	20050506	WO 2004-IB208	20040129
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				WO 2003-IB4741	A 20031028
	IN 2002MA00792	A	20050304	IN 2002-MA792	20021028
				WO 2003-IB4741	A 20031028
	AU 2004283147	A1	20050506	AU 2004-283147	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
	CA 2538630	A1	20050506	CA 2004-2538630	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
	EP 1678128	A1	20060712	EP 2004-706247	20040129
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
	BR 2004014554	A	20061107	BR 2004-14554	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
	CN 1867546	A	20061122	CN 2004-80030239	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
	JP 2007509921	T	20070419	JP 2006-537450	20040129

			WO 2003-IB4741	A	20031028
			WO 2004-IB208	W	20040129
MX 2006003019	A	20060623	MX 2006-3019		20060316
			WO 2003-IB4741	A	20031028
			WO 2004-IB208	W	20040129
NO 2006001310	A	20060728	NO 2006-1310		20060323
			WO 2003-IB4741	A	20031028
			WO 2004-IB208	W	20040129
ZA 2006002491	A	20080528	ZA 2006-2491		20060327
			WO 2003-IB4741	A	20031028
US 20070043035	A1	20070222	US 2006-575122		20060407
			WO 2003-IB4741	A	20031028
			WO 2004-IB208	W	20040129

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OS CASREACT 142:446999; MARPAT 142:446999  
GI



AB Title compds. I [Ar = (un)substituted single or fused-aryl, -heteroaryl, -heterocycle; R1 and R2 independently = H, halo, nitro, etc.; R3 and R4 independently = H, (un)substituted-alkyl, -cycloalkyl, etc.; X = O, S, NR; R = H, (un)substituted-aryl, -alkanoyl, etc.; Z = O, S, NR; R5, R6, and R7 independently = H, OH, (un)substituted alkoxy, etc.; R5 and R6 together = 5- or 6-membered ring containing one or two hetero atoms selected from O, S, or N; Y = O, NR11; R11 = H, (un)substituted-heteroaryl, -aroyl, etc.; R7 and R11 together = 5- or 6-membered ring containing one or two hetero atoms selected from O, S, or N] and their pharmaceutically acceptable salts are prepared and disclosed as useful agonists of PPAR- $\alpha$  and PPAR- $\gamma$  and inhibitors or HMG CoA reductase. Thus, e.g., II was prepared by Wittig-Horner reaction of 4-acetyl biphenyl with tri-Et phosphonoacetate followed by reduction and Mitsunobu reaction with Et 2-(4-hydroxyphenoxy)-2-methylpropanoate. The activity of I was evaluated in vivo utilizing hypercholesterolemic rat models and it was revealed that a selected compound of the invention displayed a cholesterol lowering effect of 60%, a triglyceride lowering effect of 52%, as well as an increase in

HDL of 70%. I as agonists of PPAR- $\alpha$  and PPAR- $\gamma$  should prove useful in the treatment of diseases such as diabetes and dyslipidemia. Pharmaceutical compns. comprising I are disclosed.

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of dimeric dicarboxylic acid derivatives as PPAR agonists

AN 2004:546467 CAPLUS

DN 141:106263

TI Preparation of dimeric dicarboxylic acid derivatives as PPAR agonists

IN Sauerberg, Per; Jeppesen, Lone; Polivka, Zdenek; Sindelar, Karel

PA Novo Nordisk A/S, Den.

SO PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056740	A1	20040708	WO 2003-DK895	20031218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DK 2002-1966	A 20021220
	US 20040259950	A1	20041223	US 2003-734368	20031212
				DK 2002-1966	A 20021220
				US 2003-439410P	P 20030110
	AU 2003287912	A1	20040714	AU 2003-287912	20031218
				DK 2002-1966	A 20021220
				WO 2003-DK895	W 20031218
	EP 1578716	A1	20050928	EP 2003-779752	20031218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				DK 2002-1966	A 20021220
				WO 2003-DK895	W 20031218
	JP 2006510687	T	20060330	JP 2004-561080	20031218
				DK 2002-1966	A 20021220
				WO 2003-DK895	W 20031218

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 141:106263

GI



AB The title compds. DOC(O)AXLTZUMYBC(O)OE [I; A, B = (un)substituted alkylene, O(alkylene), S(alkylene); D, E = H, alkyl, cycloalkyl; L, M = O, S; T, U = (un)substituted divalent saturated carbon chain, NR1(alkylene) (wherein R1 = H, alkyl); X, Y = (un)substituted arylene, heteroarylene; Z = (un)substituted arylene, heteroarylene, divalent polycyclic ring system] which may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR) (no specific biol. data given), were prepared and formulated. E.g., a multi-step synthesis of II, is given. The compds. I are claimed as selective PPAR $\delta$  agonists useful in treating diabetes, syndrome X, cardiovascular diseases, dyslipidemia, and hypercholesteremia.

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)  
 RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of [[[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR $\delta$  agonists for treatment of diabetes and related conditions

AN 2004:220310 CAPLUS

DN 140:270625

TI Preparation of [[[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR $\delta$  agonists for treatment of diabetes and related conditions

IN Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per

PA Novo Nordisk A/s, Den.

SO PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022533	A1	20040318	WO 2003-DK578	20030904
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
			DK 2002-1301	A 20020905
			DK 2003-784	A 20030523
CA 2499380	A1	20040318	CA 2003-2499380	20030904
			DK 2002-1301	A 20020905
			DK 2003-784	A 20030523
			WO 2003-DK578	W 20030904
AU 2003260282	A1	20040329	AU 2003-260282	20030904
			DK 2002-1301	A 20020905
			DK 2003-784	A 20030523
			WO 2003-DK578	W 20030904
US 20040143006	A1	20040722	US 2003-654699	20030904
US 7091245	B2	20060815		
			DK 2002-1301	A 20020905
			US 2002-409814P	P 20020911
			DK 2003-784	A 20030523
EP 1537076	A1	20050608	EP 2003-793608	20030904



R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
			WO 2003-DK578	W	20030904
BR 2003014335	A	20050726	BR 2003-14335		20030904
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
			WO 2003-DK578	W	20030904
CN 1688540	A	20051026	CN 2003-824179		20030904
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
JP 2005538153	T	20051215	JP 2004-533217		20030904
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
			WO 2003-DK578	W	20030904
MX 2005002411	A	20050527	MX 2005-2411		20050302
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
			WO 2003-DK578	W	20030904
IN 2005DN00976	A	20091030	IN 2005-DN976		20050314
			DK 2002-1301	A	20020905
			WO 2003-DK578	W	20030904

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 140:270625

GI



AB Title vinyl carboxylic acid derivs. I [wherein X1 and X3 = independently (un)substituted (hetero)aryl; X2 and X4 = independently (un)substituted (hetero)arylene; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH2)<sub>n</sub>; n = 1-3; R1 = H, halo, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy,

(hetero)aralkoxy, (cyclo)alkylthio, arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator-activated receptor  $\delta$  (PPAR $\delta$ ) agonists (no data). For example, 4,4'-dibromobenzophenone was coupled with tri-Et phosphonoacetate in the presence of NaH in toluene to give Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction using DIBAL-H in THF (76%), followed by ADDP-catalyzed condensation with (4-mercapto-2-methylphenoxy)acetic acid Me ester in THF (88%) afforded [4-[3,3-bis(4-bromophenyl)allylsulfanyl]-2-methylphenoxy]acetic acid Me ester. Saponification (93%) and substitution with phenylboronic acid using KF, Pd2(dba)3, and Pd[P(t-Bu)3]2 in THF (53%) provided II. Also disclosed is the use of I and their pharmaceutical compns. for the treatment of PPAR $\delta$ -mediated conditions, such as diabetes, impaired glucose tolerance, insulin resistance, or obesity (no data).

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)  
 RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN

TI Long-chain, unsaturated, aromatic dicarboxylic acid derivatives, their preparation, and therapeutic use for treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR).

AN 2003:319859 CAPLUS

DN 138:337836

TI Long-chain, unsaturated, aromatic dicarboxylic acid derivatives, their preparation, and therapeutic use for treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR).

IN Sauerberg, Per; Bury, Paul Stanley; Jeppesen, Lone; Mogensen, John Patrick

PA Novo Nordisk A/S, Den.

SO PCT Int. Appl., 104 pp.

CODEN: PIXXD2

DT Patent



LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003033453	A1	20030424	WO 2002-DK692	20021015
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2462514	A1	20030424	CA 2002-2462514	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	AU 2002336916	A1	20030428	AU 2002-336916	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	EP 1438283	A1	20040721	EP 2002-772084	20021015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	BR 2002013253	A	20041026	BR 2002-13253	20021015
				DK 2001-1524	A 20011017

HU 2004001837	A2	20041228	WO 2002-DK692	W	20021015
			HU 2004-1837		20021015
			DK 2001-1524	A	20011017
CN 1571766	A	20050126	WO 2002-DK692	A	20021015
			CN 2002-820547		20021015
			DK 2001-1524	A	20011017
JP 2005505616	T	20050224	JP 2003-536195		20021015
			DK 2001-1524	A	20011017
			WO 2002-DK692	W	20021015
US 20030109579	A1	20030612	US 2002-272613		20021016
US 7220877	B2	20070522			
			DK 2001-1524	A	20011017
			US 2001-330346P	P	20011018
IN 2004CN00771	A	20060113	IN 2004-CN771		20040415
			DK 2001-1524	A	20011017
			WO 2002-DK692	W	20021015

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OS MARPAT 138:337836  
 GI



AB A novel class of dicarboxylic acid derivs., I, is disclosed [wherein: A = (un)substituted C1-3 alkylene, or A'O or A'S where A' is (un)substituted C1-3 alkylene; B = (un)substituted C1-3 alkylene, or OB' or SB' where B' is (un)substituted C1-3 alkylene; D, E = H, C1-6 alkyl, C3-6 cycloalkyl; L, M = O or S; T, U = C3-9 divalent, (un)substituted, unsatd. carbon chain; X, Y = (un)substituted arylene or heteroarylene; Z = (un)substituted arylene, heteroarylene, or divalent polycyclic ring system]. Also disclosed is the use of I in pharmaceutical compns., pharmaceutical compns. comprising I, and methods of treatment employing I and the compns. The present compds. may be useful (no data) in the treatment and/or prevention of conditions mediated by peroxisome proliferator-activated receptors (PPAR). For example, 1,4-diiodobenzene was coupled with excess 2-penten-4-yn-1-ol in (iso-Pr)<sub>2</sub>NH in the presence of CuI and Pd(PPh<sub>3</sub>)<sub>4</sub> at 60°, to give 55%

(E,E)-5-[4-(5-hydroxypent-3-en-1-ynyl)phenyl]pent-2-en-4-yn-1-ol.

Mitsunobu reaction of this diol with

(S)-2-ethoxy-3-(4-hydroxyphenyl)propionic acid Et ester using azodicarboxylic acid dipiperidide and PBu3 in THF gave 27% invention compound II. A total of 29 synthetic examples illustrate a variety of I, mostly sym. diacids and diesters, and mostly stereoisomeric, with all stereoisomers having (E) and (S) stereochem. at double bonds and chiral centers. Claims list a wide variety of sym. and asym. I, all named without stereochem. Claimed applications include treatment of type I and II diabetes, dyslipidemia, syndrome X and its conditions, cardiovascular diseases including atherosclerosis, and hypercholesterolemia.

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)  
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	17.50	460.26
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.25	-30.60

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 06:45:50 ON 25 JAN 2010

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 08:15:58 ON 25 JAN 2010  
FILE 'CAPLUS' ENTERED AT 08:15:58 ON 25 JAN 2010  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	17.50	460.26
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.25	-30.60

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	18.00	460.76
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.25	-30.60

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 08:16:16 ON 25 JAN 2010

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 09:40:43 ON 25 JAN 2010  
FILE 'CAPLUS' ENTERED AT 09:40:43 ON 25 JAN 2010  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	18.00	460.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.25	-30.60

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	18.00	460.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.25	-30.60

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 09:40:57 ON 25 JAN 2010

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 10:30:16 ON 25 JAN 2010  
FILE 'CAPLUS' ENTERED AT 10:30:16 ON 25 JAN 2010  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	18.00	460.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.25	-30.60

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION

FULL ESTIMATED COST	18.00	460.76
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.25	-30.60

FILE 'REGISTRY' ENTERED AT 10:30:29 ON 25 JAN 2010  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 24 JAN 2010 HIGHEST RN 1203430-88-9  
 DICTIONARY FILE UPDATES: 24 JAN 2010 HIGHEST RN 1203430-88-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.



Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary  
 files\10575122\10575122 specific species.str



```

chain nodes :
7  8  9  10  11  12  13  14  19
ring nodes :
1  2  3  4  5  6  21  22  23  24  25  26
chain bonds :
6-7  7-8  8-9  9-10  10-21  11-12  12-13  13-14  13-19
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  21-22  21-26  22-23  23-24  24-25  25-26
exact/norm bonds :
7-8  9-10  10-21  11-12  13-14  13-19
exact bonds :
6-7  8-9  12-13
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  21-22  21-26  22-23  23-24  24-25  25-26

```

G1:O,S,N

G2:O,N

```

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 19:CLASS 21:CLASS 22:Atom 23:Atom
24:Atom 25:Atom 26:Atom 27:Atom


```

L20        STRUCTURE UPLOADED

=> d 120

L20 HAS NO ANSWERS

L20                STR



G1 O,S,N

G2 O,N

Structure attributes must be viewed using STN Express query preparation.

=> search 120 sss sam

SAMPLE SEARCH INITIATED 10:31:08 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -        50058 TO ITERATE

4.0% PROCESSED 2000 ITERATIONS  
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
 SEARCH TIME: 00.00.01


6 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*  
 PROJECTED ITERATIONS: 987795 TO 1014525  
 PROJECTED ANSWERS: 2268 TO 3738

L21 6 SEA SSS SAM L20

=> d scan


L21 6 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, [4-[[2-[bis(4'-methyl[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI)  
 MF C40 H38 O3 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):6


L21 6 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetamide, 2-[4-[(3-phenylpropyl)amino]phenoxy]-  
 MF C17 H20 N2 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L21 6 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2-[2-methyl-4-[[[(2E)-3-[4-(5-methyl-2-thienyl)phenyl]-3-[4-[3-(4-morpholinyl)-1-propyn-1-yl]phenyl]-2-propen-1-yl]oxy]phenoxy]-  
 MF C36 H35 N O5 S

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L21 6 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2-[2-methyl-4-[[[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]-5-phenylpentyl]thio]phenoxy]-, ethyl ester  
 MF C33 H34 F3 N O3 S2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L21 6 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN L-Leucinamide, L- $\alpha$ -glutamyl-L-valyl-N-[(1S,2R)-3-[[4-(2-amino-2-oxoethoxy)-3,5-dichlorophenyl]amino]-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]- (9CI)  
 MF C34 H46 Cl2 N6 O9

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L21 6 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Acetic acid, 2,2'-[[3,3'-bis(trifluoromethyl)[1,1'-biphenyl]-4,4'-diyl]bis(3,1-propanediyoxy-4,1-phenyleneoxy)]bis- (9CI)  
 MF C36 H32 F6 O8



PAGE 1-A

PAGE 1-B



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> search l20 sss full  
 FULL SEARCH INITIATED 10:31:39 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 1008806 TO ITERATE

100.0% PROCESSED 1008806 ITERATIONS  
 SEARCH TIME: 00.00.14

2232 ANSWERS

L22 2232 SEA SSS FUL L20

=> save temp specraw/a  
ENTER L#, L# RANGE, ALL, OR (END):l22  
ANSWER SET L22 HAS BEEN SAVED AS 'SPECRAW/A'

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	193.01	653.77
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-30.60

FILE 'CAPLUS' ENTERED AT 10:32:52 ON 25 JAN 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jan 2010 VOL 152 ISS 5  
FILE LAST UPDATED: 24 Jan 2010 (20100124/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l22  
L23 159 L22

=> d his

(FILE 'HOME' ENTERED AT 05:59:46 ON 25 JAN 2010)

FILE 'REGISTRY' ENTERED AT 06:00:06 ON 25 JAN 2010

L1 STRUCTURE UPLOADED  
L2 1 SEARCH L1 SSS SAM  
L3 0 DSCAN

FILE 'CAPLUS' ENTERED AT 06:01:42 ON 25 JAN 2010

L4 1 L2

FILE 'REGISTRY' ENTERED AT 06:04:03 ON 25 JAN 2010

L5 873 SEARCH L1 SSS FULL  
SAVE TEMP L5 OXYLTDRAW/A

FILE 'CAPLUS' ENTERED AT 06:06:52 ON 25 JAN 2010  
L6 128 L5  
SAVE TEMP L6 OXYLTDREFS/A  
L7 555427 ?LIPID?  
L8 207636 DIAB?  
L9 733476 L7 OR L8  
L10 29 L6 AND L9

FILE 'REGISTRY' ENTERED AT 06:18:48 ON 25 JAN 2010  
L11 STRUCTURE UPLOADED  
L12 43 SEARCH L11 SSS SAM SUB=L5  
L13 766 SEARCH L11 SSS FULL SUB=L5

FILE 'CAPLUS' ENTERED AT 06:21:09 ON 25 JAN 2010  
L14 68 L13  
L15 22 L9 AND L14  
SAVE TEMP L14 HOXYLTDREFS/A

FILE 'REGISTRY' ENTERED AT 06:38:02 ON 25 JAN 2010  
L16 STRUCTURE UPLOADED  
L17 15 SEARCH L16 SSS SAM SUB=L5  
L18 210 SEARCH L16 SSS FULL SUB=L5  
SAVE TEMP L17 BIPHENYLSRAW/A

FILE 'CAPLUS' ENTERED AT 06:43:19 ON 25 JAN 2010  
L19 5 L18

FILE 'REGISTRY' ENTERED AT 10:30:29 ON 25 JAN 2010  
L20 STRUCTURE UPLOADED  
L21 6 SEARCH L20 SSS SAM  
L22 2232 SEARCH L20 SSS FULL  
SAVE TEMP SPECRAW/A L22

FILE 'CAPLUS' ENTERED AT 10:32:52 ON 25 JAN 2010  
L23 159 L22

=> 19 and 123  
L24 43 L9 AND L23

=> d 124 33-43 ti

L24 ANSWER 33 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Long-chain, unsaturated, aromatic dicarboxylic acid derivatives, their preparation, and therapeutic use for treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR).

L24 ANSWER 34 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanolic acid derivatives as antagonists of prostaglandin E2 (PEG2) receptors

L24 ANSWER 35 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Preparation of thiazole and oxazole derivatives for treating human PPAR related disorders

L24 ANSWER 36 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Preparation of phenylmethylalkanoic acid derivatives as PPAR $\alpha$  agonists useful in the treatment of hyperlipidemia, arteriosclerosis, diabetes, and obesity

L24 ANSWER 37 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Preparation of biaryloxa(thia)zole derivatives as PPAR modulators

L24 ANSWER 38 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Novel inhibitors of formation of advanced glycation endproducts (AGE's)

L24 ANSWER 39 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI A new rapid method to detect inhibition of Amadori product generated by  $\delta$ -gluconolactone

L24 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Novel Inhibitors of Advanced Glycation Endproducts

L24 ANSWER 41 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Medical uses of allosteric hemoglobin modifier compounds in patient care

L24 ANSWER 42 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Trisubstituted benzene leukotriene B4 receptor antagonists: synthesis and structure-activity relationships

L24 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Benzofuran and benzothiophene derivatives and their pharmaceutical use


=> d 124 36 ti fbib abs

L24 ANSWER 36 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of phenylmethylalkanoic acid derivatives as PPAR $\alpha$  agonists useful in the treatment of hyperlipidemia, arteriosclerosis, diabetes, and obesity

AN 2002:428856 CAPLUS  
 DN 137:20225  
 TI Preparation of phenylmethylalkanoic acid derivatives as PPAR $\alpha$  agonists useful in the treatment of hyperlipidemia, arteriosclerosis, diabetes, and obesity

IN Miyachi, Hiroyuki; Nomura, Masahiro; Murakami, Kouji  
 PA Kyorin Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 67 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2002044127	A1	20020606	WO 2001-JP10355	20011128
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				JP 2000-363679	A 20001129
	AU 2002022552	A	20020611	AU 2002-22552	20011128
				JP 2000-363679	A 20001129
				WO 2001-JP10355	W 20011128
OS	MARPAT 137:20225				
GI					



AB The title compds. I [R1 represents trifluoromethyl, optionally substituted phenoxy, etc.; R2 represents hydrogen or lower alkoxy; R3, R4 and R5 represent each hydrogen or lower alkyl; A represents NHCO or CONH; X is located at the para-position relative to A and represents oxygen or sulfur, or X is located at the para-position relative to R2 and represents oxygen or sulfur; and n is an integer of from 0 to 2], useful as PPAR $\alpha$  agonists (no data) for the treatment of hyperlipidemia, arteriosclerosis, diabetes, and obesity, are prepared For example, 2-[[4-[N-[[4-(trifluoromethyl)phenyl]methyl]carbonyl]-3-methoxyphenyl]methyl]butyric acid was prepared

OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)  
 RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	10.89	664.66
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.85	-31.45

SESSION WILL BE HELD FOR 120 MINUTES  
 STN INTERNATIONAL SESSION SUSPENDED AT 10:37:03 ON 25 JAN 2010

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
 SESSION RESUMED IN FILE 'CAPLUS' AT 10:44:26 ON 25 JAN 2010  
 FILE 'CAPLUS' ENTERED AT 10:44:26 ON 25 JAN 2010  
 COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	10.89	664.66
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.85	-31.45

=> d his

(FILE 'HOME' ENTERED AT 05:59:46 ON 25 JAN 2010)

FILE 'REGISTRY' ENTERED AT 06:00:06 ON 25 JAN 2010

L1 STRUCTURE UPLOADED  
L2 1 SEARCH L1 SSS SAM  
L3 0 DSCAN

FILE 'CAPLUS' ENTERED AT 06:01:42 ON 25 JAN 2010

L4 1 L2

FILE 'REGISTRY' ENTERED AT 06:04:03 ON 25 JAN 2010

L5 873 SEARCH L1 SSS FULL  
SAVE TEMP L5 OXYLTDRAW/A

FILE 'CAPLUS' ENTERED AT 06:06:52 ON 25 JAN 2010

L6 128 L5  
SAVE TEMP L6 OXYLTDFEFS/A  
L7 555427 ?LIPID?  
L8 207636 DIAB?  
L9 733476 L7 OR L8  
L10 29 L6 AND L9

FILE 'REGISTRY' ENTERED AT 06:18:48 ON 25 JAN 2010

L11 STRUCTURE UPLOADED  
L12 43 SEARCH L11 SSS SAM SUB=L5  
L13 766 SEARCH L11 SSS FULL SUB=L5

FILE 'CAPLUS' ENTERED AT 06:21:09 ON 25 JAN 2010

L14 68 L13  
L15 22 L9 AND L14  
SAVE TEMP L14 HOXYLTDFEFS/A

FILE 'REGISTRY' ENTERED AT 06:38:02 ON 25 JAN 2010

L16 STRUCTURE UPLOADED  
L17 15 SEARCH L16 SSS SAM SUB=L5  
L18 210 SEARCH L16 SSS FULL SUB=L5  
SAVE TEMP L17 BIPHENYLSRAW/A

FILE 'CAPLUS' ENTERED AT 06:43:19 ON 25 JAN 2010

L19 5 L18

FILE 'REGISTRY' ENTERED AT 10:30:29 ON 25 JAN 2010

L20 STRUCTURE UPLOADED  
L21 6 SEARCH L20 SSS SAM  
L22 2232 SEARCH L20 SSS FULL  
SAVE TEMP SPECRAW/A L22

FILE 'CAPLUS' ENTERED AT 10:32:52 ON 25 JAN 2010

L23 159 L22  
L24 43 L9 AND L23

=> d l24 22-32 ti

L24 ANSWER 22 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Preparation of dimeric dicarboxylic acid derivatives as PPAR agonists

L24 ANSWER 23 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Receptor function controlling agent

L24 ANSWER 24 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of [[(diarylallyl)sulfanyl]phenoxy]acetic acids and esters as PPAR activators for treatment of diabetes and related conditions

L24 ANSWER 25 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of biphenylallylsulfanylphenoxyacetates and related compounds for treating peroxisome proliferator activated receptor (PPAR) mediated diseases

L24 ANSWER 26 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of [[[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR $\delta$  agonists for treatment of diabetes and related conditions

L24 ANSWER 27 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of phenoxyacetic acids and indanyloxyacetic acids that modulate PPAR activity

L24 ANSWER 28 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of imidazole and benzimidazole derivatives that inhibit the interaction of ligands with RAGE

L24 ANSWER 29 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of (arylalkyl)thiazoles and oxazoles as peroxisome proliferator activated receptor modulators for treating diabetes mellitus, syndrome X, and cardiovascular disease

L24 ANSWER 30 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of pyrazolopyrimidines and related compounds as hPPAR $\alpha$  and hPPAR $\gamma$  ligands

L24 ANSWER 31 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of vanilloid receptor ligands and their use in treatments

L24 ANSWER 32 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of 5-amino-4-phenyl-1H-imidazoles as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)

=> d 124 26 ti fbib abs

L24 ANSWER 26 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of [[[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR $\delta$  agonists for treatment of diabetes and related conditions

AN 2004:220310 CAPLUS

DN 140:270625

TI Preparation of [[[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR $\delta$  agonists for treatment of diabetes and related conditions

IN Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per

PA Novo Nordisk A/s, Den.

SO PCT Int. Appl., 78 pp.  
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2004022533	A1	20040318	WO 2003-DK578	20030904
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				



LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,  
 PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,  
 TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
CA 2499380	A1	20040318	CA 2003-2499380		20030904
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
			WO 2003-DK578	W	20030904
AU 2003260282	A1	20040329	AU 2003-260282		20030904
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
			WO 2003-DK578	W	20030904
US 20040143006	A1	20040722	US 2003-654699		20030904
US 7091245	B2	20060815			
			DK 2002-1301	A	20020905
			US 2002-409814P	P	20020911
			DK 2003-784	A	20030523
EP 1537076	A1	20050608	EP 2003-793608		20030904
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
			WO 2003-DK578	W	20030904
BR 2003014335	A	20050726	BR 2003-14335		20030904
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
			WO 2003-DK578	W	20030904
CN 1688540	A	20051026	CN 2003-824179		20030904
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
JP 2005538153	T	20051215	JP 2004-533217		20030904
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
			WO 2003-DK578	W	20030904
MX 2005002411	A	20050527	MX 2005-2411		20050302
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
			WO 2003-DK578	W	20030904
IN 2005DN00976	A	20091030	IN 2005-DN976		20050314
			DK 2002-1301	A	20020905
			WO 2003-DK578	W	20030904

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 140:270625

GI



AB Title vinyl carboxylic acid derivs. I [wherein X1 and X3 = independently (un)substituted (hetero)aryl; X2 and X4 = independently (un)substituted (hetero)arylene; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; R1 = H, halo, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator-activated receptor  $\delta$  (PPAR $\delta$ ) agonists (no data). For example, 4,4'-dibromobenzophenone was coupled with tri-Et phosphonoacetate in the presence of NaH in toluene to give Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction using DIBAL-H in THF (76%), followed by ADDP-catalyzed condensation with (4-mercapto-2-methylphenoxy)acetic acid Me ester in THF (88%) afforded [4-[3,3-bis(4-bromophenyl)allylsulfanyl]-2-methylphenoxy]acetic acid Me ester. Saponification (93%) and substitution with phenylboronic acid using KF, Pd<sub>2</sub>(dba)<sub>3</sub>, and Pd[P(t-Bu)<sub>3</sub>]<sub>2</sub> in THF (53%) provided II. Also disclosed is the use of I and their pharmaceutical compns. for the treatment of PPAR $\delta$ -mediated conditions, such as diabetes, impaired glucose tolerance, insulin resistance, or obesity (no data).

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
20.28	674.05

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.70	-32.30

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 10:47:07 ON 25 JAN 2010

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 11:10:54 ON 25 JAN 2010  
FILE 'CAPLUS' ENTERED AT 11:10:54 ON 25 JAN 2010  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	20.78	674.55
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.70	-32.30

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	20.78	674.55
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.70	-32.30

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 11:11:05 ON 25 JAN 2010

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'REGISTRY' AT 10:30:06 ON 15 JUN 2010  
FILE 'REGISTRY' ENTERED AT 10:30:06 ON 15 JUN 2010  
COPYRIGHT (C) 2010 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.49	1.41

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.49	1.41

FILE 'REGISTRY' ENTERED AT 10:30:17 ON 15 JUN 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2010 HIGHEST RN 1227665-04-4  
DICTIONARY FILE UPDATES: 14 JUN 2010 HIGHEST RN 1227665-04-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary  
files\10575122\10575122 barebones core.str



chain nodes :  
2 3 4 5 17 18 19  
ring nodes :  
1 6 7 8 9 10 11 12 13 14 15 16  
chain bonds :  
1-2 2-3 3-4 4-5 5-6 14-17 17-18 18-19  
ring bonds :  
1-7 1-11 6-12 6-16 7-8 8-9 9-10 10-11 12-13 13-14 14-15 15-16  
exact/norm bonds :  
4-5 5-6 14-17 17-18  
exact bonds :  
1-2 2-3 3-4 18-19  
normalized bonds :  
1-7 1-11 6-12 6-16 7-8 8-9 9-10 10-11 12-13 13-14 14-15 15-16

Match level :


1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS

L10        STRUCTURE UPLOADED

=> d 110

L10 HAS NO ANSWERS



L10                STR



Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10575122\10575122 Core specific species.str



chain nodes :

2 3 4 5 17 18 19 20 21

ring nodes :

```

1  6  7  8  9  10  11  12  13  14  15  16
chain bonds :
1-2  2-3  3-4  4-5  14-17  17-18  18-19  18-20  18-21
ring bonds :
1-7  1-11  6-16  6-12  7-8  8-9  9-10  10-11  12-13  13-14  14-15  15-16
exact/norm bonds :
4-5  14-17  17-18
exact bonds :
1-2  2-3  3-4  18-19  18-20  18-21
normalized bonds :
1-7  1-11  6-16  6-12  7-8  8-9  9-10  10-11  12-13  13-14  14-15  15-16

```

G1:O,S,N

Match level :

```

1:Atom  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 24:Atom


```

L11 STRUCTURE UPLOADED

=> d l11

L11 HAS NO ANSWERS

L11 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> search l11 sss sam

SAMPLE SEARCH INITIATED 10:37:36 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 28 TO ITERATE

100.0% PROCESSED 28 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*


PROJECTED ITERATIONS: 243 TO 877

PROJECTED ANSWERS: 2 TO 124

L12 2 SEA SSS SAM L11

=> d scan


L12 2 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[4-[2-([1,1'-biphenyl]-4-ylmethylene)-3-methylbutoxy]phenoxy]-2-methyl-  
MF C29 H32 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L12 2 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Propanoic acid, 2-methyl-2-[4-[[3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-buten-1-yl]oxy]phenoxy]-  
MF C27 H25 F3 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> search l11 sss full  
FULL SEARCH INITIATED 10:38:38 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 427 TO ITERATE


100.0% PROCESSED 427 ITERATIONS 43 ANSWERS  
SEARCH TIME: 00.00.01

L13 43 SEA SSS FUL L11

=> d scan

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-methyl-2-[4-[[ (2E)-3-[4'-[(methylsulfonyl)oxy][1,1'-  
 biphenyl]-4-yl]-2-propen-1-yl]oxy]phenoxy]-  
 MF C26 H26 O7 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):42


L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-[4-[[ (2E)-3-[1,1'-biphenyl]-4-yl-2-butenyl]oxy]phenoxy]-2-  
 methyl-, (2S)-, compd. with (βS)-β-aminobenzeneethanol (1:1)  
 (9CI)  
 MF C27 H28 O4 . C8 H11 N O  
 CM 1

Absolute stereochemistry. Rotation (-).  
 Double bond geometry as shown.



CM 2


Absolute stereochemistry. Rotation (+).



L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-[4-[(3-[1,1'-biphenyl]-4-yl-2-propen-1-yl)oxy]phenoxy]-2-  
 methyl-, (2R)-

MF C26 H26 O4


Absolute stereochemistry.  
Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[[4-[(3-[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenyl]thio]-2-methyl-, (2R)-  
MF C27 H28 O3 S


Absolute stereochemistry.  
Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[[4-[[3-(4'-fluoro[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-, (2R)-  
MF C27 H27 F O4


Absolute stereochemistry.  
Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-methyl-2-[[4-[[3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-buten-1-yl]oxy]phenyl]thio]-, (2S)-  
MF C28 H27 F3 O3 S


Absolute stereochemistry.  
Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-methyl-2-[4-[[3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-buten-1-yl]oxy]phenoxy]-, (2S)-  
MF C28 H27 F3 O4

Absolute stereochemistry.  
Double bond geometry unknown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[4-[[3-(10-ethyl-10H-phenothiazin-2-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
MF C29 H31 N O4 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-methyl-2-[4-[[3-[4-[(methylsulfonyl)oxy]phenyl]-2-propen-1-yl]oxy]phenoxy]-  
 MF C21 H24 O7 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-[4-[(3-[1,1'-biphenyl]-4-yl)-2-propen-1-yl]oxy]phenoxy]-2-methyl-  
 MF C26 H26 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-methyl-2-[[4-[[3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-buten-1-yl]oxy]phenyl]thio]-  
 MF C28 H27 F3 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-[[4-[(3-{[1,1'-biphenyl]-4-yl}-2-buten-1-yl)oxy]phenyl]thio]-2-methyl-  
 MF C27 H28 O3 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-[4-[[3-(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
 MF C27 H26 Cl2 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-[4-[[3-(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-, (2S)-  
 MF C27 H28 O4  
 CI COM

Absolute stereochemistry. Rotation (-).  
 Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-methyl-2-[4-[3-[4-[(methanesulfonyl)oxy]phenyl]-2-propen-  
 1-yl]oxy]phenoxy]-  
 MF C20 H22 O7 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-methyl-2-[4-[3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-  
 yl]-2-buten-1-yl]oxy]phenyl]thio]-  
 MF C27 H25 F3 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-methyl-2-[4-[3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-  
 yl]-2-buten-1-yl]oxy]phenoxy]-  
 MF C27 H25 F3 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-[4-[(3-[1,1'-biphenyl]-4-yl)-2-buten-1-yl)oxy]phenoxy]-2-methyl-  
 MF C27 H28 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-[4-[2-([1,1'-biphenyl]-4-ylmethylene)-3-methylbutoxy]phenoxy]-2-methyl-  
 MF C28 H30 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-[4-[[3-(10-ethyl-10H-phenoxazin-2-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
 MF C28 H29 N O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-[4-[[3-(4'-fluoro[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
 MF C26 H25 F O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-[4-[[3-(4'-fluoro[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
 MF C28 H30 O4

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-methyl-2-[4-[(3-phenyl-2-propen-1-yl)oxy]phenoxy]-  
 MF C19 H20 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-[4-[(2E)-3-[1,1'-biphenyl]-4-yl-2-butenyl]oxy]phenoxy]-2-methyl-, (2R)-, compd. with (βR)-β-aminobenzeneethanol (1:1)  
 (9CI)  
 MF C27 H28 O4 . C8 H11 N O  
 CM 1

Absolute stereochemistry. Rotation (+).  
 Double bond geometry as shown.




CM 2

Absolute stereochemistry. Rotation (-).



L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-methyl-2-[[4-[[3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-buten-1-yl]oxy]phenyl]thio]-, (2R)-  
 MF C28 H27 F3 O3 S


Absolute stereochemistry.  
 Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-methyl-2-[4-[[3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-buten-1-yl]oxy]phenoxy]-, (2R)-  
 MF C28 H27 F3 O4


Absolute stereochemistry.  
 Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-[4-[(3-[1,1'-biphenyl]-4-yl)-2-propen-1-yl]oxy]phenoxy]-2-methyl-, (2S)-  
 MF C26 H26 O4


Absolute stereochemistry.  
 Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[[4-[(3-[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenyl]thio]-2-methyl-, (2S)-  
MF C27 H28 O3 S


Absolute stereochemistry.  
Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[4-[[3-(4'-fluoro[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-, (2S)-  
MF C27 H27 F O4

Absolute stereochemistry.  
Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[4-[2-([1,1'-biphenyl]-4-ylmethylene)-3-methylbutoxy]phenoxy]-2-methyl-  
MF C29 H32 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-[4-[[3-[4-(1H-imidazol-1-yl)phenyl]-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
 MF C24 H26 N2 O4

PAGE 1-A




PAGE 2-A



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-[4-[[3-(10-ethyl-10H-phenoxazin-2-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
 MF C24 H26 N2 O4

MF yl]oxy]phenoxy]-2-methyl-  
C29 H31 N O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[4-[[3-(9H-fluoren-2-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
MF C28 H28 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-methyl-2-[4-[[3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-buten-1-yl]oxy]phenoxy]-  
MF C28 H27 F3 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Butanoic acid, 2-[4-[[3-[[1,1'-biphenyl]-4-yl]-2-buten-1-yl]oxy]phenoxy]-2-methyl-, (2R)-  
MF C27 H28 O4


CI COM

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Propanoic acid, 2-[4-[[3-(10-ethyl-10H-phenothiazin-2-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
MF C28 H29 N O4 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Propanoic acid, 2-[4-[(3-{[1,1'-biphenyl]-4-yl}-2-propen-1-yl)oxy]phenoxy]-2-methyl-  
MF C25 H24 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN Propanoic acid, 2-[[4-[(3-{[1,1'-biphenyl]-4-yl}-2-buten-1-yl)oxy]phenylthio]-2-methyl-

MF C26 H26 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-[4-[[3-(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
 MF C26 H24 Cl2 O4





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Butanoic acid, 2-[4-[[3-(4'-fluoro[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
 MF C27 H27 F O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-[4-[[3-[4-(1H-imidazol-1-yl)phenyl]-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
 MF C23 H24 N2 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-[4-[[3-(9H-fluoren-2-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
 MF C27 H26 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L13 43 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
 IN Propanoic acid, 2-[4-[(3-[1,1'-biphenyl]-4-yl)-2-buten-1-yl]oxy]phenoxy]-2-methyl-  
 methyl-

MF C26 H26 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

198.40

199.81

FILE 'CAPLUS' ENTERED AT 10:39:16 ON 15 JUN 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Jun 2010 VOL 152 ISS 25

FILE LAST UPDATED: 14 Jun 2010 (20100614/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l13

L14 2 L13

=> d l14

L14 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2007:723007 CAPLUS

DN 148:205299

TI Synthesis of phenyloxy isobutyric acid derivatives and their antidiabetic activity in vitro  
 AU Zeng, Qingle; Wang, Heqing; Luo, Huan; Gao, Xiaoping; Liu, Zhongrong; Li, Bogang; Wang, Fengpeng; Zhao, Yufen  
 CS Department of Chemistry, Xiamen University, Xiamen, 361005, Peop. Rep. China  
 SO Yaoxue Xuebao (2006), 41(2), 108-114  
 CODEN: YHHPAL; ISSN: 0513-4870  
 PB Yaoxue Xuebao Bianjibu  
 DT Journal  
 LA English  
 OS CASREACT 148:205299  
 OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 114 1-2 ti fbib abs

L14 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Synthesis of phenyloxy isobutyric acid derivatives and their antidiabetic activity in vitro  
 AN 2007:723007 CAPLUS  
 DN 148:205299  
 TI Synthesis of phenyloxy isobutyric acid derivatives and their antidiabetic activity in vitro  
 AU Zeng, Qingle; Wang, Heqing; Luo, Huan; Gao, Xiaoping; Liu, Zhongrong; Li, Bogang; Wang, Fengpeng; Zhao, Yufen  
 CS Department of Chemistry, Xiamen University, Xiamen, 361005, Peop. Rep. China  
 SO Yaoxue Xuebao (2006), 41(2), 108-114  
 CODEN: YHHPAL; ISSN: 0513-4870  
 PB Yaoxue Xuebao Bianjibu  
 DT Journal  
 LA English  
 OS CASREACT 148:205299  
 AB The objective was to design and synthesize new phenyloxy isobutyric acid analogs as antidiabetic compds. Eight new target compds. were synthesized by combination of lipophilic moieties and acidic moiety with nucleophilic replacement or Mitsunobu condensation. The eight compds. were confirmed by <sup>1</sup>H NMR, <sup>13</sup>CN MR, IR, and MS. In vitro insulin-sensitizing activity (3T3-L1 adipocyte) demonstrated, that the cultured glucose concentration of up-clear solution detected with GOD-POD assay were 5.942, 6.339, 6.226, and 6.512 mmol/L-1, resp., when rosiglitazone, pioglitazone, compds. A and B were added to the insulin-resistant system. In vitro insulin-sensitizing activity of target compound A is in between that of rosiglitazone and pioglitazone, and activity of target compound B is slightly less than that of pioglitazone.  
 OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase  
 AN 2005:395261 CAPLUS  
 DN 142:446999  
 TI Preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase  
 IN Gurram, Ranga Madhavan; Bhuniya, Debnath; Das, Saibal Kumar; Chakrabarti, Ranjan; Iqbal, Javed; Sharma, Sudhir Kumar  
 PA Reddy's Laboratories Ltd., India

SO PCT Int. Appl., 115 pp.

CODEN: PIXXD2

DT Patent

LA English



FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040104	A1	20050506	WO 2004-IB208	20040129
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	IN 2002MA00792	A	20050304	WO 2003-IB4741	A 20031028
	IN 202812	A1	20070202	IN 2002-MA792	20021028
				WO 2003-IB4741	A 20031028
AU	2004283147	A1	20050506	AU 2004-283147	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
CA	2538630	A1	20050506	CA 2004-2538630	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
EP	1678128	A1	20060712	EP 2004-706247	20040129
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
BR	2004014554	A	20061107	BR 2004-14554	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
CN	1867546	A	20061122	CN 2004-80030239	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
JP	2007509921	T	20070419	JP 2006-537450	20040129
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
MX	2006003019	A	20060623	MX 2006-3019	20060316
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
NO	2006001310	A	20060728	NO 2006-1310	20060323
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129
ZA	2006002491	A	20080528	ZA 2006-2491	20060327
				WO 2003-IB4741	A 20031028
US	20070043035	A1	20070222	US 2006-575122	20060407
				WO 2003-IB4741	A 20031028
				WO 2004-IB208	W 20040129

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:446999; MARPAT 142:446999

GI



AB Title compds. I [Ar = (un)substituted single or fused-aryl, -heteroaryl, -heterocycle; R1 and R2 independently = H, halo, nitro, etc.; R3 and R4 independently = H, (un)substituted-alkyl, -cycloalkyl, etc.; X = O, S, NR; R = H, (un)substituted-aryl, -alkanoyl, etc.; Z = O, S, NR; R5, R6, and R7 independently = H, OH, (un)substituted alkoxy, etc.; R5 and R6 together = 5- or 6-membered ring containing one or two hetero atoms selected from O, S, or N; Y = O, NR11; R11 = H, (un)substituted-heteroaryl, -aroyl, etc.; R7 and R11 together = 5- or 6-membered ring containing one or two hetero atoms selected from O, S, or N] and their pharmaceutically acceptable salts are prepared and disclosed as useful agonists of PPAR- $\alpha$  and PPAR- $\gamma$  and inhibitors of HMG CoA reductase. Thus, e.g., II was prepared by Wittig-Horner reaction of 4-acetyl biphenyl with tri-Et phosphonoacetate followed by reduction and Mitsunobu reaction with Et 2-(4-hydroxyphenoxy)-2-methylpropanoate. The activity of I was evaluated in vivo utilizing hypercholesterolemic rat models and it was revealed that a selected compound of the invention displayed a cholesterol lowering effect of 60%, a triglyceride lowering effect of 52%, as well as an increase in HDL of 70%. I as agonists of PPAR- $\alpha$  and PPAR- $\gamma$  should prove useful in the treatment of diseases such as diabetes and dyslipidemia. Pharmaceutical compns. comprising I are disclosed.

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
	ENTRY	SESSION	
FULL ESTIMATED COST	11.00	210.81	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL	
	ENTRY	SESSION	
CA SUBSCRIBER PRICE	-1.70	-1.70	

FILE 'REGISTRY' ENTERED AT 10:43:19 ON 15 JUN 2010  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2010 HIGHEST RN 1227665-04-4  
DICTIONARY FILE UPDATES: 14 JUN 2010 HIGHEST RN 1227665-04-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary  
files\10575122\10575122 barebones core.str



chain nodes :  
2 3 4 5 17 18 19  
ring nodes :  
1 6 7 8 9 10 11 12 13 14 15 16  
chain bonds :  
1-2 2-3 3-4 4-5 5-6 14-17 17-18 18-19  
ring bonds :  
1-7 1-11 6-12 6-16 7-8 8-9 9-10 10-11 12-13 13-14 14-15 15-16  
exact/norm bonds :  
4-5 5-6 14-17 17-18  
exact bonds :  
1-2 2-3 3-4 18-19  
normalized bonds :  
1-7 1-11 6-12 6-16 7-8 8-9 9-10 10-11 12-13 13-14 14-15 15-16

Match level :


1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS

L15        STRUCTURE UPLOADED

=> d    l15

L15 HAS NO ANSWERS

L15                STR



Structure attributes must be viewed using STN Express query preparation.

=> search l15 sss full

FULL SEARCH INITIATED 10:43:56 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -        1040 TO ITERATE

100.0% PROCESSED        1040 ITERATIONS

342 ANSWERS

SEARCH TIME: 00.00.01

L16                342 SEA SSS FUL L15

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

192.03

402.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-1.70

FILE 'CAPLUS' ENTERED AT 10:44:19 ON 15 JUN 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Jun 2010 VOL 152 ISS 25

FILE LAST UPDATED: 14 Jun 2010 (20100614/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> 116

L17 11 L16

=> d 117 1-11 ti

L17 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

TI Process for the production of phenoxy acetic acid derivatives

L17 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

TI E/Z Isomerization of 3,3-disubstituted allylic thioethers

L17 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

TI Novel selective PPAR $\delta$  agonists: Optimization of activity by modification of alkynylallylic moiety

L17 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

TI Synthesis of phenyloxy isobutyric acid derivatives and their antidiabetic activity in vitro

L17 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of cyclic alkenyl compounds as PPAR $\delta$  activators for treating various disease including diabetes and obesity

L17 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of bis-phenylethynyl-phenyl-allylsulfanyl-phenoxy acetic acids as agonists of PPAR

L17 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of alkynyl substituted phenoxyacetic acids as PPAR $\delta$  agonists

L17 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase

L17 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of [[(diarylallyl)sulfanyl]phenoxy]acetic acids and esters as PPAR activators for treatment of diabetes and related conditions

L17 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of [[[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR $\delta$  agonists for treatment of diabetes and related conditions

L17 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

TI Long-chain, unsaturated, aromatic dicarboxylic acid derivatives, their preparation, and therapeutic use for treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR).

=> d 117 1-11 ti fbib abs

L17 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Process for the production of phenoxy acetic acid derivatives  
AN 2007:1420361 CAPLUS  
DN 148:54743  
TI Process for the production of phenoxy acetic acid derivatives  
IN Rasmussen, Kaare Gyberg; Christensen, Signe Maria; Humble, Rikke Eva  
PA Novo Nordisk A/S, Den.  
SO PCT Int. Appl., 44pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007141295	A1	20071213	WO 2007-EP55568	20070606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 2029507	A1	20090304	EP 2006-115124	A 20060608
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
EP 2007-729943 20070606				
EP 2006-115124 A 20060608				
WO 2007-EP55568 W 20070606				
OS CASREACT 148:54743; MARPAT 148:54743				
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB The invention relates to a process for the production of phenoxy acetic acid I, known as a partial PPAR $\delta$  agonist, via intermediates II (wherein X is halo and OSO<sub>2</sub>R<sub>2</sub>, R<sub>2</sub> is C1-6 alkyl or alkylaryl) and III (wherein R<sub>1</sub> is C1-6 alkyl). For instance, Wittig reaction of 4,4'-dibromobenzophenone with tri-Et phosphonoacetate (90%) followed by reduction (93%) and halogenation (77%) gave the intermediate compound II (X = Cl). Substitution of 1-(4-hydroxy-3-methylphenyl)-ethanone with Me bromoacetate (90%) followed by Baeyer-Villiger oxidation (99%) and hydrolysis (77%) gave the intermediate compound III (R<sub>1</sub> = Me). The phenoxy acetic acid I was then prepared by substitution of compound II (X = Cl) with compound III (R<sub>1</sub> = Me) followed by hydrolysis (94%).

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN  
TI E/Z Isomerization of 3,3-disubstituted allylic thioethers  
AN 2007:982258 CAPLUS  
DN 147:468952

TI E/Z Isomerization of 3,3-disubstituted allylic thioethers  
 AU Havranek, Miroslav; Sauerberg, Per; Kratina, Pavel; Pihera, Pavel  
 CS RE&D VUFB, Prague, 180 66, Czech Rep.  
 SO Tetrahedron Letters (2007), 48(39), 6970-6973  
 CODEN: TELEAY; ISSN: 0040-4039  
 PB Elsevier Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 147:468952  
 AB Allylic thioethers of the general structure 1 underwent E/Z isomerization during both basic and acidic hydrolysis of the ester moiety at the remote end of the mol. The isomerization was dependent on the substitution of the allylic moiety. The presence of a 5-membered heterocycle on the double bond supported the isomerization. However, analogous oxy-ethers were stable.  
 RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Novel selective PPAR $\delta$  agonists: Optimization of activity by modification of alkynylallylic moiety  
 AN 2007:746419 CAPLUS  
 DN 147:343462  
 TI Novel selective PPAR $\delta$  agonists: Optimization of activity by modification of alkynylallylic moiety  
 AU Havranek, Miroslav; Sauerberg, Per; Mogensen, John P.; Kratina, Pavel; Jeppesen, Claus B.; Pettersson, Ingrid; Pihera, Pavel  
 CS RE&D VUFB, s.r.o., Prague, 180 66 9, Czech Rep.  
 SO Bioorganic & Medicinal Chemistry Letters (2007), 17(15), 4144-4149  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 147:343462  
 GI



AB Y-shaped mols. bearing alkynylallylic moieties were found to be potent and selective PPAR $\delta$  activators. The alkynylallylic moiety was synthesized from alkyn-1-ols by hydroalumination followed by a cross-coupling reaction. Series of active compds. were obtained by stepwise changing the structure of a known PPARpan agonist into Y-shaped compds. The most active and selective compound, I, had a PPAR $\delta$  potency of 0.13  $\mu$ M.  
 OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)  
 RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD

## ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Synthesis of phenyloxy isobutyric acid derivatives and their antidiabetic activity in vitro  
AN 2007:723007 CAPLUS  
DN 148:205299  
TI Synthesis of phenyloxy isobutyric acid derivatives and their antidiabetic activity in vitro  
AU Zeng, Qingle; Wang, Heqing; Luo, Huan; Gao, Xiaoping; Liu, Zhongrong; Li, Bogang; Wang, Fengpeng; Zhao, Yufen  
CS Department of Chemistry, Xiamen University, Xiamen, 361005, Peop. Rep. China  
SO Yaoxue Xuebao (2006), 41(2), 108-114  
CODEN: YHHPAL; ISSN: 0513-4870  
PB Yaoxue Xuebao Bianjibu  
DT Journal  
LA English  
OS CASREACT 148:205299  
AB The objective was to design and synthesize new phenyloxy isobutyric acid analogs as antidiabetic compds. Eight new target compds. were synthesized by combination of lipophilic moieties and acidic moiety with nucleophilic replacement or Mitsunobu condensation. The eight compds. were confirmed by <sup>1</sup>H NMR, <sup>13</sup>CN MR, IR, and MS. In vitro insulin-sensitizing activity (3T3-L1 adipocyte) demonstrated, that the cultured glucose concentration of up-clear solution detected with GOD-POD assay were 5.942, 6.339, 6.226, and 6.512 mmol/L-1, resp., when rosiglitazone, pioglitazone, compds. A and B were added to the insulin-resistant system. In vitro insulin-sensitizing activity of target compound A is in between that of rosiglitazone and pioglitazone, and activity of target compound B is slightly less than that of pioglitazone.  
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN  
TI Preparation of cyclic alkenyl compounds as PPAR $\delta$  activators for treating various disease including diabetes and obesity  
AN 2007:705845 CAPLUS  
DN 147:118032  
TI Preparation of cyclic alkenyl compounds as PPAR $\delta$  activators for treating various disease including diabetes and obesity  
IN Sauerberg, Per; Pihera, Pavel; Polivka, Zdenek; Havranek, Miroslav; Pettersson, Ingrid; Mogensen, John Patrick  
PA Novo Nordisk A/S, Den.  
SO PCT Int. Appl., 216 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007071766	A2	20070628	WO 2006-EP70096	20061221
WO 2007071766	A3	20070913		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
AU 2006327003	A1	20070628	AU 2006-327003		20061221
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
CA 2631390	A1	20070628	CA 2006-2631390		20061221
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
EP 1979311	A2	20081015	EP 2006-830789		20061221
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,					
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
JP 2009520769	T	20090528	JP 2008-546470		20061221
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
MX 2008008098	A	20080710	MX 2008-8098		20080620
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
CN 101356155	A	20090128	CN 2006-80048573		20080620
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
IN 2008DN05418	A	20080815	IN 2008-DN5418		20080623
			EP 2005-112758	A	20051222
			WO 2006-US70096	W	20061221
KR 2008078707	A	20080827	KR 2008-716288		20080704
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221
US 20090093484	A1	20090409	US 2008-97564		20081023
			EP 2005-112758	A	20051222
			EP 2006-115631	A	20060619
			WO 2006-EP70096	W	20061221

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 147:118032; MARPAT 147:118032

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Novel compds. of the general formula I (wherein the "large X" is a double bond, X1 is heterocyclyl, aryl, heteroaryl, etc.; X2 is (un)substituted arylene or heteroarylene; X3 is (un)substituted aryl or heteroaryl; Ar is (un)substituted arylene; Y1 is O or S; and Y2 is O, S or CH<sub>2</sub>; and Z is -(CH<sub>2</sub>)<sub>n</sub>- wherein n = 1-3; and R1 = H, halo, etc.) the use of these compds. as pharmaceuticals, pharmaceutical compns. comprising the compds. and methods of treatment employing these compds. and compns. are claimed. The present compds. are activators of PPAR $\delta$  and should be useful for treating conditions mediated by the same, such as diabetes, impaired glucose tolerance, insulin resistance, cardiovascular disease, etc.; no

biol. data is given in the patent. Example compound II was prepared by reacting Me (Z)-[4-[3-(4-iodophenyl)-3-(4-trifluoromethylphenyl)allyloxy]-2-methylphenoxy]acetate with 2-ethynylpyridine and converting the ester obtained to the acid.

L17 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of bis-phenylethynyl-phenyl-allylsulfanyl-phenoxy acetic acids as agonists of PPAR  
 AN 2005:1193221 CAPLUS  
 DN 143:459867  
 TI Preparation of bis-phenylethynyl-phenyl-allylsulfanyl-phenoxy acetic acids as agonists of PPAR  
 IN Polivka, Zdenek; Sindelar, Karel; Sauerberg, Per; Pettersson, Ingrid  
 PA Novo Nordisk A/S, Den.  
 SO PCT Int. Appl., 103 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005105735	A1	20051110	WO 2005-EP52012	20050503
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				DK 2004-717	A 20040505
EP	1763511	A1	20070321	EP 2005-742988	20050503
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
				DK 2004-717	A 20040505
				WO 2005-EP52012	W 20050503
JP	2007536341	T	20071213	JP 2007-512187	20050503
				DK 2004-717	A 20040505
				WO 2005-EP52012	W 20050503
OS	CASREACT 143:459867; MARPAT 143:459867				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [X1 = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; X2 and X4 independently = (un)substituted arylene or heteroarylene; X3 = (un)substituted aryl, heteroaryl, alkyl, etc.; Ar = (un)substituted arylene; Y1 and Y2 independently = O or S; Z = (CH2)n; n = 1-3; R1 = H, halo, (un)substituted alkyl, etc.; R2 = H, alkenyl, alkynyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as agonists of PPAR. Thus, e.g., II was prepared by coupling of 4,4'-(phenyl-ethynyl)benzophenone with tri-Et phosphonoacetate followed by reduction/bromination sequence to give 3,3-bis[4-(phenylethynyl)phenyl]allyl bromide (III). Then, III underwent coupling with Et (4-mercapto-2-methylphenoxy)acetate and subsequent hydrolysis yielded acid

II. The activity of I was evaluated using in vitro transactivation assay using human HEK293 cells (no data). I as agonist of PPAR should prove useful in the treatment of diabetes type I, diabetes type II and metabolic syndrome X. Pharmaceutical compns. comprising I are disclosed.

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

TI Preparation of alkynyl substituted phenoxyacetic acids as PPAR $\delta$  agonists

AN 2005:1193203 CAPLUS

DN 143:459868

TI Preparation of alkynyl substituted phenoxyacetic acids as PPAR $\delta$  agonists

IN Havranek, Miroslav; Sauerberg, Per; Pettersson, Ingrid

PA Novo Nordisk A/S, Den.

SO PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005105725	A1	20051110	WO 2005-EP52010	20050503
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1745002	A1	20070124	DK 2004-716 EP 2005-747382	A 20040505 20050503
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
				DK 2004-716 WO 2005-EP52010	A 20040505 W 20050503
	JP 2007536340	T	20071213	JP 2007-512186	20050503
				DK 2004-716 WO 2005-EP52010	A 20040505 W 20050503
	US 20080114036	A1	20080515	US 2007-579303	20071010
				DK 2004-716 WO 2005-EP52010	A 20040505 W 20050503

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 143:459868; MARPAT 143:459868

GI



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE.FORMAT

TI Preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase

```
DN      142:446999
```

TI Preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase

IN Gurram, Ranga Madhavan; Bhuniya, Debnath; Das, Saibal Kumar; Chakrabarti, Ranjan; Iqbal, Javed; Sharma, Sudhir Kumar

PA Reddy's Laboratories Ltd., India

SO PCT Int. Appl., 115 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040104	A1	20050506	WO 2004-IB208	20040129
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				



GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IN 2002MA00792	A	20050304	WO 2003-IB4741	A	20031028
IN 202812	A1	20070202	IN 2002-MA792		20021028
			WO 2003-IB4741	A	20031028
AU 2004283147	A1	20050506	AU 2004-283147		20040129
			WO 2003-IB4741	A	20031028
			WO 2004-IB208	W	20040129
CA 2538630	A1	20050506	CA 2004-2538630		20040129
			WO 2003-IB4741	A	20031028
			WO 2004-IB208	W	20040129
EP 1678128	A1	20060712	EP 2004-706247		20040129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			WO 2003-IB4741	A	20031028
			WO 2004-IB208	W	20040129
BR 2004014554	A	20061107	BR 2004-14554		20040129
			WO 2003-IB4741	A	20031028
			WO 2004-IB208	W	20040129
CN 1867546	A	20061122	CN 2004-80030239		20040129
			WO 2003-IB4741	A	20031028
			WO 2004-IB208	W	20040129
JP 2007509921	T	20070419	JP 2006-537450		20040129
			WO 2003-IB4741	A	20031028
			WO 2004-IB208	W	20040129
MX 2006003019	A	20060623	MX 2006-3019		20060316
			WO 2003-IB4741	A	20031028
			WO 2004-IB208	W	20040129
NO 2006001310	A	20060728	NO 2006-1310		20060323
			WO 2003-IB4741	A	20031028
			WO 2004-IB208	W	20040129
ZA 2006002491	A	20080528	ZA 2006-2491		20060327
			WO 2003-IB4741	A	20031028
US 20070043035	A1	20070222	US 2006-575122		20060407
			WO 2003-IB4741	A	20031028
			WO 2004-IB208	W	20040129

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:446999; MARPAT 142:446999

GI



AB Title compds. I [Ar = (un)substituted single or fused-aryl, -heteroaryl, -heterocycle; R1 and R2 independently = H, halo, nitro, etc.; R3 and R4 independently = H, (un)substituted-alkyl, -cycloalkyl, etc.; X = O, S, NR; R = H, (un)substituted-aryl, -alkanoyl, etc.; Z = O, S, NR; R5, R6, and R7 independently = H, OH, (un)substituted alkoxy, etc.; R5 and R6 together = 5- or 6-membered ring containing one or two hetero atoms selected from O, S, or N; Y = O, NR11; R11 = H, (un)substituted-heteroaryl, -aroyl, etc.; R7 and R11 together = 5- or 6-membered ring containing one or two hetero atoms selected from O, S, or N] and their pharmaceutically acceptable salts are prepared and disclosed as useful agonists of PPAR- $\alpha$  and PPAR- $\gamma$  and inhibitors or HMG CoA reductase. Thus, e.g., II was prepared by Wittig-Horner reaction of 4-acetyl biphenyl with tri-Et phosphonoacetate followed by reduction and Mitsunobu reaction with Et 2-(4-hydroxyphenoxy)-2-methylpropanoate. The activity of I was evaluated in vivo utilizing hypercholesterolemic rat models and it was revealed that a selected compound of the invention displayed a cholesterol lowering effect of 60%, a triglyceride lowering effect of 52%, as well as an increase in HDL of 70%. I as agonists of PPAR- $\alpha$  and PPAR- $\gamma$  should prove useful in the treatment of diseases such as diabetes and dyslipidemia. Pharmaceutical compns. comprising I are disclosed.

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of [[(diarylallyl)sulfanyl]phenoxy]acetic acids and esters as PPAR activators for treatment of diabetes and related conditions  
 AN 2004:370892 CAPLUS  
 DN 140:374984  
 TI Preparation of [[(diarylallyl)sulfanyl]phenoxy]acetic acids and esters as PPAR activators for treatment of diabetes and related conditions  
 IN Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav  
 PA Novo Nordisk A/S, Den.  
 SO PCT Int. Appl., 124 pp.  
 CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004037776	A2	20040506	WO 2003-DK722	20031027
	WO 2004037776	A3	20040610		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DK 2002-1631	A 20021028
				DK 2003-793	A 20030526
	US 20050070583	A1	20050331	US 2003-693161	20031024
	US 7129268	B2	20061031		
				DK 2002-1631	A 20021028
				US 2002-423467P	P 20021104
				DK 2003-793	A 20030526
	CA 2503280	A1	20040506	CA 2003-2503280	20031027
				DK 2002-1631	A 20021028
				DK 2003-793	A 20030526
				WO 2003-DK722	W 20031027
	AU 2003273783	A1	20040513	AU 2003-273783	20031027
	AU 2003273783	B2	20100318		
				DK 2002-1631	A 20021028
				DK 2003-793	A 20030526
				WO 2003-DK722	W 20031027
	EP 1558572	A2	20050803	EP 2003-757741	20031027
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				DK 2002-1631	A 20021028
				DK 2003-793	A 20030526
				WO 2003-DK722	W 20031027
	BR 2003015683	A	20050830	BR 2003-15683	20031027
				DK 2002-1631	A 20021028
				DK 2003-793	A 20030526
				WO 2003-DK722	W 20031027
	CN 1708468	A	20051214	CN 2003-80102228	20031027
	CN 100491316	C	20090527		
				DK 2002-1631	A 20021028
				DK 2003-793	A 20030526
	JP 2006503908	T	20060202	JP 2005-501509	20031027
				DK 2002-1631	A 20021028
				DK 2003-793	A 20030526
				WO 2003-DK722	W 20031027
	RU 2349582	C2	20090320	RU 2005-116243	20031027
				DK 2002-1631	A 20021028
				DK 2003-793	A 20030526
				WO 2003-DK722	W 20031027
	IN 2005DN01364	A	20080808	IN 2005-DN1364	20050405
	IN 232024	A1	20090403		
				DK 2002-1631	A 20021028
				WO 2003-DK722	W 20031027
	ZA 2005002814	A	20051018	ZA 2005-2814	20050407
				DK 2002-1631	A 20021028
	MX 2005004402	A	20050726	MX 2005-4402	20050425

			DK 2002-1631	A	20021028
			DK 2003-793	A	20030526
			WO 2003-DK722	W	20031027
NO 2005002575	A	20050527	NO 2005-2575		20050527
			DK 2002-1631	A	20021028
			DK 2003-793	A	20030526
			WO 2003-DK722	W	20031027
AU 2010201560	A1	20100506	AU 2010-201560		20100419
			DK 2002-1631	A	20021028
			DK 2003-793	A	20030526
			AU 2003-273783	A3	20031027
			WO 2003-DK722	W	20031027

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 140:374984

GI



AB Title compds. I [wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH2)*n*; *n* = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, alkenynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixts. of stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPAR $\delta$ , such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesteremia (no data). For example, coupling of 4,4'-dibromobenzophenone with tri-Et phosphonoacetate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction of the ester to the alc. (76%) using DIBAL-H in THF and toluene, followed by reaction with (4-mercapto-2-methylphenoxy)acetic acid Me ester in the presence of ADDP and tributylphosphine in THF gave II (88%).

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

## ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Preparation of [[[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and  
 analogs as PPAR $\delta$  agonists for treatment of diabetes and related  
 conditions  
 AN 2004:220310 CAPLUS  
 DN 140:270625  
 TI Preparation of [[[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and  
 analogs as PPAR $\delta$  agonists for treatment of diabetes and related  
 conditions  
 IN Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per  
 PA Novo Nordisk A/s, Den.  
 SO PCT Int. Appl., 78 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022533	A1	20040318	WO 2003-DK578	20030904
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DK 2002-1301	A 20020905
				DK 2003-784	A 20030523
	CA 2499380	A1	20040318	CA 2003-2499380	20030904
				DK 2002-1301	A 20020905
				DK 2003-784	A 20030523
				WO 2003-DK578	W 20030904
	AU 2003260282	A1	20040329	AU 2003-260282	20030904
				DK 2002-1301	A 20020905
				DK 2003-784	A 20030523
				WO 2003-DK578	W 20030904
	US 20040143006	A1	20040722	US 2003-654699	20030904
	US 7091245	B2	20060815		
				DK 2002-1301	A 20020905
				US 2002-409814P	P 20020911
				DK 2003-784	A 20030523
	EP 1537076	A1	20050608	EP 2003-793608	20030904
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				DK 2002-1301	A 20020905
				DK 2003-784	A 20030523
				WO 2003-DK578	W 20030904
	BR 2003014335	A	20050726	BR 2003-14335	20030904
				DK 2002-1301	A 20020905
				DK 2003-784	A 20030523
				WO 2003-DK578	W 20030904
	CN 1688540	A	20051026	CN 2003-824179	20030904
				DK 2002-1301	A 20020905
				DK 2003-784	A 20030523
	JP 2005538153	T	20051215	JP 2004-533217	20030904
				DK 2002-1301	A 20020905
				DK 2003-784	A 20030523

MX 2005002411	A	20050527	WO 2003-DK578	W	20030904
			MX 2005-2411		20050302
			DK 2002-1301	A	20020905
			DK 2003-784	A	20030523
			WO 2003-DK578	W	20030904
IN 2005DN00976	A	20091030	IN 2005-DN976		20050314
			DK 2002-1301	A	20020905
			WO 2003-DK578	W	20030904

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 140:270625

GI



AB Title vinyl carboxylic acid derivs. I [wherein X1 and X3 = independently (un)substituted (hetero)aryl; X2 and X4 = independently (un)substituted (hetero)arylene; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; R1 = H, halo, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator-activated receptor  $\delta$  (PPAR $\delta$ ) agonists (no data). For example, 4,4'-dibromobenzophenone was coupled with tri-Et phosphonoacetate in the presence of NaH in toluene to give Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction using DIBAL-H in THF (76%), followed by ADDP-catalyzed condensation with (4-mercapto-2-methylphenoxy)acetic acid Me ester in THF (88%) afforded [4-[3,3-bis(4-bromophenyl)allylsulfanyl]-2-methylphenoxy]acetic acid Me ester. Saponification (93%) and substitution with phenylboronic acid using KF, Pd<sub>2</sub>(dba)<sub>3</sub>, and Pd[P(t-Bu)<sub>3</sub>]<sub>2</sub> in THF (53%) provided II. Also disclosed is the use of I and their pharmaceutical compns. for the treatment of PPAR $\delta$ -mediated conditions, such as diabetes, impaired glucose tolerance, insulin resistance, or obesity (no data).

OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)  
 RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L17 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN  
 TI Long-chain, unsaturated, aromatic dicarboxylic acid derivatives, their  
 preparation, and therapeutic use for treatment of conditions mediated by  
 peroxisome proliferator-activated receptors (PPAR).  
 AN 2003:319859 CAPLUS  
 DN 138:337836  
 TI Long-chain, unsaturated, aromatic dicarboxylic acid derivatives, their  
 preparation, and therapeutic use for treatment of conditions mediated by  
 peroxisome proliferator-activated receptors (PPAR).  
 IN Sauerberg, Per; Bury, Paul Stanley; Jeppesen, Lone; Mogensen, John Patrick  
 PA Novo Nordisk A/S, Den.  
 SO PCT Int. Appl., 104 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003033453	A1	20030424	WO 2002-DK692	20021015
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
	CA 2462514	A1	20030424	DK 2001-1524	A 20011017
				CA 2002-2462514	20021015
				DK 2001-1524	A 20011017
	AU 2002336916	A1	20030428	WO 2002-DK692	W 20021015
				AU 2002-336916	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	EP 1438283	A1	20040721	EP 2002-772084	20021015
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK	
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	BR 2002013253	A	20041026	BR 2002-13253	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	HU 2004001837	A2	20041228	HU 2004-1837	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	A 20021015
	CN 1571766	A	20050126	CN 2002-820547	20021015
				DK 2001-1524	A 20011017
	JP 2005505616	T	20050224	JP 2003-536195	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	US 20030109579	A1	20030612	US 2002-272613	20021016
	US 7220877	B2	20070522		
				DK 2001-1524	A 20011017
				US 2001-330346P	P 20011018
	IN 2004CN00771	A	20060113	IN 2004-CN771	20040415
				DK 2001-1524	A 20011017

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 138:337836

GI



AB A novel class of dicarboxylic acid derivs., I, is disclosed [wherein: A = (un)substituted C1-3 alkylene, or A'O or A'S where A' is (un)substituted C1-3 alkylene; B = (un)substituted C1-3 alkylene, or OB' or SB' where B' is (un)substituted C1-3 alkylene; D, E = H, C1-6 alkyl, C3-6 cycloalkyl; L, M = O or S; T, U = C3-9 divalent, (un)substituted, unsatd. carbon chain; X, Y = (un)substituted arylene or heteroarylene; Z = (un)substituted arylene, heteroarylene, or divalent polycyclic ring system]. Also disclosed is the use of I in pharmaceutical compns., pharmaceutical compns. comprising I, and methods of treatment employing I and the compns. The present compns. may be useful (no data) in the treatment and/or prevention of conditions mediated by peroxisome proliferator-activated receptors (PPAR). For example, 1,4-diiodobenzene was coupled with excess 2-penten-4-yn-1-ol in (iso-Pr)<sub>2</sub>NH in the presence of CuI and Pd(PPh<sub>3</sub>)<sub>4</sub> at 60°, to give 55%

(E,E)-5-[4-(5-hydroxypent-3-en-1-ynyl)phenyl]pent-2-en-4-yn-1-ol.

Mitsunobu reaction of this diol with

(S)-2-ethoxy-3-(4-hydroxyphenyl)propionic acid Et ester using azodicarboxylic acid dipiperidide and PBu<sub>3</sub> in THF gave 27% invention compound II. A total of 29 synthetic examples illustrate a variety of I, mostly sym. diacids and diesters, and mostly stereoisomeric, with all stereoisomers having (E) and (S) stereochem. at double bonds and chiral centers. Claims list a wide variety of sym. and asym. I, all named without stereochem. Claimed applications include treatment of type I and II diabetes, dyslipidemia, syndrome X and its conditions, cardiovascular diseases including atherosclerosis, and hypercholesterolemia.

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

=>

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

66.39

469.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-9.35

-11.05

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 11:18:05 ON 15 JUN 2010